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ABSTRACT
The actions of the C-C chemokine, monocyte chemotactic peptide-1 (MCP-1) 
have been investigated on the human monocytic cell line THP-1, human 
embryonic kidney (HEK) 293 cells transfected with the high affinity MCP-1 
receptors A and B and in human blood derived monocytes.
MCP-1 specifically bound to high affinity receptors on THP-1 cells and HEK 
293 cells transfected with the type B receptor. MCP-1 bound to only a small 
population of HEK 293 cells transfected with the type A receptor.
MCP-1 also induced a dose-dependent increase in [Ca2+]j in THP-1 cells, 
type B receptor transfectants and human monocytes, although the source of this 
intracellular Ca2+ varied. The Ca2+ chelator EGTA, the Ca2+ channel blocker Ni2+ 
and the surrogate Ca2+ ion Mn2+, all demonstrated the requirement of 
extracellular Ca2+ in the MCP-1-induced responses in type B receptor 
transfected cells and monocytes. In contrast, THP-1 cells did not require 
extracellular calcium. Time-dependent increases in IP3 were also detected in 
THP-1 cells and both the type A and type B receptor transfected cells, 
demonstrating the activation of PLC by MCP-1.
The novel signal transduction pathway, phosphatidylinositol 3-kinase (PI 3- 
kinase) was also activated by MCP-1 in a dose- and time-dependent manner in 
THP-1 cells and both the receptor transfected cells. However, by using two 
methods of studying PI 3-kinase activation, namely D-3 phospholipid 
accumulation or immunoprecipitation of the p85 subunit and in vitro lipid kinase 
assay, variations between the cell types were observed. MCP-1 induced the 
pertussis toxin sensitive accumulation of D-3 phospholipids in THP-1 cells, which 
was relatively insensitive to the PI 3-kinase inhibitor wortmannin. MCP-1 also 
induced an increase in a wortmannin sensitive, pertussis toxin insensitive PI 3- 
kinase activity in p85 immunoprecipitates. The type A receptor transfected cells 
only demonstrated MCP-1-induced D-3 phospholipid accumulation and the type 
B receptor transfected cells only demonstrated increased immunoprecipitated PI 
3-kinase activity in response to MCP-1.
Three proteins, of molecular weight 120, 80 and 50kDa,were observed to be 
tyrosine phosphorylated in response to MCP-1 in the THP-1 cells and the type B 
receptor transfected cells. In addition, in THP-1 cells it was a distinct 55kDa 
phosphorylated protein which co-precipitated with the p85 subunit of PI 3-kinase.
Finally, MCP-1 induced an increase in chemotaxis in both human monocytes 
and THP-1 cells as well as adhesion molecule upregulation and superoxide 
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SECTION 1 : INTRODUCTION
1.1 Background
The classical signs of inflammation (redness, heat, swelling and pain) were reported 
as early as the second century when Celsius first described acute inflammation.
These signs were further investigated in the eighteenth century by Hunter who 
characterised the four phases proposed by Celsius. He recognised that the redness 
and heat were due to increased blood flow following vasodilatation and the formation 
of new blood vessels (Hunter, 1794). He also suggested that the swelling was due to 
plasma exudation and that the pain was caused by hyperalgesia. Further advances 
were made by Cohnheim (Cohnheim, 1882). Using microscopic techniques on frog 
blood vessels, he traced the migration of white cells from the vasculature into the 
tissues. He proposed that it was this initial humoral response, arising from vascular 
changes due to a given stimulus, that was the basis of inflammation. In contrast, 
Metchnikoff recognised the phagocytic role of cells in the removal of microbial 
infection and proposed a cellular basis to the inflammatory response (Metchnikoff,
1893). It is now clear that both the humoral and cellular theories are very closely 
linked.
The inflammatory response involves the infiltration of circulating blood cells into the 
site of infection. Their primary role is to eliminate foreign particles, whether in the 
form of bacterial, viral or parasitic organisms. The roles played by the infiltrating cells 
are very different. Neutrophils and monocytes are involved in phagocytosis, basophils 
with the release of inflammatory mediators such as histamine and eosinophils in the 
destruction of larger parasitic infections by degranulation and release of toxic 
substances. Lymphocytes play an important role in the production of antibodies and 
the acquired immune response.
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1.2 Adhesion molecules
Although it was Cohnheim who first observed that before leukocytes migrated into a 
tissue they engaged in an adhesion interaction with endothelial cells, it has only been 
over the last ten years that a number of ligand-counterligand molecules have been 
identified on leukocytes and endothelial cells. It is these adhesion molecules which 
provide the basis for leukocyte-endothelial cell adhesion (Butcher, 1991) (Springer,
1994) (Carlos & Harlan, 1994).
There are three main structural classes of adhesion molecules which are found on 
leukocytes and endothelial cells and these are summarised in table 1.1. The integrins 
are found on leukocytes, the Ig superfamily members on endothelial cells and the 
selectins on both cell types. It has become clear that there are three main steps 
involved in the transmigration of leukocytes into the site of inflammation and these are 
summarised in figure 1.1.
The first step involves the rolling of leukocytes along the surface of the endothelium 
and this can be recreated in vitro under conditions of shear stress using cultured 
endothelial cells (Lawrence et ai. 1990). This initial rolling is mediated by L-selectin on 
leukocytes and P- and E- selectin on the endothelial layer (Lawrence & Springer, 
1991). Interestingly, L-selectin is shed upon leukocyte activation and if the leukocytes 
becomes activated before their initial contact with the endothelium then they lose their 
ability to adhere and transmigrate (Kishimoto etal. 1989).
The second adhesion step involves the integrins and their counter-receptors the Ig 
superfamily. This second adhesion step cannot take place under conditions of shear 
stress if the preceding selectin-mediated step does not occur (Lawrence & Springer,
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Table 1.1 - Receptors involved in leukocyte adhesion to the endothelium. The integrins are upregulated on leukocytes in response 
to various stimuli. Expression of the Ig superfamily on endothelial cells increases upon stimulation by pro-inflammatory stimuli such as 
IL-1 and TNF (except ICAM-2 which is constitutively expressed) as are the endothelial selectins. L-selectin is rapidly shed from activated 
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Figure 1.1 - Diagram to represent leukocyte transmigration. There are three stages involved in the infiltration 
of leukocytes into the site of inflammation. These three stages are characterised by the expression of various 
adhesion molecules. The chemokines play an important role in the upregulation of integrins for the firm adhesion 
of leukocytes as well as providing a chemotactic concentration gradient down which they can migrate.
1991). It allows firm adhesion of the leukocytes to the endothelial cells which is crucial 
for emigration and which is not provided by the selectins. The use of monoclonal 
antibodies has provided vital evidence for the interaction between various members of 
the adhesion molecule families on leukocytes and endothelial cells. It is mainly 
CD11b/CD18 that has been found to be of importance in the firm adhesion of 
leukocytes (Luscinskas etal. 1991) (Meerschaert & Furie, 1995). More recently, VLA- 
4 has also been shown to play a part in this firm adhesion (Meerschaert & Furie,
1994).
It is the continued expression of the integrins and Ig superfamily members that leads 
to the eventual transmigration of the leukocytes into the extravascular space. The Ig 
superfamily members are expressed at the intercellular junctions which direct the cells 
through the endothelial layer.
Thus, the movement of leukocytes from the peripheral vasculature into a site of 
inflammation involves the expression of these adhesion molecules on both leukocytes 
and endothelial cells. Although the expression of these molecules is very similar in all 
leukocytes, the arrival of leukocytes into a site of inflammation is kinetically different. 
For example; 1) there is a characteristic absence of monocytes in acute inflammatory 
responses but higher numbers are observed in chronic inflammation and 2) the 
chronic responses characterised by large numbers of monocytes are quite often 
preceded by a neutrophil mediated acute phase. This is particularly important 
considering that these cells perform different roles in an inflammatory site and thus, 
neutrophils appear more important in acute inflammation and monocytes in chronic 
inflammation. Some of the well characterised chemotactic factors such as C5a, 
leukotriene B4 (LtB4) and formyl methionyl leucyl phenylalanine (fMLP) are potent 
inducers of both monocyte and neutrophil chemotaxis but they cannot explain the
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differential appearance of these leukocytes as they do not show any leukocyte 
specificity.
There are a number of possible explanations for these differences. Firstly, it could 
simply be a question of relative leukocyte numbers. Granulocytes make up about 
80% of the circulating blood leukocytes and it may be that the infiltration of monocytes 
is masked by the neutrophils. Secondly, the positioning of the circulating cells may be 
important. Neutrophils marginate very close to the endothelial layer under normal 
conditions, unlike monocytes. Therefore, the delay in monocyte infiltration may be 
due to the prolonged time taken for the monocytes to interact with the endothelium. 
Thirdly, the presence of leukocyte specific factors which attract distinct leukocyte 
subsets may explain the disparate appearance of these leukocyte subtypes.
Concerning the third point, a breakthrough was made in 1987, when a neutrophil 
specific chemoattractant was isolated from lipopolysaccharide (LPS)-stimulated 
human monocyte-conditioned media (Yoshimura etal. 1987). This monocyte-derived 
neutrophil chemotactic factor (MDNCF) was isolated by a number of groups and given 
various names including neutrophil activating factor (NAF) (Baggiolini etal. 1989), 
granulocyte chemotactic factor (GCF) (Van Damme etal. 1988), neutrophil 
chemotactic factor (NCF) (Strieter et al. 1989) and polymorph stimulating factor (PSF) 
(Watson etal. 1989a) (Watson etal. 1988). All these groups had discovered a 
peptide of approximately 72 amino acids in length containing four cysteine residues.
At a symposium entitled ‘Novel neutrophil stimulating peptides’, the decision was 
made to call this peptide interleukin-8 (IL-8) (Westwick etal. 1989).
Examination of the amino acid sequence of IL-8 led to the discovery of a group of 
proteins with conserved sequences which had been first identified as early as 1977 
(Deuel etal. 1977). The increasing number of these chemotactic cytokines (Lindley et
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al. 1993) and the discovery of two separate sub-families led to the term chemokines 
being adopted for all the conserved peptides.
1.3 Chemokines
All the members of the chemokine family have molecular weights of between 8-10kDa 
and they are basic heparin binding polypeptides. They are characterised by the 
presence of four conserved cysteine residues (review (Oppenheim etal. 1991)).
There are two main subfamilies which can be distinguished by the position of the first 
two of the four cysteine residues. The C-X-C group, of which IL-8 is the best known 
member, possess an amino acid which separates the first two cysteine residues. In 
the C-C group, the two cysteine residues are juxtapositioned. Members of this group 
include monocyte chemotactic peptide-1 (MCP-1), regulated on activation normal T 
cell expressed and secreted (RANTES) and macrophage inflammatory protein (MIP)- 
1a and -1p.
The two chemokine sub-families differ both in their cell specificity and their 
chromosomal location. The C-X-C chemokines activate neutrophils and lymphocytes 
but not monocytes and their genes are co-localised on chromosome 4. The C-C 
chemokines activate monocytes, lymphocytes, basophils and eosinophils but not 
neutrophils and their genes are clustered on chromosome 17.
Very recently, a third chemokine subfamily, the C chemokines have been identified 
(Kelner et al. 1994). To date, only one member has been isolated and it has been 
named lymphotactin, due to its chemotactic properties for T lymphocytes. It only 
possesses the second and the fourth cysteine residue and its gene is positioned on 
chromosome 1.
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A full listing of the human C-X-C, C-C and C chemokines is shown in table 1.2, and is 
current up to September 1996. The chemokines represented in bold in the table, 
indicate those which have been discovered in the last three years, that is during my 
research project.
1.3.1 C-X-C chemokines
The C-X-C chemokines are known to be released from a number of different cells in 
response to pro-inflammatory agents such as LPS, interleukin-1 a (IL-1 a), tumour 
necrosis factor a (TNFa) and phytohemagglutinin (PHA). These cells include 
monocytes (Yoshimura etal. 1987) (Haskill etal. 1990), neutrophils (Takahashi etal.
1993), epithelial cells (Cromwell etal. 1992), endothelial cells (Sica etal. 1990). 
fibroblasts (Golds et al. 1989) (Watson et al. 1989b) mesangial cells (Brown et al. 
1991) and microvascular endothelial cells (Brown etal. 1994).
The C-X-C chemokines were originally reported as specific neutrophil activators with 
IL-8 inducing neutrophil chemotaxis (Schroeder & Christophers, 1992), degranulation 
and lysosomal enzyme release (Thelen et al. 1988), increased release of LtB4 (Smith 
etal. 1992) and increased adherence to unstimulated endothelial cells (Carveth etal.
1989). More recently, IL-8 has also been observed to induce chemotaxis and the 
release of histamine from basophils (Krieger etal. 1992) as well as attract particular 
sub-sets of T lymphocytes (Larsen etal. 1989) (Bacon etal. 1989).
1.3.2 C-C chemokines
The C-C chemokines are produced by a number of different inflammatory and non­
inflammatory cells including monocytes (Yoshimura etal. 1989b) (Chang etal. 1989), 
endothelial cells (Antoniades etal. 1992) (Brown etal. 1992) epithelial cells 
(Standiford etal. 1991) and fibroblasts (Bedard etal. 1993) (Watson etal. 1995). 
Their production is in response to various pro-inflammatory stimuli such as IL-1 a,
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TNFa and LPS. The C-C chemokines are potent activators of monocytes, 
eosinophils, lymphocytes and basophils, stimulating responses such as chemotaxis, 
histamine release, intracellular calcium rise and respiratory burst.
1.3.3 Chemokine receptors
A full listing of all the chemokine receptors identified to date is given in table 1.3. The 
receptors in the shaded boxes indicate those which have been identified in the last 
three years and demonstrate that the chemokine receptor list is in no way complete.
1.3.3.1 C-X-C chemokine receptors
By 1991, the effects of the C-X-C chemokines had been attributed to their ability to 
bind to and activate receptors on the surface of the neutrophils (Moser et al. 1991). It 
was Holmes etal. that first reported the cloning of a high affinity IL-8 receptor from a 
neutrophil cDNA library. This receptor bound IL-8 with high affinity but did not bind 
other members of the C-X-C chemokine group (Holmes etal. 1991).
Melanocyte growth stimulatory activity (MGSA), another C-X-C member, had also 
been observed to bind to human neutrophils and compete for the IL-8 binding sites 
and so this group went on to isolate and clone a second, distinct high affinity IL-8 
receptor which also had a high affinity site for MGSA (Lee etal. 1992). These 
receptors were named IL-8 type A and IL-8 type B receptors respectively. They did 
not bind other, unrelated chemotactic factors such as C5a or fMLP.
Both of these receptors possess seven transmembrane domains which are typical of 
receptors linked to heterotrimeric G-proteins (Boulay etal. 1990) (Gerard & Gerard,
1994). The role of the G-proteins in IL-8 receptor signal transduction was further 
confirmed by the inhibition of the calcium responses by pertussis toxin, known to 
inactivate the Gr and G0-type G-proteins by adenosine diphosphate (ADP)- 
ribosylation (Thelen etal. 1988).
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Table 1.2 - Members of the human chemokine family. The chemokine family is 
divided into three main sub-families, namely the C-X-C, C-C and C, based on the 
arrangement of the first two cysteine residues. The C-X-C group is then further sub­
divided into E-L-R and non-E-L-R members, depending on the presence/absence of 
the E-L-R residues immediately upstream of the C-X-C motif. Three of the C-X-C (E- 
L-R) group are also separate as they are all derived from platelet basic protein (PBP) 
and are breakdown products of each other i.e. p-TG is a cleavage product of PBP 
which is cleaved to produce CTAP-III which is in turn cleaved to produce NAP-2. The 
asterisks indicate chemokines which have, to date, only been identified in mouse or 




IL-8 (Baggiolini et al. 1989)
MGSA/gro a, p, y (Thomas et al. 1991)
C-X-C ENA78 (Walz etal. 1991)
(E-L-R) SDF-1a/1 p (Tashiro etal. 1993)
GCP-2 (Proost et al. 1993)
MIP-2 (Wolpe et al. 1989)
*LIX (Smith & Herschman, 1995)
C-X-C (E-L-R) P-TG (Begg et al. 1978)
(platelet basic protein CTAP-III (Castor et al. 1983)
cleavage products) NAP-2 (Farber, 1993)
C-X-C PF-4 (Deuel etal. 1977)
(non E-L-R) IP-10 (Luster & Ravetch, 1987)
Mig (Farber, 1993)
10






RANTES (Schall et al. 1988)
MCP-1 (Leonard & Yoshimura, 1990)
MCP-2 (Van Damme et al. 1992)
C-C MCP-3 (Van Damme et al. 1992)
MCP-4 (Uguccioni etal. 1996)
MIP-1a (Obaru et al. 1986)
MIP-ip (Lipes et al. 1988)
Eotaxin (Ponath et al. 1996)
I309/TCA3 (Miller etal. 1989)
*MRP-1/C10 (Orlofsky et al. 1994)
*MRP-2 (Youn et al. 1995)
*CCF18 (Hara et al. 1995)
*MIP-1y (Mohamadzadeh et al. 1996)
C Lymphotactin (Kennedy et al. 1995)
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Very recently (September 1996), two more C-X-C chemokine receptors were 
identified. These have been named CXC R3 and CXC R4 respectively. CXC R3 has 
been observed to bind monokine induced by gamma interferon (Mig) and IP-10. CXC 
R4 was originally described as an orphan chemokine receptor in 1993 by Loetscher et 
al. and called leukocyte-expressed seven-transmembrane-domain receptor (LESTR). 
Until recently, no ligands for this receptor had been found but it has now been 
observed to bind the C-X-C chemokine stromal-cell-derived factor-1 (SDF-1) 
(Loetscher et al. 1996) (Bleul et al. 1996). Due to the nomenclature adopted for these 
two receptors, the IL-8 RA and RB receptors are now also known as CXC R1 and 
CXC R2 respectively (Gordon Conference on Chemokines, 1996).
1.3.3.2 C-C chemokine receptors
The C-C chemokines were found to bind to high affinity receptors on the cell surface 
(Yoshimura & Leonard, 1990). The presence of multiple receptors for the various 
members of the C-C family were discovered by desensitisation experiments in which 
the calcium responses become desensitised upon repeated stimulation of the same 
receptor.
It was Neote et al. who cloned the first C-C chemokine receptor (CC CKR 1) from a 
number of different hematopoetic cell types known to respond to the C-C chemokines 
(Neote et al. 1993). This receptor was found to produce a calcium response to very 
low concentrations of MIP-1a and RANTES when transfected into human embryonic 
kidney (HEK) 293 cells. No effects were seen in the presence of either C-X-C 
chemokines or unrelated chemoattractant factors such as fMLP or C5a. However, this 
receptor did not account for the potent responses to other C-C chemokines such as 
MCP-1 (Van Riper etal. 1993).
12
In the last two years a number of C-C chemokine receptors have been identified. 
Firstly, Charo etal. cloned two high affinity MCP-1 receptors from monocytes. These 
receptors possess alternatively spliced C-terminal tails and have been named C-C 
CKR 2A and 2B (Charo etal. 1994). When expressed into human embryonic kidney 
(HEK) 293 cells they were confirmed as high affinity binding sites for MCP-1 and they 
were also found to bind MCP-3 (Franci etal. 1995).
Within the last year, two groups have identified a CC chemokine receptor (CC CKR 3) 
which is only found in eosinophils although there is some dispute as to the ligands 
which bind to it (Combadiere etal. 1995a) (Kitaura etal. 1996) (Daugherty etal. 1996) 
(Combadiere etal. 1995b). Two other CC chemokine receptors, namely CC CKR 4 
and CC CKR 5, have also been identified. CC CKR 4 is found primarily on basophils. 
CC CKR 5 has not been fully characterised (Combadiere et al. 1995a) (Combadiere et 
al. 1995b) although, recently Samson et al. reported a new CC chemokine receptor 
which has been identified in a promyeloblastic cell line and which they have tentatively 
named CC CKR 5 (Samson etal. 1996). The CC CKR 5 has also recently been 
identified on human monocytes, macrophages and T-cells (Deng etal. 1996).
All the known C-C chemokine receptors possess the same structure as the C-X-C 
chemokine receptors with seven transmembrane spanning domains linked to 
heterotrimeric G-proteins. This was confirmed by the sensitivity of the C-C chemokine 
responses to pertussis toxin (Sozzani etal. 1991).
1.3.3.3 Other chemokine receptors
There is one other main chemokine receptor known as the Duffy antigen receptor for 
chemokines (DARC). This is the same as the Duffy blood group antigen that is found 
on red blood cells and has been found to be the binding site for both C-X-C and C-C 
chemokines as well as the malaria parasite Plasmodium wVax(Horuk etal. 1993).
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Table 1.3 - Members of the chemokine receptor family. Where binding affinities have not been reported the chemokines which elicit 
a response have been included as binding to the receptors. The receptors in the shaded boxes were discovered following the start of this 
project.
Chemokine Receptor Agonist Expression Reference
IL-8 RA 
(CXC R1)
High affinity IL-8 
Low affinity MGSA




High affinity IL-8 
High affinity MGSA
Neutrophils, T cells Lee et al. 1992
CXC R3 Binds Mig and IP-10 ? Loetscher et al. 1996
CXC R4 Binds SDF-1 T cells, monocytes Bleul etal. 1996
CC CKR 1 High affinity MIP-1oc, RANTES and MCP-3 
Low affinity MCP-1 and MIP-1{3
HL60, U937, THP-1, B cells, T 
cells , neutrophils, monocytes, 
(eosinophils?)
Neote etal. 1993 
Gao et al. 1993 
Combadiere etal. 1995
CC CKR 2A 
and 2B
High affinity MCP-1 
Binds MCP-3 with slightly lower affinity
Monocytes, THP-1, 
MonoMac 6
Charo et al. 1994 
Franci etal. 1995
C-C CC CKR 3 Binds eotaxin 
High affinity for eotaxin, RANTES and MCP-3
Eosinophils, small amount on 
neutrophils and monocytes
Kitaura et al. 1996 
Daugherty et al. 1996
CC CKR 4 Binds MIP-1a, RANTES and MCP-1 KU812, T cells, B cells, 
monocytes, platelets
Power et al. 1995
CC CKR 5 Binds MIP-1a, MIP-ip and RANTES ?
KG-1A promyeloblastic cell line 
Monocytes, macrophages, T cells
Combadiere et al. 1995 
Samson etal. 1996 
Deng etal. 1996
Promiscuous DARC Binds all C-X-C and C-C chemokines except 
MIP-1a and MIP-ip
Red blood cells, postcapillary 
venule endothelial cells, T cells, 
B cells
Darbonne etal. 1991 
Hadley et al. 1994 
Wallace etal. 1995
Unlike all the other chemokine receptors DARC appears to have nine transmembrane 
spanning domains and is not coupled to heterotrimeric G-proteins (Chaudhuri et al. 
1993). Recently, binding studies have been performed to examine which of the C-X-C 
and C-C chemokines bind to DARC (Chaudhuri etal. 1994). The only chemokines 
found not to bind to this promiscuous receptor were MIP-1a, MIP-113 and the C 
chemokine lymphotactin (Szabo etal. 1995).
Whether DARC tranduces a biological signal is not clear and the exact role of DARC 
has not yet been fully elucidated. It has been proposed as a ‘sink’ for IL-8 and other 
chemokines, keeping their levels in the circulation low (Darbonne etal. 1991). 
Interestingly, IL-8 which is bound to DARC on red blood cells cannot facilitate 
neutrophil activation. The fact that DARC is also expressed on endothelial cells lining 
the postcapillary venules indicates that it may play a role in the chemokine gradient 
and the leukocyte-endothelial cell interaction (Hadley etal. 1994). Also, the 
expression of DARC on T cells and the finding that antibodies to DARC induce 
proliferation of certain T cell subsets, could indicate a biological role for DARC 
(Wallace etal. 1995) (Horuk etal. 1996).
1.3.4 Role of chemokines in disease
The chemokines have been identified in a number of different diseases in the past few 
years. For example, the C-X-C chemokine IL-8 has been identified in psoriatic scales 
as well as in patients with eczema (Schroder etal. 1992) and in patients with 
rheumatoid arthritis (Seitz etal. 1991), osteoarthritis and gout (Rampart etal. 1992). 
IL-8 is also increased in alveolar macrophages from patients with idiopathic pulmonary 
fibrosis (Carre etal. 1991).
C-C chemokines have also been identified in a number of diseases including asthma 
(Sousa etal. 1994), rheumatoid arthritis (Koch etal. 1992) and atherosclerosis 
(Nelken etal. 1991). Interestingly, RANTES, MIP-1 a and MIP-1 p have been identified
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as major human immunodeficiency virus (HlV)-suppressive factors (Cocchi et al.
1995) and in Vol 381 of Nature published in June 1996 Dragic etal. reported that the 
CC CKR5 had been identified as the second receptor for primary non-syncytium- 
inducing HIV-1 (NSI HIV-1) strains and MIP-1 a, MIP-1 p and RANTES all inhibited 
infection of the CD4+ T cells at the virus entry stage (Dragic et al. 1996).
1.4 Role of adhesion molecules and chemokines in leukocyte 
migration
It is interesting to note that both chemokines and adhesion molecules play an 
important and closely related role in leukocyte migration. The chemokines are 
important in both the upregulation of integrins on the surface of leukocytes as well as 
in directing the leukocytes to the site of inflammation (see figure 1.2). The chemokine 
induced direction of leukocytes can occur by one of two mechanisms, chemotaxis or 
haptotaxis. In chemotaxis, the cells move in the direction of increasing concentration 
of a soluble chemokine. Its concentration is greatest at its site of production and 
diffuses away (Devreotes & Zigmond, 1988). In haptotaxis, the chemokine becomes 
bound to the surface of the endothelial cells, for example to surface proteoglycans. A 
chemokine gradient is still formed but it is fixed to the endothelial layer. There is still 
some controversy as to which mechanism is demonstrated In vivo (Rot, 1992). The 
haptotactic response may be more important when considering the fact that soluble 
chemokines released into the blood stream would be rapidly diluted and swept 
downstream. Although this would provide a gradient it may be quickly dispersed. 
Chemokines attached to the endothelium would be able to form a gradient but it would 
be more easily accessible to the leukocytes as they rolled along the endothelium.
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Therefore, the adhesion and subsequent transmigration of leukocytes into a site of 
inflammation does not only require one signal but a number of consecutive signals 
which together lead to leukocyte migration.
1.5 Monocyte chemotactic peptide-1
Of particular interest in this study was the C-C chemokine MCP-1 and its effects on 
human monocytes.
1.5.1 Identification of MCP-1
In 1973, Altman etal. reported that the stimulation of blood mononuclear leukocytes 
by tuberculin caused the production of a chemotactic factor for human monocytes 
(Altman etal. 1973). They later referred to this molecule as leukocyte-derived 
chemotactic factor (LDCF) (Altman, 1978). It was ten years later that Yoshimura et al. 
purified monocyte chemotactic activity (MCA) from PHA stimulated human peripheral 
blood mononuclear cells (PBMC) (Yoshimura etal. 1989b). Due to the limited amount 
of MCA which could be collected from these cells this group went on to discover that 
the human gliomal cell line U-105MG also secreted this protein (Yoshimura etal. 
1989a). Large enough quantities were then obtained to purify, sequence and clone 
this protein which they named MCP-1. This group also proposed that MCP-1 is the 
monocyte chemotactic activity first identified by Altman etal. some fifteen years 
earlier.
Concurrently, Valente etal. isolated a monocyte chemotactic peptide from baboon 
aortic smooth muscle cells which they called smooth muscle cell derived chemotactic 
factor (SMC-CF) (Valente etal. 1988). Examination of the peptide sequence identified 
that SMF-CF was identical to MCP-1.
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1.5.2 MCP-1 structure
Figure 1.2 - Amino acid sequence and structure of MCP-1. The parallel lines 
indicate where the four cysteine residues form disulphide bonds. The one letter amino 
acid codes are as given in the abbreviations list. (Figure taken from Baggiolini et al. 
1994).
Figure 1.2 shows the structure of MCP-1 which is characterised by two intrachain 
disulphide bonds. The precursor for MCP-1 is a polypeptide of 99 amino acids. The 
mature 76 amino acid peptide possesses a long C-terminal sequence and a short N- 
terminal sequence. Synthesis of MCP-1 analogues which lack the amino terminal 
region have identified it as crucial for receptor binding and for functional activity 
(Gong & Clark-Lewis, 1995) (Zhang et al. 1994). Deletion of residues 7-10 prevented 
receptor desensitisation and removal of residues 1 -6 inhibited functional activity. 
Although these N-terminal residues are important for functional activity other regions 
of the protein are also required as a peptide of residues 1-10 was inactive by itself. 
These structure-activity relationships have also led to the proposal that MCP-1 forms 
dimers in physiological conditions (Zhang etal. 1994). By chemically cross-linking 
MCP-1 dimers and studying their activity compared to non-cross-linked MCP-1, the
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role for MCP-1 dimerisation was investigated (Zhang & Rollins, 1995). Both the cross- 
linked and non-cross-linked MCP-1 peptides were equipotent at inducing monocyte 
chemotaxis, indicating that MCP-1 is functionally active in the dimeric form. More 
extensive studies using heteronuclear multidimensional nuclear magnetic resonance 
have confirmed that MCP-1 does form homodimers, although the exact role of 
monomers versus dimers in vivo is still not entirely clear (Handel & Domaille, 1996).
MCP-1 occurs as two electrophoretically distinct forms due to its glycosylation. Both 
the 9kDa and the 13kDa MCP-1 variants are equipotent biologically (Jiang et ai.
1991).
1.5.3 Biological effects of MCP-1
MCP-1 is a particularly potent basophil degranulator and monocyte activator (Sozzani 
etal. 1991) (Alam etai. 1992). The main effects of MCP-1 on basophils include the 
rise in intracellular free calcium, histamine release and the generation of leukotriene 
C4 (LtC4) in interleukin-3 (IL-3), interleukin-5 (IL-5) and granulocyte-macrophage- 
colony stimulating factor (GM-CSF) pre-treated basophils (Bischoff etal. 1992). The 
activation and subsequent release of pro-inflammatory agents from basophils is of 
primary importance in the maintenance of the inflammatory response.
The effects of MCP-1 on monocytes have not been studied in detail. When MCP-1 
was first purified from PHA stimulated human blood mononuclear leukocytes it was 
observed to induce a chemotactic response in human monocytes (Yoshimura et al. 
1989b). In 1990, Zachariae etal. discovered that MCP-1 activated monocyte 
functions such as cytostatic activity against tumour cells and lysosomal enzyme and 
superoxide anion release (Zachariae etal. 1990). In 1991, Sozzani etal. extended 
this study to characterise the MCP-1-induced monocyte chemotaxis and intracellular 
calcium rises and to identify their sensitivity to pertussis toxin (Sozzani et al. 1991).
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This group went on to look at the rise in intracellular calcium and identified a calcium 
influx pathway activated by MCP-1, unrelated to voltage operated calcium channels 
(Sozzani etal. 1993).
At about the same time, the effects of MCP-1 on the cell surface expression of certain 
adhesion molecules involved in monocyte migration and diapedesis were investigated 
(Jiang etal. 1992). The results showed that MCP-1 was capable of upregulating two 
of the (32 integrins studied, further identifying a role for MCP-1 in inflammation via the 
activation of monocytes. However, the signal transduction pathways involved in this 
adhesion molecule upregulation and other monocyte functional responses were not 
investigated and, until the start of my project, this was the only data available on the 
activation of monocytes by MCP-1.
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1.6 Signalling pathways
The binding of an agonist to its receptor expressed on the surface of a cell leads to 
the activation of intracellular signalling pathways followed by the induction of a 
functional response. The initial coupling of the receptor to the signalling cascade can 
occur via the activation of either protein tyrosine kinases (PTK) or through the 
activation of G-proteins.
PTKs can be subdivided into two groups, the transmembrane receptor family and the 
cytosolic non-receptor family (review (Hunter, 1995)). Signalling of the receptor PTK 
family involves ligand-mediated receptor dimerisation which results in the 
transphosphorylation of the receptor subunits within the dimer and activation of the 
PTK. Some examples of receptors with this intrinsic PTK activity include the 
epidermal growth factor receptor (EGFR), the platelet derived growth factor receptor 
(PDGFR) and the insulin receptor. The receptors coupled to the non-receptor PTKs 
do not possess a PTK catalytic domain but signal through the interaction of one of the 
receptor subunits with the non-receptor PTKs. By far the most well characterised 
family of non-receptor PTKs is the Src family of tyrosine kinases. Examples of the 
receptors which signal through non-receptor PTKs include cytokine receptors, such as 
IL-3 and IL-5, as well as the T cell and B cell antigen receptors. It is the Jak and the 
Src family non-receptor PTKs respectively that serve as the signalling molecules for 
these receptors.
There are a number of receptors which, rather than coupling to PTKs, couple to G- 
proteins (reviews (Birnbaumer, 1990) (Clapham & Neer, 1993)). G-proteins consist of 
three subunits, the a, p and y subunits. When a G-protein-coupled receptor, which 
usually possesses a seven transmembrane domain topology, is bound by an agonist, 
it leads to the activation of the G-protein. Upon activation, the a subunit binds GTP 
and dissociates from the py subunit. It was originally proposed that only the a subunit
21
controlled the activity of the effectors, following the observation that the a subunit 
activated adenylyl cyclase and retinal cyclic GMP phosphodiesterase. However, it is 
now clear that both the a and the py subunits can activate a number of cellular 
enzymes and ion channels. It is the intrinsic GTPase activity of the a subunit that 
leads to GTP hydrolysis, the reassociation of the a with the py subunit and inactivation 
of the G-protein. Some examples of the receptors that are coupled to G-proteins 
include chemokine receptors, the fMLP receptor and the C5a receptor.
The following section will discuss two signalling pathways, namely the relatively well 
characterised phospholipase C (PLC) pathway and the putative signalling cascade 
regulated by phosphatidylinositol 3-kinase (PI 3-kinase). Both PTKs and G-proteins 
have been implicated in the activation of PLC and PI 3-kinase isoforms.
1.6.1 Phospholipase C
Elevations in intracellular calcium have been found to be instrumental in a number of 
different cellular processes including fertilisation, cell growth, smooth muscle 
contraction, neuronal conductance and sensory perception (Berridge, 1993). It has 
been during the last fifteen years that a role for PLC and its products have been 
identified (Berridge, 1984) (Streb etal. 1983). PLC catalyses the formation of inositol 
(1,4,5) trisphosphate (IP3) and diacylglycerol (DAG) from the hydrolysis of their 
membrane bound substrate phosphatidylinositol (4,5) bisphosphate (Ptdlns (4,5)P2). 
The IP3 then binds to IP3 receptors on the endoplasmic reticulum and stimulates the 
release of intracellular calcium stores and, in some cases, regulates calcium entry 
(see section 1.6.1.3). DAG binds to and activates several isoenzymes of the protein 
kinase C (PKC) superfamily (Nishizuka, 1988).
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1.6.1.1 PLC subtypes and their activation
The PLC family is sub-divided into three groups (p, y, 8) which differ in the method of 
their activation. Each of these groups consists of more than isoform. The members 
of the PLC family are summarised in table 1.4.
Table 1.4 - PLC isoforms identified in mammalian tissues. Summary of the PLC
isoforms and their methods of activation. Activators in brackets activate these 
isoforms to a lesser extent
PLC isoforms Activators
P i 1-  a-subunit of Gq G-protein (py-subunit of Gi-G-protein)
P2 J
Ps a-subunit of Gq G-protein and py-subunit of Gi G-protein
Yi Receptor -coupled or non-receptor -coupled tyrosine kinase
Y2 receptors via SH2 domain of PLC
81 -1
82 -  ? - calcium -sensitive isoform of the enzyme?
83 -
1.6.1.1.1 PLC B activation
The PLC-p family is sub-divided into Pi, P2 and p3> as well as no receptor potential 
(norp) A, found in Drosophila. They are activated by heterotrimeric G proteins (review 
Sternwies & Smrcka, 1992). Activation of a G-protein-coupled receptor leads to the 
exchange of guanosine diphosphate (GDP) for guanosine triphosphate (GTP) on the 
a-subunit. This is facilitated by Mg2+ which binds to the G(GDP) complex and causes 
GDP to dissociate and allows GTP to bind to the a subunit (Birnbaumer, 1990). This 
leads to the dissociation of the a-subunit from the py-subunit. PLC p isoforms can be 
activated by both the a subunits of the Gq class and by the py subunits, depending on 
the agonist (Wu etal. 1993) (Katz etal. 1992). For example, the a subunit activates
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PLC p following thromboxane A2, bradykinin and histamine receptor stimulation 
(Shenker etal. 1991) (Rozengurt, 1986). The Py subunits activate PLC p following the 
muscarinic m2 and IL-8 receptor stimulation (Park etal. 1993) (Thelen etal. 1988). 
These subunits bind to different sites on the PLCp molecule, with the py subunits 
binding to the N-terminal and the a subunit binding to the C-terminal region of PLC p 
(Clapham & Neer, 1993). Once activated, the PLC p can hydrolyse Ptdlns(4,5)P2 to 
produce IP3 and DAG. This reaction is turned off by the hydrolysis of the GTP to GDP 
by the GTPase activity associated with the a-subunit. The a-subunit then recombines 
with the py-subunit and the complex is inactive once more (figure 1.3a).
1.6.1.1.2 PLC v activation
The PLC-y family is sub-divided into yi and y2 and these PLC members are activated 
by tyrosine kinase-linked receptors. Specific tyrosine residues become 
phosphorylated by either receptor-coupled tyrosine kinases, as for platelet derived 
growth factor (PDGF), or by non-receptor-coupled tyrosine kinases such as src 
kinases in the case of the T cell receptor (TCR) (Samelson etal. 1990). These 
phosphorylated tyrosine residues provide docking sites for the src homology 2 (SH2) 
domains of the PLC-y. PLCy, which is usually present in the cytosol, then becomes 
located very close to the plasma membrane where its substrate is positioned. Once 
the enzyme has become attached to these docking sites the PLC-y is itself 
phosphorylated on specific tyrosine residues and then begins to hydrolyse 
Ptdlns(4,5)P2. This reaction is switched off by the uncoupling of the PLC-y from the 
tyrosine residues on the receptor and dephosphorylation (figure 1.3b).
1.6.1.1.3 PLC 5 activation
The exact role of the PLC-5 is not well characterised. There are three members of 
this family, namely 82 and 83. It is possible that it may be a calcium sensitive form
24
AGONIST




Ptdlns(4,5)P2-^ -Yp ^ r^ r







Figure 1.3 - Activation of PLC. a) The activation of PLC-p by heterotrimeric G-proteins. Upon receptor activation 
the Ga subunit dissociates from the Gpy subunit and both of these subunits can then activate different isoforms 
of PLCp depending on the cell type. The hydrolysis of GTP for GDP on the a subunit inactivates the system, 
b) The activation of PLC-y by either receptor-coupled (clear box) or non-receptor-coupled (filled circle) tyrosine 
kinases. Specific residues on the receptor become phosphorylated which then provide a docking site for PLCy. 
Upon phosphorylation of PLC Ptdlns(4,5)P2 is hydrolysed. The reaction is turned off by dephosphorylation and 
uncoupling of PLC (adapted from Berridge, 1993).
of the enzyme due to the specific motifs it contains and its enzymatic activity observed 
in the micromolar concentration range of calcium (Bairoch & Cox, 1990).
The PLC product IP3 subsequently binds to receptors on the intracellular calcium 
stores, most probably the endoplasmic reticulum and induces calcium mobilisation 
(Berridge & Irvine, 1989). The structure of the IP3 receptors and their role in calcium 
mobilisation has been well characterised.
1.6.1.2 IP3 receptors and their function
The IP3 receptor possesses two properties, namely an IP3 binding property and a 
calcium release channel property. There are three main members of the IP3 receptor 
family, IP3 receptor (IP3R) 1,2 and 3 and they are all characterised as large, tetrameric 
proteins with a molecular weight of about 300kDa and six membrane spanning regions 
(Furuichi et al. 1989). The C-terminal domain of each tetramer is the membrane 
spanning domain which anchors the receptor in the membrane and the N-terminal 
domain lies free in the cytoplasm and contains the IP3 binding site (Mignery & Sudhof, 
1990). Upon binding of IP3 to its receptor, the receptor undergoes a conformational 
change which most probably leads to the opening of a channel in the centre of the IP3 
receptor. However, there is some controversy as to whether channel opening 
depends on the sequential binding of IP3 to all four binding sites, each binding step 
inducing partial opening of the channel, or whether the binding of a single IP3 
molecule is sufficient for channel opening (Meyer & Stryer, 1990) (Watras etal. 1991).
Once IP3 has bound to its receptor it can then either be metabolised by a 5- 
phosphatase to produce inositol (1,4) bisphosphate (IP2) (Connolly etal. 1986) or it 
can be phosphorylated by a 3-kinase to produce inositol (1,3,4,5) tetrakisphosphate 
(IP4) and even higher polyphosphoinositols (Koppler etal. 1993).
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As well as calcium mobilisation from the intracellular calcium stores there is also a 
second source of intracellular calcium, namely influx from the extracellular medium. 
Upon activation of the cell, calcium has been demonstrated to enter the cells through 
channels operated by a number of different mechanisms such as voltage operated 
channels (VOC), receptor operated channels (ROC) and second messenger operated 
channels (SMOC).
There are six classes of VOCs, namely L, N, P, T, R and Q, which have been defined 
on the basis of their physiological and pharmacological properties (review (Godfraind 
& Govoni, 1995)). Interestingly, monocytes, as well as neutrophils, are two of a 
number of blood derived cells which do not possess VOCs (Merritt et al. 1989) 
(Sozzani et al. 1993) as defined by the lack of calcium influx in the presence of 
depolarising concentrations of potassium as well as by the lack of inhibition of agonist- 
induced elevations of [Ca2+]j by agents such as nifedipine, diltiazem and verapamil, 
which interact with VOCs (Hagiwara & Byerly, 1981). ROCs have been proposed to be 
activated by a variety of agonists on cell types such as endothelial cells, platelets and 
parotid acinar cells as well as monocytes (Mendolesi etal. 1991) (Sozzani etal. 1993). 
With regard to the SMOCs, IP3 and IP4 have both been thoroughly investigated (Irvine,
1990). Although IP3 and IP4-sensitive calcium channels have been identified on the 
surface of a number of cells, such as lymphocytes (Khan etal. 1992), olfactory cells 
(Kalinoski etal. 1992) and endothelial cells (Luckhoff & Clapham, 1992) this is not the 
only method by which calcium influx can be influenced by IP3. Depletion of the 
intracellular calcium stores has also been found to induce a influx of calcium and it 
was Putney in 1986 who adopted the term ‘capacitative calcium entry’ (Putney, Jr. 
1986).
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1.6.1.3 Capacitative calcium entry
When certain hormones, growth factors or other agonists induce a rise in intracellular 
calcium via the generation of IP3, the response is biphasic. The initial increase is due 
the mobilisation of the intracellular calcium stores. This is followed by a second, 
prolonged phase which is the result of calcium entry (Westwick & Poll, 1986). In 
1992, Hoth and Penner named the current induced by calcium entry through these 
channels the calcium-release-activated calcium current ( I c r a c )  (Hoth & Penner, 1992). 
This entry of calcium is dependent upon initial store depletion, as demonstrated by the 
calcium ATPase inhibitor, thapsigargin, which can induce the same response by 
depleting the calcium stores but preventing refilling (Putney etal. 1981) (Clementi et 
al. 1995). This calcium entry can also be induced by IP3, as intracellular application of 
IP3 mimics the response and the IP3 receptor blocker, heparin inhibits the calcium 
entry (Bird et al. 1992). However, in some cells neither IP3 nor IP4 were found to 
induce calcium entry (Murphy etal. 1995).
A large number of experiments have been performed over the last few years to try to 
establish the mechanism for this calcium entry. The various models which have been 
proposed to explain how information on the filling state of the calcium stores is 
transmitted to the membrane can be separated into two groups, those based on the 
presence of diffusible factors and those dependent on protein-protein interactions and 
conformational coupling (review (Berridge, 1995)).
There are two versions of the model based on the activation of capacitative calcium 
entry by diffusible factors. Firstly, the injection of the non-hydrolysable analogues of 
GTP or GDP, namely guanosine 5’-3-0-(thio)triphosphate (GTPyS) and guanosine 5’- 
O(thio)diphosphate (GDPpS), were found to inhibit the calcium entry thus indicating a 
role for GTP hydrolysis (Bird & Putney, 1993). Other groups have postulated that 
these guanine analogues may cause disruption of a small GTP binding protein (SMG)
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indicating a direct role for this SMG in calcium entry (Fasolato et al. 1993). However, 
these results must be interpreted cautiously, as these non-metabolisable guanine 
nucleotides may also interfere with other G-protein -coupled events such as the 
activation of PLC and the subsequent activation of PKC isotypes by DAG, resulting in 
the inhibition of capacitative calcium entry.
Secondly, a diffusible factor was identified by Randriamampita and Tsien 
(Randriamampita & Tsien, 1993). Following calcium depletion of a Jurkat lymphocyte 
cell line the cells were lysed and the crude extract applied to three different cell types. 
It induced a sustained elevation of intracellular calcium. This calcium influx factor 
(CIF) as it was called, was proposed to be a low molecular mass phosphorylated 
compound that is stored in the endoplasmic reticulum and is released upon store 
depletion. More recent work has identified the presence of at least two factors in this 
crude cell extract. One factor induces calcium influx when applied extracellularly and 
the second factor when applied intracellularly (Thomas & Hanley, 1995). It is the latter 
of the two activities which appears to be the one originally isolated by Randriamampita 
and Tsien, with a molecular weight o f» 500 (Randriamampita & Tsien, 1993). 
However, with the suggestion that Jurkat cells release acetylcholine which could be 
acting on the recipient cells (Murphy etal. 1995), the purification and identification of 
CIF is essential before this model can proceed.
The more direct role for IP3 in the calcium entry has been proposed to be via a 
protein-protein interaction (review (Berridge, 1995)). Briefly, it is thought that the large 
head structure of the IP3 receptor integrates a number of both positive and negative 
signals which it then transmits to the calcium channel via a conformational change. 
One of the main feedback signals is thought to be calcium itself (Zweifach & Lewis,
1995). For example, depletion of the intracellular calcium stores and low 
concentrations of calcium in the cellular cytosol lead to the transfer of this information
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through the IP3 receptor to the calcium channel. High concentrations of calcium in the 
cellular cytosol lead to a negative feedback effect preventing calcium influx.
However, there are a number of other components which may act to regulate this 
capacitative calcium entry. For example, protein phosphorylation has been reported 
to play an important role in capacitative calcium entry (Hoth & Penner, 1992). Both 
serine/threonine kinases, such as PKC, and tyrosine kinases have been demonstrated 
to regulate capacitative calcium entry, although the precise target of phosphorylation 
is not entirely clear (Petersen & Berridge, 1994) (Lee etal. 1993). The channel itself 
and the IP3 receptor may both be likely phosphorylation targets. IP3 binding to its 
receptor may also directly activate the CRAC channel. It has also been proposed that 
the presence of different isoforms of the IP3 receptor may mean that they possess 
different functions. This led to experiments to identify whether the calcium release 
from the intracellular stores and the transfer of information to the channel were 
performed by different receptors. Results so far have indicated that the type 1 
receptor may mediate calcium release and a separate receptor, perhaps type 3, may 
mediate calcium entry (Berridge, 1995). It is also possible that one IP3 receptor is 
responsible for both calcium influx and calcium release from intracellular stores, but 
when it is coupled to the CRAC channel, its release properties are lost. The lack of 
calcium binding sites on the parts of the IP3 receptor which face the lumen of the 
calcium store indicate the possibility that another calcium binding protein, for example 
calsequestrin or calreticulin, may sense the luminal calcium concentration and pass 
the message onto the IP3 receptor. The recent identification of an IP4 binding protein 
may implicate IP4 in the transfer of information from the IP3 receptor to the CRAC 
channel (Cullen etal. 1995). The exact nature of the protein-protein coupling between 
the IP3 receptor and the CRAC channel is not known and far more investigation is 
required before a definitive answer can be given (see figure 1.4 for a summary of the 
calcium pathways).
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The actual structure of the channel involved in this calcium entry has recently been 
carefully scrutinised. Work carried out on Drosophila photoreceptors led to the 
discovery of a transient receptor potential (trp) gene product which functions as a 
plasma membrane channel (Phillips etal. 1992). Concurrently, a second channel, 
named the trp-like (trpl) (Phillips etal. 1992) channel was identified. When trp and trpl 
were expressed into Sf9 cells both were demonstrated to be calcium channels.
These two channels were observed to differ with respect to their cation selectivity and 
activation following depletion of the intracellular calcium stores, trp was found to be a 
selective channel for calcium and magnesium ions and to be sensitive to store 
depletion. In contrast, trpl was a non-selective ion channel which was not sensitive to 
store depletion and was activated by agonists of G-protein-coupled receptors via IP3 
(Vaca etal. 1994) (Hu & Schilling, 1995). The trp channel has been demonstrated to 
possess a higher conductance than the CRAC channel and to be less specific but it is 
possible that the calcium store-sensitive trp channel may be the functional analogue of 
the CRAC channel involved in capacitative calcium entry. Interestingly, a human 
homologue of the trp channel has recently been reported by two separate groups 
(Wes et al. 1995) (Zhu et al. 1995) and has been named transient receptor potential 
channel-related protein 1 (TRPC1) and human trp homologue 1 (Htrpl) respectively.
It is proposed to be a member of a family of at least six related human proteins (Wes 
et al. 1995). Expression of the Htrpl into COS-M6 cells demonstrated the ability to 
increase calcium influx into these cells by 75% (Zhu et al. 1996). Also, anti-ftp 
sequences are capable of suppressing capacitative calcium entry in a fibroblast cell 
line, thus providing the first tentative links between the human trp homologues and 
capacitative calcium entry. It is important to note that both the Drosophila trp and trpl 
and the human homologue, trpcl/Htrp, contain three ankyrin repeats. The IP3 
receptors expressed in a number of mammalian tissues have been demonstrated to 
bind directly to ankyrin (Joseph & Samanta, 1993), thus providing a possible method
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by which the IP3 receptors may mediate activation of the channel, as proposed in the 
conformational change hypothesis.
1.6.1.4 Activation of PKC isoforms by DAG
The second product of Ptdlns(4,5)P2 hydrolysis by PLC is DAG, which can activate 
certain isotypes of PKC. Not only can DAG be produced as a result of Ptdlns(4,5)P2 
hydrolysis, but it can also be produced as a result of hydrolysis of phosphatidylcholine 
(PtdC) by the PC-specific PLC. However, the time-course of the production of DAG 
from these two sources varies, with the production of DAG from inositol phospholipids 
being very rapid in onset and the DAG generated from PtdC relatively slow in onset.
To date, eleven isoforms of PKC have been identified and they differ quite markedly in 
their requirements for activation. Table 1.5 lists the PKC isoenzymes identified thus 
far and some of the various factors required for their activation (review (Nishizuka,
1995)). Briefly, the conventional PKCs (a, p, y) require the presence of both calcium 
and DAG for activation. Activation of PKCs 8, e, r\, 0 and p is independent of calcium 
but they are still activated by DAG. The atypical PKCs (<; and X) are not activated by 
either calcium or DAG. Phorbol esters have been demonstrated to substitute for DAG 
in the activation of the DAG-sensitive isoforms of PKC. Interestingly, the product of PI 
3-kinase, namely Ptdlns(3,4,5)P3> has also been demonstrated to activate the PKC 8, 














Figure 1.4 - Pathway to show the calcium mobilisation and calcium influx interrelationship. The stimulatory 
effects are shown in green and the inhibitory effects are shown in red. 1) IP3 is generated by the hydrolysis of 
Ptdlns(4,5)P2 by PLC. 2) PKC, certain isoforms of which are activated by calcium as well as the other product of PLC,
DAG, can inhibit calcium mobilisation by inhibiting PLC and increasing IP3 breakdown. There have also been some reports 
that PKC can inhibit the CRAC channel. 3) IP3 induces calcium mobilisation from intracellular stores by binding to its 
receptor. 4) An IP3 receptor, either the same one that induces calcium mobilisation or a distinct IP3 receptor, may 
activate the CRAC channel by conformational coupling. 5) Factors may be released by the stores upon calcium 
depletion to activate the CRAC channel. 6) High cytosolic concentrations of calcium may inhibit calcium entry via the 
CRAC channel. 7) IP4 may play a role in the activation of the CRAC channel via an IP4 binding protein.
Table 1.5 - PKC isoforms found in mammalian tissues. The PKC isoforms and 
some of their activators are given below (adapted from (Nishizuka, 1995)). These 
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Calcium plays a very important role in a number of different cellular responses and 
investigations into the source of an agonist-induced calcium rise may provide vital 
evidence as to the activation pathway utilised by the agonist on a given cell type.
1.6.2 Phosphatidylinositol 3-kinase
1.6.2.1 Formation of D-3 Ptdlns lipids
PI 3-kinase is a lipid kinase which phosphorylates Ptdlns lipids at the D-3 position of 
the inositol ring (figure 1.5) (reviews (Downes & Carter, 1991) (Stephens etal. 1993)). 
The potential products of this phosphorylation are phosphatidylinositol (3)-phosphate 
(Ptdlns (3) P), phosphatidylinositol (3,4)-bisphosphate (Ptdlns(3,4)P2) and 
phosphatidylinositol (3,4,5)-trisphosphate (Ptdlns (3,4,5)P3). Although these three 
products can all potentially originate from PI 3-kinase activation, the rates at which
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these product levels change following agonist stimulation vary quite markedly. The 
levels of Ptdlns (3)P remain unchanged following agonist stimulation, Ptdlns(3,4,5)P3 
levels rise very rapidly and the increase in Ptdlns(3,4)P2 levels are often delayed 
(Stephens etal. 1991) (Kucera & Rittenhouse, 1990). The rapid and transient 
increases in Ptdlns(3,4,5)P3 implicate this molecule as a possible signalling molecule, 
as does the agonist induced increase in Ptdlns(3,4)P2. The fact that very small or 
non-existent changes in Ptdlns(3)P have been detected in response to agonists 
indicates a lack of importance of this inositol lipid as a signalling molecule. The 
relative sizes of the phospholipid pools may explain the lack of detection of agonist- 
induced changes in Ptdlns(3)P. The Ptdlns(3)P pool is usually large and as only small 
changes in the other 3-phosphorylated lipids are required for cellular activation, then a 
significant difference in the levels of Ptdlns(3)P may not be detected. However, it is 
interesting to note that a mammalian Ptdlns-specific PI 3-kinase and yeast PI 3-kinase 
activity (Vps34) have been identified, both of which can only phosphorylate in the D-3 
position of Ptdlns (sections 1.6.2.2.4 and 1.6.2.2.5) (Auger etal. 1989).
The possibility that the agonist-induced changes in these D-3 phosphorylated lipids 
may be due to other enzymes have been studied in detail by a number of groups, 
using [32P]Pj or [y-32P]ATP labelled cells (Stephens etal. 1991) (Hawkins etal. 1992) 
(Stephens et al. 1993c). Experiments performed under pre-isotopic equilibrium 
conditions demonstrated that the generation of Ptdlns(3,4,5)P3 was by the 3- 
phosphorylation of Ptdlns(4,5)P2, consistent with the presence of a PI 3-kinase. 
However, the origin of Ptdlns(3,4)P2 and Ptdlns(3)P was not clear, particularly in light 
of the evidence for the presence of a Ptdlns(3,4,5)P3 5-phosphatase (Jackson et al. 
1995) (Woscholski etal. 1995) (Ono etal. 1996) and a Ptdlns(3,4)P2 4-phosphatase 
(Stephens et al. 1991). Despite the ambiguity over the possible sources of Ptdlns(3)P 
and Ptdlns(3,4)P2, there is little doubt that the presence of a PI 3-kinase is responsible 
for the agonist-induced increases in Ptdlns(3,4,5)P3.
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Figure 1.5 - The synthesis of D-3 phosphorylated phosphoinositides.
a) The structure of Ptdlnsindicating the numbering on the inositol ring.
b) The products formed by the phosphorylation in the D-3 position by 
PI 3-kinase. The other enzymes which also contribute to the formation 
and breakdown of these products are also shown.
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1.6.2.2 The PI 3-kinase family
1.6.2.2.1 PI 3-kinase identification
PI 3-kinase was first isolated from cells tightly attached to two virally encoded PTKs, v- 
srcand v-ros (Sugimoto etal. 1984). The relationship between this PI 3-kinase and 
PTKs was further clarified by the fact that the PDGF receptor, which possess intrinsic 
PTK activity, could recruit PI 3-kinase within less than a minute after PDGF stimulation 
(Whitman etal. 1987) (Kaplan etal. 1987). Further experiments were then performed 
using a mutated PDGF receptor. Mutation of the PDGF receptor in the ‘kinase insert’ 
domain, which has been demonstrated to be the region which interacts with PI 3- 
kinase, prevented PDGF-induced cell proliferation (Coughlin etal. 1989).
About the same time, a uniquely polar phospholipid was identified in human 
neutrophils which increased rapidly following fMLP stimulation and, from the 
chromatographic properties of its head group, it was identified as Ptdlns(3,4,5)P3 
(Traynor-Kaplan etal. 1988). The identification of the agonist-induced generation of a 
second 3-phosphorylated lipid, namely Ptdlns (3,4)P2 in the same cells (Traynor- 
Kaplan et al. 1989), led to the connection between the PI 3-kinase activity and the 
generation of these lipids. This connection was further corroborated by the 
demonstration that PDGF could not only stimulate the translocation of PI 3-kinase to 
its receptor but also the rapid appearance of Ptdlns(3,4,5)P3 and Ptdlns(3,4)P2 (see 
table 1.6 for a complete listing of the PI 3-kinase family members identified to date).
1.6.2.2.2 PTK/SH2 -coupled PI 3-kinase structure
The PI 3-kinase activity first identified as being tightly associated with PTKs, i.e. the 
PDGF receptor-associated PI 3-kinase, has been fairly well characterised and will be 
referred to as the PTK/SH2-coupled PI 3-kinase throughout this thesis. The 
PTK/SH2-coupled PI 3-kinase has been purified from rodent liver (Carpenter etal.
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1990), mouse fibroblasts (Escobedo etal. 1991) and bovine brain (Otsu etal. 1991).
It consists of two subunits, p85 and p110.
The p85 subunit is the regulatory subunit and two isoforms have been isolated from 
bovine brain, namely p85a and p85p (Otsu etal. 1991). They show extensive amino 
acid homology and both bind to the activated PDGF protein tyrosine kinase receptor. 
These p85 subunits contain several domains of homology to other proteins, namely 
one SH3 domain and two SH2 domains (src homology domains 3 and 2), which are 
involved in the regulation of PI 3-kinase (section 1.6.2.3.1), in addition to a breakpoint 
cluster region (BCR)-like domain. The latter has been found to confer GTPase activity 
for small molecular weight GTP-binding proteins (Fry etal. 1992).
Upon isolation of the p85 subunit, a second protein with a molecular weight of 110kDa 
was observed to be tightly associated with this p85 subunit (Carpenter etal. 1990). 
Following the expression of this 110kDa protein into Sf9 cells, p110 was demonstrated 
to possess PI 3-kinase activity and designated the catalytic subunit of PI 3-kinase 
(Hiles etal. 1992). A second p110 isoform has more recently been identified, namely 
p110p from a human library. This also has PI 3-kinase activity and associates with 
the p85 subunit (Hu etal. 1993). The p85 and p110 subunits associate with each other 
via one region corresponding to the sequences between the two SH2 domains of p85 
(Hu etal. 1993) (Klippel etal. 1994).
It is interesting to note that the p85 subunit of PI 3-kinase, as well as facilitating the 
interaction of the p110 subunit with activated receptors, has also been proposed as a 
mediator of other protein-protein interactions (Kapeller & Cantley, 1994). For 
example, p85 has been reported to function as an adaptor molecule, linking the 
activated insulin receptor to the multifunctional SH2 and SH3 domain binding protein 
p62, as well as to the GTPase-activating protein (GAP) (Sung etal. 1994).
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The p110 subunit also has the potential for cross-talk with other pathways present 
within cells. For example, the GTP binding protein Ras has been demonstrated to 
bind directly with the p110 subunit of PI 3-kinase in a GTP-dependent manner. The 
dominant negative Ras mutant has been demonstrated to inhibit the accumulation of 
D-3 phospholipids in PC12 cells following growth factor stimulation (Rodriguez-Viciana 
et al. 1994). The proteins encoded by the ras genes serve as essential transducers of 
diverse physiological signals (Lowy & Willumsen, 1993) and the observation that the 
dominant negative Ras mutant can inhibit PKB activation indirectly points to the 
possibility that the interaction of p110 with Ras may contribute to the activation of PKB 
(Downward, 1995).
Other than the lipid kinase activity of the p110 subunit of PI 3-kinase, it has also been 
demonstrated to possess a serine kinase activity, similar to the Vps15 which interacts 
with Vps34 in yeast (section 1.6.2.2.5). This intrinsic protein kinase activity has been 
proposed to play a role in the regulation of PI 3-kinase in vivo (section 1.6.2.3.1).
1.6.2.2.3 G-protein -coupled PI 3-kinase
A significant number of receptors which belong to the seven transmembrane G- 
protein-coupled receptor family can also stimulate PI 3-kinase. Examples of these are 
fMLP (Stephens etai. 1991), LtB4 (Traynor-Kaplan etal. 1989), adenosine 
triphosphate (ATP), platelet activating factor (PAF) (Stephens etal. 1993a), C5a 
(Dobos etal. 1992) and thrombin (Kucera & Rittenhouse, 1990). None of these 
receptors possess intrinsic PTK activity nor do they associate with non-receptor PTKs. 
Therefore, the heterotrimeric G-proteins with which they interact must lead to PI 3- 
kinase activation. This theory was further substantiated by two other findings. Firstly, 
mastoparan, a peptide which activates heterotrimeric G-proteins, can induce rapid 
activation of PI 3-kinase in human neutrophils (Norgauer etal. 1992). Secondly,
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fMLP-, PAF-, and ATP-stimuiated PI 3-kinase activity in neutrophils and thrombin- 
stimulated PI 3-kinase activity in platelets were all completely abrogated or reduced 
respectively following pertussis toxin pre-treatment (Traynor-Kaplan etal. 1988) 
(Stephens etal. 1993b) (Stephens etal. 1993a) (King etal. 1991).
It was originally thought that this G-protein-coupled PI 3-kinase also possessed a 
heterodimeric structure consisting of a p85 and a p110 subunit. However, more 
recent evidence has lead to the conclusion that this PI 3-kinase only possesses a 
p110 subunit which is separate from that seen in the PTK/SH2-coupled PI 3-kinase 
(Stoyanov et al. 1995). This p110 subunit was called p110y. Throughout this thesis, 
this PI 3-kinase isoform will be referred to as PI 3-kinase y.
1.6.2.2.4 Ptdlns-specific PI 3-kinase
A Ptdlns-specific PI 3-kinase has recently been identified in mammalian cells 
(Stephens etal. 1994) (Volina etal. 1995). This isoform of PI 3-kinase has a 
molecular weight of 100kDa and does not appear to associate with the p85 regulatory 
subunit. In vivo, this Ptdlns-specific PI 3-kinase is detected in a complex with a 
150kDa protein. The Ptdlns-specific PI 3-kinase demonstrates a similar sensitivity to 
wortmannin as is observed with the PTK/SH2-coupled PI 3-kinase but, unlike the 
PTK/SH2-coupled PI 3-kinase, the Ptdlns-specific PI 3-kinase was relatively 
insensitive to non-ionic detergents.
1.6.2.2.5 PI 3-kinase activity in veast
A PI 3-kinase activity was identified in yeast following the observation that a large 
number of Saccharomyces cerevisiae mutants are specifically defective in vacuolar 
protein sorting (Bankaitis etal. 1986) (Rothman etal. 1986). Analyses of two such 
Vps genes, namely Vps34 and Vps15, demonstrated that these genes encode 
homologues of a PI 3-kinase and a serine/threonine kinase respectively (Herman &
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Emr, 1990) (Hiles etal. 1992). Vps34 is homologous to the p110 catalytic subunit of 
mammalian PTK/SH2-coupled PI 3-kinase, although, unlike the mammalian 
PTK/SH2-coupled PI 3-kinase, Vps34 can only phosphorylate in the D-3 position of 
Ptdlns. Point mutations in the conserved region of the lipid kinase domain resulted in 
almost complete abrogation of the PI 3-kinase activity as well as severe defects in 
vacuolar protein sorting (Schu etal. 1993). Vps34 and Vps15 have been 
demonstrated to form a complex that is associated with the cytoplasmic face of the 
intracellular membrane fraction, most likely to be the Golgi apparatus (Herman et al.
1991). Not only does Vps15 recruit Vps34 to the membrane, it also serves to activate 
the PI 3-kinase activity in Vps34. The protein kinase activity of Vps15 has been 
demonstrated to be a prerequisite for association with and activation of Vps34 (Stack 
etal. 1995).
1.6.2.2.6 Other PI 3-kinase activities
A number of other putative PI 3-kinase activities have been identified, including Cpk in 
Drosophila, Cpk-m and p170 in mice as well as TOR1/TOR2, mTOR, RAFT, FRAP, 
ATM and DNA-PKcs, all of which show homology with the p110 subunit of the 
PTK/SH2-coupled PI 3-kinase (Virbasius etal. 1996) (Molz etal. 1996) (Hartley etal. 
1995) (Sabatini etal. 1995). However, no real functional evidence has yet been 
provided for these isoforms.
1.6.2.3 PI 3-kinase coupling and activation
1.6.2.3.1 PTK/SH2 -coupled PI 3-kinase
PI 3-kinase is predominantly a soluble enzyme which uses membrane-associated 
substrates. Therefore, the enzyme must translocate to and become associated with 
the membrane before it can phosphorylate the substrates. For the comparatively well 
characterised PTK/SH2-coupled PI 3-kinase, this appears to occur via tyrosine 
phosphorylated residues associated with the receptor. These proteins can either be
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phosphorylated by a receptor-coupled PTK or a non-receptor-coupled PTK, such as 
srotype PTKs, in a similar manner to that seen by PLC y (Cantley etal. 1991). The 
possible mechanism of activation of PI 3-kinase by these two systems is relatively 
similar and both are summarised in figure 1.6a.
The tyrosine phosphorylated proteins either on the receptor itself or on a target protein 
are thought to bind, via specific amino acid sequences, to the SH2 domains of the p85 
subunit of PI 3-kinase. The sequences which bind the SH2 domains of PI 3-kinase 
have been studied in some detail and, to date, a number of binding motifs have been 
identified. For example, the binding of the PDGF receptor or the CD28, CTLA-4 and 
CD7 molecules on T cells to PI 3-kinase, appears to occur through the YXXM motif in 
the middle of the kinase domain of the PDGF receptor or in the cytoplasmic tails of the 
T cell molecules (Escobedo etal. 1991) (Kapeller & Cantley, 1994). This YXXM 
consensus sequence has also been observed to be present on PKC 5 and PKC e 
(Ettinger et al. 1996). The association of the hepatocyte growth factor receptor and 
the erythropoietin receptor have been demonstrated to be mediated by sequences 
such as YVXV and YLVL respectively (Ponzetto etal. 1993) (He etal. 1993) and TCR 
signal transduction has been proposed to be mediated by two YXXL/I repeats 
separated by 6-8 amino acid residues (Weiss & Littman, 1994). There is strong 
evidence that doubly phosphorylated peptides are more effective than singly 
phosphorylated peptides at activating PI 3-kinase (Carpenter etal. 1993a). It is 
thought that binding of the phosphopeptides to the SH2 domains of p85 induces a 
conformational change which allows activation of the p110 catalytic subunit.
The only major difference between the receptor-coupled PTK systems e.g. the PDGF 
and EGF receptors (reviewed (Cantley etal. 1991) and the non-receptor-coupled PTK 
systems e.g. fyn and Ick in T cells (reviewed (Ward etal. 1996)) is the proteins which 
become phosphorylated.
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Table 1.6 - PI 3-kinase family members. All the members of the PI 3-kinase family to 
date are given below along with the species in which they have been identified and the 
substrates upon which they can act. The shaded columns indicate the putative PI 3- 
kinase activities (adapted from Ward etal. 1996).
PI 3-kinase Species Substrate Potential products
PTK/SH2 - 
coupled













Vps34 Yeast Ptdlns Ptdlns(3)P
Cpk Drosophila Ptdlns, Ptdlns(4)P Ptdlns(3)P,
Ptdlns(3,4)P2
p170 Mouse Ptdlns, Ptdlns(4)P Ptdlns(3)P,
Ptdlns(3,4)P2
TOR1/TOR2 Yeast Not known Not known
mTOR Human Not known Not known
RAFT Rat Not known Not known 
(N.B. RAFT may co­
precipitate with a 
Ptdlns 4-kinase)
FRAP Human Not known Not known
ATM Human Not known Not known
DNA-PKcs Human None None
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In the former system, it is the PTK or, in the case of the insulin receptor the insulin 
receptor substrate-1 (IRS-1) (Backer etal. 1992), which becomes phosphorylated and 
thus activates PI 3-kinase. With the non-receptor-coupled PTK system, either the 
PTK, the receptor or a target protein becomes phosphorylated which then 
subsequently activates PI 3-kinase via the SH2 domains.
The p85 subunit of PI 3-kinase possess one SH3 domain and one or more SH3 
binding domains which may regulate PI 3-kinase activity. The function of SH3 
domains in proteins is still not entirely clear but they are thought to function as 
potential sites for specific and tight interactions with certain proline-rich regions 
present in other proteins (Ren etal. 1993). The SH3 domain of p85, expressed as a 
GST fusion protein, has been demonstrated to bind the microtubule-associated 
protein, dynamin (Gout etal. 1993). Although the exact role for this interaction is not 
entirely clear, it may have important biological significance as the binding of dynamin 
to the SH3 domain further augments the GTPase activity of dynamin. The potential 
SH3 binding domains, or proline-rich regions, of p85 have also been demonstrated to 
interact with the SH3 domains in various non-receptor-coupled PTKs such as Ick, fyn 
and lyn (Kapeller etal. 1994) (Pleiman etal. 1993) as well as the interaction of the 
SH3 domain of p85 with its own SH3 binding domains (Prasad etal. 1993). These 
interactions do not alter the activity of PI 3-kinase.
Another method of activation of the PTK/SH2-coupled PI 3-kinase may come from 
phosphorylation of the p85 subunit itself. p85 has been observed to be 
phosphorylated in response to the activation of many tyrosine kinases (Courtneidge & 
Heber, 1987) (Panayotou etal. 1992). The manganese-dependent serine-threonine 
kinase which is tightly associated with PI 3-kinase may also be important in cellular 
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Figure 1.6 - The activation of PI 3-kinase isoforms, a) The activation of PI 3-kinase either by a receptor-coupled PTK 
or a non-receptor-coupled PTK. The phosphorylation of either the receptor itself or a target protein by either a receptor 
coupled PTK or a non-receptor coupled PTK allows the interaction of the phosphotyrosine with the SH2 domains of 
PI 3-kinase and thus PI 3-kinase activation, b) The activation of PI 3-kinase y by G-protein-coupled receptors. The py 
subunits of the G-protein bind to and activate the PI 3-kinase y. It has been proposed that the PTK/SH2 coupled 
PI 3-kinase can also be activated by G-protein coupled receptors via PKC and calcium activation of a PTK 
(adapted from Stephens et al. (1993)).
p85 has also been observed to be tyrosine phosphorylated in PDGF-stimulated, 
polyoma middle t antigen-transformed and nerve growth factor (NGF) stimulated cells 
as well as insulin stimulated cells (Cohen etal. 1990) (Courtneidge & Heber, 1987) 
(Kaplan etal. 1987) (Hayashi etal. 1993). The exact role of the phosphorylation of 
the p85 subunit is not yet clear, although it has been suggested to play a role in the 
dissociation of tyrosine phosphorylated residues as well as to regulate the interaction 
with catalytic subunits (Cohen etal. 1990) (Kavanaugh etal. 1992).
1.6.2.3.2 PI 3-kinase v
Activation of PI 3-kinase y is not completely understood. A schematic representation 
of its activation is given in figure 1.6b. Recent evidence has indicated that it is the py 
subunits which lead to the activation of PI 3-kinase. This has been demonstrated by 
the activation of PI 3-kinase in U937 cells, human platelets and neutrophils by purified 
bovine brain G
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cells overexpressing src, the PKC phosphorylation site is a requirement for agonist- 
induced increases in cAMP (Gould etal. 1985) (Moyers etal. 1993).
1.6.2.4 Inhibitors of PI 3-kinase
The exact role of the D-3 phosphorylated products of PI 3-kinase is not entirely clear. 
They are definitely not substrates for PLC and thus do not play a role in inositol 
phosphate metabolism and calcium mobilisation (Lips et al. 1989) (Serunian et al. 
1989). The similarities with the yeast Vps34, involved in vacuolar protein sorting, 
indicate that vesicular trafficking may be a role for mammalian PI 3-kinase (Hiles etal.
1992). However, further studies into the roles of PI 3-kinase and its products have 
been made possible by the discovery of the inhibitor wortmannin (Arcaro & Wymann,
1993) (review (Ui etal. 1995)).
1.6.2.4.1 Wortmannin
Wortmannin is a fungal metabolite which was originally described by Baggiolini etal. 
in 1987 as an inhibitor of respiratory burst in neutrophils (Baggiolini etal. 1987). It 
was subsequently found to inhibit other pathways including PLC and D (Bonser et al. 
1993), myosin light chain kinase (Nakanishi etal. 1992) and pleckstrin 
phosphorylation in platelets (Yatomi etal. 1992), although the concentrations of 
wortmannin required for these effects were in the micromolar range. However, at 
100nM or less, wortmannin has been found to be a potent inhibitor of PI 3-kinase by 
covalently interacting with the p110 catalytic subunit (Yano et al. 1993). Recently, a 
study carried out by Wymann et al. identified the residues required for the covalent 
binding of wortmannin to PI 3-kinase (Wymann etal. 1996). Wortmannin was found 
to bind to Lys-802 on the p110 a subunit of PI 3-kinase. Point mutation of this residue 
completely abolished wortmannin binding. However, the different isoforms of PI 3- 
kinase demonstrate differing sensitivities to wortmannin. The PTK/SH2-coupled PI 3- 
kinase is very sensitive to wortmannin with an IC50 of 10nM, as is the Ptdlns-specific
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PI 3-kinase with an IC5o of 2.5nM (Wolscholski etal. 1994) (Volinia etal. 1995). In 
contrast, PI 3-kinase y is much less sensitive to wortmannin with an IC50 of 43nM on 
the purified enzyme (Stephens etal. 1994). Other PI 3-kinase isoforms such as 
Vps34, RAFT and FRAP are almost insensitive to wortmannin (Sabatini etal. 1995).
However, there are limitations as to the use of wortmannin as an indicator of PI 3- 
kinase activation due to its effective inhibition of at least two other signalling pathways, 
namely Ptdlns 4-kinase and PLA2 (Nakanishi etal. 1995) (Cross etal. 1995). The 
inhibition of these pathways may have profound effects on the PI 3-kinase pathway by 
affecting the generation of the PI 3-kinase substrate, Ptdlns(4,5)P2, or by affecting 
other pathways which may be directly or indirectly connected to PI 3-kinase.
1.6.2.4.2 Other inhibitors of PI 3-kinase
A novel PI 3-kinase inhibitor, namely 2-(4-morpholinyl)-8-phenyl-4H-1 -benzopyran-4- 
one (LY294002) was synthesised and demonstrated to inhibit purified bovine brain PI 
3-kinase with an IC5o of 1.4pM (Vlahos et al. 1994). LY294002 was also found to 
inhibit the PI 3-kinase-dependent proliferation of cultured rabbit aortic smooth muscle 
cells as well as completely abolish fMLP-induced PI 3-kinase activity in human 
neutrophils. The effects of this inhibitor were also investigated on several other 
enzymes including Ptdlns 4-kinase, src, MAP-kinase, S6 kinase, DAG kinase, PKA 
and PKC (Vlahos etal. 1994). None of these enzymes were significantly inhibited by 
LY294002.
There is another inhibitor of PI 3-kinase that has recently been identified. 
Demethoxyviridin is structurally related to wortmannin but is a distinct compound and 
was observed to inhibit purified PTK/SH2-coupled PI 3-kinase with an IC50 of 3.4nM 
(Wolscholski etal. 1994). However, demethoxyviridin, like wortmannin, has also been 
observed to inhibit Ptdlns 4-kinase with an IC5o of approximately 50nM.
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These inhibitors, particularly wortmannin, have been used to identify a number of 
functional responses which are dependent on PI 3-kinase activation (see table 1.7). 
These responses include fMLP activation of neutrophils, IL-2 production following 
CD28 ligation by B7 in T cells (Ward etal. 1995) and PDGF-mediated actin 
rearrangements in human fibroblasts and membrane ruffling in endothelial cells 
(Wymann & Arcaro, 1994) (Wennstrom etal. 1994).
1.6.2.4.3 Alternative approaches to studying PI 3-kinase 
More recently, other approaches to the identification of PI 3-kinase-dependent 
responses have been initiated. A p85 deletion mutant, which lacks a small domain 
between the SH2 domains (inter-SH2 region) required for the interaction of the p85 
subunit with the p110 catalytic subunit has been developed (Dhand etal. 1994). This 
prevents the interaction of the two subunits of PI 3-kinase and, when expressed in 
excess of the endogenous PI 3-kinase, can act as a dominant negative mutant due to 
its retained ability to associate with the phosphotyrosine binding sites that would 
activate endogenous PI 3-kinase. This dominant negative mutant has been observed 
to inhibit insulin-stimulated Ptdlns(3,4,5)P3 accumulation in U937 cells (Stephens,
1995).
A consitutively active PI 3-kinase has also been developed (Hu et al. 1995). In this 
mutant PI 3-kinase the catalytic p110 subunit is a chimeric protein in which the inter- 
SH2 region of the p85 subunit is covalently linked to its binding site on the p110 
subunit. This consitutively active PI 3-kinase has been demonstrated to activate a 
number of signalling pathways, such as p70 S6 kinase, mitogen-activated protein 
(MAP) kinase and Ras, independent of growth factor stimulation (Weng etal. 1995).
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1.6.2.4.4 Downstream effectors of PI 3-kinase
The development of PI 3-kinase inhibitors and active and dominant negative mutants 
has lead to a number of possible downstream effectors of PI 3-kinase being identified.
p70 S6 kinase is a serine/threonine kinase which phosphorylates the ribosomal protein 
S6. This results in enhanced mRNA translation and increased protein synthesis 
(Kozma and Thomas 1994) (review (Woodgett, 1994)). The activation of this kinase 
has not been well characterised but it is thought to involve multiple phosphorylation 
sites by more than one protein kinase and experiments using wortmannin have 
identified PI 3-kinase as an important regulator of p70 S6 kinase phosphorylation and 
activation (Parry & Ward, 1996) (Chung etal. 1994) (Monfar etal. 1995) (Kilgour etal.
1996). Also, mutations of the PDGF receptor, which prevent the binding of the p85 
subunit of PI 3-kinase, prevented the activation of p70 S6 kinase by PDGF, further 
implicating PI 3-kinase in the activation of p70 S6 kinase (Chung etal. 1994).
Some groups have demonstrated that the macrolide antibiotic rapamycin also inhibits 
p70 S6 kinase activation (Downward, 1994). The proposed pathway involves the 
putative PI 3-kinase target of rapamycin (TOR). Rapamycin, when complexed with its 
binding protein FK506 binding protein (FKBP) 12, can bind to and inhibit the functions 
of TOR. Thus, the inhibition of both TOR and p70 S6 kinase by rapamycin implicates 
TOR in the activation of p70 S6 kinase. Similar results have also been observed with 
another putative PI 3-kinase in T cells (Brown etal. 1994). FK506-binding protein 
rapamycin-associated protein (FRAP) has been demonstrated to be required for p70 
S6 kinase regulation and is sensitive to rapamycin (Brown etal. 1995). However, 
more work is required before a definitive answer can be given.
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Another serine/threonine protein kinase has also been linked to PI 3-kinase activation. 
PKB is a product of the Akt gene and is ubiquitously expressed (Bellacosa et al.
1993). The catalytic domain of PKB is homologous to the catalytic domains of all 
members of the PKC family (Coffer & Woodgett, 1991). Wortmannin has been 
demonstrated to inhibit the PDGF-induced activation of PKB (Franke etal. 1995). The 
coexpression of a dominant negative mutant of PI 3-kinase has also been 
demonstrated to inhibit PDGF-induced PKB activation (Burgering etal. 1995). The 
link between the activation of PI 3-kinase and PKB by PDGF was also suggested by 
the fact that the addition of Ptdlns(3)P induced activation of PKB in in vitro assays 
(Franke etal. 1995).
It is very interesting to note that Burgering et al. observed that the expression of a 
consitutively active PKB form resulted in the increased activity of p70 S6 kinase 
(Burgering etal. 1995). Therefore, the observations that both PKB and p70 S6 kinase 
are downstream effectors of PI 3-kinase and that PKB can activate p70 S6 kinase 
suggests that PKB may be positioned upstream of p70 S6 kinase.
Certain PKC isoforms have also been proposed as downstream effectors of PI 3- 
kinase following the observations that PI 3-kinase can associate with PKC 8 in both 
GM-CSF stimulated TF-1 cells and PAF stimulated platelets (Ettinger etal. 1996) and 
that Ptdlns(3,4,5)P3 can stimulate PKC s, 8, £ and ti isoforms in in vitro assays (Toker 
etal. 1994) (Nakanishi etal. 1993).
Finally, the identification of a proposed Ptdlns(3,4,5)P3 binding protein, namely 
centaurin-a, in rat brain has possibly identified another downstream effector for 
Ptdlns(3,4,5)P3 (Hammonds-Odie etal. 1996). Hammonds-Odie etal. proposed that
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centaurin-a may have a role in mediating the downstream events activated following 
growth factor stimulation of PI 3-kinase in the brain.
Although the exact roles for PI 3-kinase and its products have not yet been fully 
identified, it is apparent that they may play an important role in the activation of a 
number of different cell types.
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Table 1.7 - Responses observed to be potently inhibited by wortmannin. Some 
of the functional responses sensitive to nM concentrations of wortmannin are given 
below (adapted from Ward etal. 1996).




Respiratory burst from 
neutrophils
fMLP 5 Arcaro & 
Wymann, 1993
T cell chemotaxis RANTES 5 Turner et al., 
1996
IL-2 production from T 
cells
CD28 10 Ward etal., 
1995
T cell proliferation CD28 + CD3 10-100 Karnitz etal., 
1995
Actin rearrangements in 
fibroblasts
PDGF 5 Wymann & 
Arcaro, 1994
Membrane ruffling in 
endothelial cells
PDGF 10-100 Wennstrom et 
al., 1994
(31 integrin upregulation 
in HL60 cells transfected 




10-100 Shimizu etal., 
1995
Histamine secretion and 
leukotriene release from 
RBL cells
FceR1 3 Yano etal., 1993




10-100 Ninomiya et al., 
1994
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1.7 Monocyte functional changes
The main objective of this study was to characterise the action of the C-C chemokine 
MCP-1 on human monocytes and monocytic cell lines. Blood monocytes are 
immature cells that are produced in the bone marrow. They migrate into tissues and 
body cavities where they mature into macrophages. The monocyte-macrophage 
system plays a vital role in multiple host-defence mechanisms (Boggs & Winklestein, 
1985). For example, macrophages can initiate the immune response by acting as 
antigen presenting cells (Scala & Oppenheim, 1985). Macrophages engulf antigens 
and partly degrade them. A fraction then reappears on the surface of the macrophage 
along with gene products of the major histocompatibility complex (MHC) which are 
then presented to the lymphocyte inducing an immune response. This immune 
response is further mediated by macrophages which produce IL-1. IL-1 production 
stimulates T cells to produce IL-2, thus promoting T cell proliferation. Monocytes are 
also potent effectors of the inflammatory processes by their capacity to release 
arachidonic acid-derived mediators and respiratory burst products. They are chiefly 
involved in defending those organisms which give rise to a chronic inflammation.
Upon the development of an inflammatory response the monocytes will adhere to the 
endothelial layer, via the interaction of p-integrins with the Ig superfamily members 
expressed on the endothelial layer (see section 1.2) and move down the specific 
chemokine concentration gradient towards the site of inflammation. In the last stage, 
the monocyte will transmigrate through the endothelial layer into the tissue. The 
release of cytokines and arachidonic acid-derived mediators provide signals to the 
other cells involved in the inflammatory response and act as a positive feedback 
mechanism. The production of respiratory burst products such as superoxide ions is 
of great importance in the killing of bacteria. This is made very clear in patients 
suffering from the rare genetic disease, chronic granulomatous disease (CGD). Both 
the monocytes and the neutrophils lack one or more of the protein components of the
superoxide-generating system and the patients suffer repeated infections (Cross & 
Jones, 1991) (Hamers etal. 1984).
During the production of superoxide anions, there is an increase in oxygen uptake 
followed by the passing of two electrons from reduced nicotinamide adenine 
dinucleotide phosphate (NADPH), formed by the hexose monophosphate pathway, 
down two redox active components, namely a flavin adenine dinucleotide (FAD)- 
containing protein, and cytochrome b-245. This results in the eventual reduction of 
oxygen to produce superoxide (Cross & Jones, 1991). This system is known as 
NADPH oxidase. It becomes activated upon stimulation of the monocytes and the 
superoxide produced is released onto the outer face of the cell (Jones etal. 1993). 
The presence of superoxide dismutase (SOD) in the cells converts the superoxide 
ions into hydrogen peroxide (Root & Metcalfe, 1977).
Apart from the adhesion molecules that are upregulated on the surface of monocytes 
following stimulation there is another cell surface molecule which has been found to 
be upregulated on the surface of monocytes, namely CD23 (Vercelli etal. 1988). 
CD23 was first identified as a B cell activation marker and is a low affinity receptor for 
immunoglobulin E (IgE). It is also known as FCsRII (review (Delespesse etal. 1991)). 
CD23 is an integral type II membrane glycoprotein and several cytokines, including 
interleukin-4 (IL-4) (Vercelli etal. 1988), IL-3 (Alderson etal. 1992), GM-CSF and 
interferon-a (IFN-a) (Williams etal. 1992) stimulate its upregulation on monocytes. 
There are two isoforms of CD23, namely CD23a and b, that differ in their cytoplasmic 
domain and they have been shown to perform distinct functions (Yokota et al. 1988).
It is the type b CD23 which is expressed on monocytes.
When CD23 expression is increased on the cell surface it can be cleaved into 
biologically active soluble fragments and this cleavage process has been
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demonstrated to be involved in the differentiation of the myelomonocytic leukaemia 
cell line U937 into mature monocyte/macrophage cells (Ouaaz etal. 1993). CD23 
upregulation has also been identified in phagocytosis of IgE-coated particles by 
monocytes (Boltz-Nitulescu etal. 1988).
The upregulation of this cell surface CD23 molecule appears to be important in the 
monocytes regulation in IgE -dependent diseases and its upregulation on monocytes 
from patients suffering from allergic asthma has already been confirmed (Demoly et 
al. 1994).
Due to the difficulty in obtaining large numbers of blood-derived monocytes, the 
monocytic cell line THP-1 was utilised in this study. THP-1 cells were originally 
derived from a patient suffering from acute monocytic leukaemia (Tsuchiya etal. 
1980). They are a pre-monocytic cell line but, like monocytes, they possess Fc and 
C3b receptors. However, they lack surface and cytoplasmic immunoglobulins. They 
are a phagocytic cell line and can be differentiated into macrophage-like cells by 
factors such as phorbol ester (Tsuchiya etal. 1982).
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1.8 Aims of study
1. To determine the binding of MCP-1 to the human monocytic cell line THP-1 and to 
human embryonic kidney (HEK) 293 cells stably transfected with the CC CKR 2 A 
or B, using both radioligand binding studies and biotinylated MCP-1 and FACS 
analysis.
2. To examine the increase in intracellular calcium in response to MCP-1 using fura-2 
labelled cells and to explore the source of this calcium rise with the aid of various 
calcium influx and calcium mobilisation inhibitors in THP-1 cells compared to the 
transfected cells and human blood derived monocytes and to identify the possible 
role for PLC by studying IP3 generation.
3. To demonstrate the activation of PI 3-kinase by MCP-1 in THP-1 cells compared 
with the transfected cells by monitoring the production of PI 3-kinase products and 
to identify whether the PTK/SH2 -coupled PI 3-kinase and/or the G-protein -coupled 
PI 3-kinase are activated following MCP-1 stimulation using both a whole cell assay 
and an in vitro lipid kinase assay.
4. To determine whether MCP-1 induces tyrosine phosphorylation of proteins in THP- 
1 cells and the MCP-1 receptor transfected cells and to identify the role of these 
proteins in PI 3-kinase activation using Western blotting techniques.
5. To study the activation of various functional responses in monocytes following 
MCP-1 stimulation including chemotaxis, adhesion molecule upregulation, 
superoxide release and low affinity IgE receptor expression and to try to identify a 
possible role for the signal transduction pathways activated by MCP-1.
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cells overexpressing src, the PKC phosphorylation site is a requirement for agonist- 
induced increases in cAMP (Gould etal. 1985) (Moyers etal. 1993).
1.6.2.4 Inhibitors of PI 3-kinase
The exact role of the D-3 phosphorylated products of PI 3-kinase is not entirely clear. 
They are definitely not substrates for PLC and thus do not play a role in inositol 
phosphate metabolism and calcium mobilisation (Lips et al. 1989) (Serunian et al. 
1989). The similarities with the yeast Vps34, involved in vacuolar protein sorting, 
indicate that vesicular trafficking may be a role for mammalian PI 3-kinase (Hiles etal.
1992). However, further studies into the roles of PI 3-kinase and its products have 
been made possible by the discovery of the inhibitor wortmannin (Arcaro & Wymann,
1993) (review (Ui etal. 1995)).
1.6.2.4.1 Wortmannin
Wortmannin is a fungal metabolite which was originally described by Baggiolini et al. 
in 1987 as an inhibitor of respiratory burst in neutrophils (Baggiolini etal. 1987). It 
was subsequently found to inhibit other pathways including PLC and D (Bonser et al.
1993), myosin light chain kinase (Nakanishi etal. 1992) and pleckstrin 
phosphorylation in platelets (Yatomi etal. 1992), although the concentrations of 
wortmannin required for these effects were in the micromolar range. However, at 
10OnM or less, wortmannin has been found to be a potent inhibitor of PI 3-kinase by 
covalently interacting with the p110 catalytic subunit (Yano et al. 1993). Recently, a 
study carried out by Wymann et al. identified the residues required for the covalent 
binding of wortmannin to PI 3-kinase (Wymann etal. 1996). Wortmannin was found 
to bind to Lys-802 on the p110 a subunit of PI 3-kinase. Point mutation of this residue 
completely abolished wortmannin binding. However, the different isoforms of PI 3- 
kinase demonstrate differing sensitivities to wortmannin. The PTK/SH2-coupled PI 3- 
kinase is very sensitive to wortmannin with an IC5o of 10nM, as is the Ptdlns-specific
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PI 3-kinase with an IC50 of 2.5nM (Wolscholski etal. 1994) (Volinia etal. 1995). In 
contrast, PI 3-kinase y is much less sensitive to wortmannin with an IC5o of 43nM on 
the purified enzyme (Stephens etal. 1994). Other PI 3-kinase isoforms such as 
Vps34, RAFT and FRAP are almost insensitive to wortmannin (Sabatini etal. 1995).
However, there are limitations as to the use of wortmannin as an indicator of PI 3- 
kinase activation due to its effective inhibition of at least two other signalling pathways, 
namely Ptdlns 4-kinase and PLA2 (Nakanishi etal. 1995) (Cross etal. 1995). The 
inhibition of these pathways may have profound effects on the PI 3-kinase pathway by 
affecting the generation of the PI 3-kinase substrate, Ptdlns(4,5)P2, or by affecting 
other pathways which may be directly or indirectly connected to PI 3-kinase.
1.6.2.4.2 Other inhibitors of PI 3-kinase
A novel PI 3-kinase inhibitor, namely 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4- 
one (LY294002) was synthesised and demonstrated to inhibit purified bovine brain PI 
3-kinase with an IC5o of 1.4pM (Vlahos et al. 1994). LY294002 was also found to 
inhibit the PI 3-kinase-dependent proliferation of cultured rabbit aortic smooth muscle 
cells as well as completely abolish fMLP-induced PI 3-kinase activity in human 
neutrophils. The effects of this inhibitor were also investigated on several other 
enzymes including Ptdlns 4-kinase, src, MAP-kinase, S6 kinase, DAG kinase, PKA 
and PKC (Vlahos et al. 1994). None of these enzymes were significantly inhibited by 
LY294002.
There is another inhibitor of PI 3-kinase that has recently been identified. 
Demethoxyviridin is structurally related to wortmannin but is a distinct compound and 
was observed to inhibit purified PTK/SH2-coupled PI 3-kinase with an IC5o of 3.4nM 
(Wolscholski etal. 1994). However, demethoxyviridin, like wortmannin, has also been 
observed to inhibit Ptdlns 4-kinase with an IC5o of approximately 50nM.
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These inhibitors, particularly wortmannin, have been used to identify a number of 
functional responses which are dependent on PI 3-kinase activation (see table 1.7). 
These responses include fMLP activation of neutrophils, IL-2 production following 
CD28 ligation by B7 in Tcells (Ward etal. 1995) and PDGF-mediated actin 
rearrangements in human fibroblasts and membrane ruffling in endothelial cells 
(Wymann & Arcaro, 1994) (Wennstrom etal. 1994).
1.6.2.4.3 Alternative approaches to studying PI 3-kinase 
More recently, other approaches to the identification of PI 3-kinase-dependent 
responses have been initiated. A p85 deletion mutant, which lacks a small domain 
between the SH2 domains (inter-SH2 region) required for the interaction of the p85 
subunit with the p110 catalytic subunit has been developed (Dhand etal. 1994). This 
prevents the interaction of the two subunits of PI 3-kinase and, when expressed in 
excess of the endogenous PI 3-kinase, can act as a dominant negative mutant due to 
its retained ability to associate with the phosphotyrosine binding sites that would 
activate endogenous PI 3-kinase. This dominant negative mutant has been observed 
to inhibit insulin-stimulated Ptdlns(3,4,5)P3 accumulation in U937 cells (Stephens,
1995).
A consitutively active PI 3-kinase has also been developed (Hu et al. 1995). In this 
mutant PI 3-kinase the catalytic p110 subunit is a chimeric protein in which the inter- 
SH2 region of the p85 subunit is covalently linked to its binding site on the p110 
subunit. This consitutively active PI 3-kinase has been demonstrated to activate a 
number of signalling pathways, such as p70 S6 kinase, mitogen-activated protein 
(MAP) kinase and Ras, independent of growth factor stimulation (Weng etal. 1995).
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1.6.2.4.4 Downstream effectors of PI 3-kinase
The development of PI 3-kinase inhibitors and active and dominant negative mutants 
has lead to a number of possible downstream effectors of PI 3-kinase being identified.
p70 S6 kinase is a serine/threonine kinase which phosphorylates the ribosomal protein 
S6. This results in enhanced mRNA translation and increased protein synthesis 
(Kozma and Thomas 1994) (review (Woodgett, 1994)). The activation of this kinase 
has not been well characterised but it is thought to involve multiple phosphorylation 
sites by more than one protein kinase and experiments using wortmannin have 
identified PI 3-kinase as an important regulator of p70 S6 kinase phosphorylation and 
activation (Parry & Ward, 1996) (Chung et al. 1994) (Monfar et al. 1995) (Kilgour et al.
1996). Also, mutations of the PDGF receptor, which prevent the binding of the p85 
subunit of PI 3-kinase, prevented the activation of p70 S6 kinase by PDGF, further 
implicating PI 3-kinase in the activation of p70 S6 kinase (Chung etal. 1994).
Some groups have demonstrated that the macrolide antibiotic rapamycin also inhibits 
p70 S6 kinase activation (Downward, 1994). The proposed pathway involves the 
putative PI 3-kinase target of rapamycin (TOR). Rapamycin, when complexed with its 
binding protein FK506 binding protein (FKBP) 12, can bind to and inhibit the functions 
of TOR. Thus, the inhibition of both TOR and p70 S6 kinase by rapamycin implicates 
TOR in the activation of p70 S6 kinase. Similar results have also been observed with 
another putative PI 3-kinase in T cells (Brown etal. 1994). FK506-binding protein 
rapamycin-associated protein (FRAP) has been demonstrated to be required for p70 
S6 kinase regulation and is sensitive to rapamycin (Brown etal. 1995). However, 
more work is required before a definitive answer can be given.
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Another serine/threonine protein kinase has also been linked to PI 3-kinase activation. 
PKB is a product of the Akt gene and is ubiquitously expressed (Bellacosa et al.
1993). The catalytic domain of PKB is homologous to the catalytic domains of all 
members of the PKC family (Coffer & Woodgett, 1991). Wortmannin has been 
demonstrated to inhibit the PDGF-induced activation of PKB (Franke etal. 1995). The 
coexpression of a dominant negative mutant of PI 3-kinase has also been 
demonstrated to inhibit PDGF-induced PKB activation (Burgering etal. 1995). The 
link between the activation of PI 3-kinase and PKB by PDGF was also suggested by 
the fact that the addition of Ptdlns(3)P induced activation of PKB in in vitro assays 
(Franke etal. 1995).
It is very interesting to note that Burgering et al. observed that the expression of a 
consitutively active PKB form resulted in the increased activity of p70 S6 kinase 
(Burgeririg etal. 1995). Therefore, the observations that both PKB and p70 S6 kinase 
are dowrstream effectors of PI 3-kinase and that PKB can activate p70 S6 kinase 
§ligg@§t§that PKB may be positioned upstream of p70 S6 kinase.
Certain FKC isoforms have also been proposed as downstream effectors of PI 3- 
kinase fclowing the observations that PI 3-kinase can associate with PKC 5 in both 
GM-CSFstimulated TF-1 cells and PAF stimulated platelets (Ettinger etal. 1996) and 
that Ptdlis(3,4,5)P3 can stimulate PKC s, 5, £ and ri isoforms in in vitro assays (Toker 
etal. 1994) (Nakanishi etal. 1993).
Finally, tie identification of a proposed Ptdlns(3,4,5)P3 binding protein, namely 
centaurira, in rat brain has possibly identified another downstream effector for 
Ptdlns(3t,5)P3 (Hammonds-Odie etal. 1996). Hammonds-Odie etal. proposed that
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centaurin-a may have a role in mediating the downstream events activated following 
growth factor stimulation of PI 3-kinase in the brain.
Although the exact roles for PI 3-kinase and its products have not yet been fully 
identified, it is apparent that they may play an important role in the activation of a 
number of different cell types.
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Table 1.7 - Responses observed to be potently inhibited by wortmannin. Some 
of the functional responses sensitive to nM concentrations of wortmannin are given 
below (adapted from Ward et al. 1996).




Respiratory burst from 
neutrophils
fMLP 5 Arcaro & 
Wymann, 1993
T cell chemotaxis RANTES 5 Turner et al., 
1996
IL-2 production from T 
cells
CD28 10 Ward etal., 
1995
T cell proliferation CD28 + CD3 10-100 Karnitz etal., 
1995
Actin rearrangements in 
fibroblasts
PDGF 5 Wymann & 
Arcaro, 1994
Membrane ruffling in 
endothelial cells
PDGF 10-100 Wennstrom et 
al., 1994
p1 integrin upregulation 
in HL60 cells transfected 




10-100 Shimizu etal., 
1995
Histamine secretion and 
leukotriene release from 
RBL cells
FceR1 3 Yano etal., 1993




10-100 Ninomiya et al., 
1994
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1.7 Monocyte functional changes
The main objective of this study was to characterise the action of the C-C chemokine 
MCP-1 on human monocytes and monocytic cell lines. Blood monocytes are 
immature cells that are produced in the bone marrow. They migrate into tissues and 
body cavities where they mature into macrophages. The monocyte-macrophage 
system plays a vital role in multiple host-defence mechanisms (Boggs & Winklestein, 
1985). For example, macrophages can initiate the immune response by acting as 
antigen presenting cells (Scala & Oppenheim, 1985). Macrophages engulf antigens 
and partly degrade them. A fraction then reappears on the surface of the macrophage 
along with gene products of the major histocompatibility complex (MHC) which are 
then presented to the lymphocyte inducing an immune response. This immune 
response is further mediated by macrophages which produce IL-1. IL-1 production 
stimulates T cells to produce IL-2, thus promoting T cell proliferation. Monocytes are 
also potent effectors of the inflammatory processes by their capacity to release 
arachidonic acid-derived mediators and respiratory burst products. They are chiefly 
involved in defending those organisms which give rise to a chronic inflammation.
Upon the development of an inflammatory response the monocytes will adhere to the 
endothelial layer, via the interaction of (3-integrins with the Ig superfamily members 
expressed on the endothelial layer (see section 1.2) and move down the specific 
chemokine concentration gradient towards the site of inflammation. In the last stage, 
the monocyte will transmigrate through the endothelial layer into the tissue. The 
release of cytokines and arachidonic acid-derived mediators provide signals to the 
other cells involved in the inflammatory response and act as a positive feedback 
mechanism. The production of respiratory burst products such as superoxide ions is 
of great importance in the killing of bacteria. This is made very clear in patients 
suffering from the rare genetic disease, chronic granulomatous disease (CGD). Both 
the monocytes and the neutrophils lack one or more of the protein components of the
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superoxide-generating system and the patients suffer repeated infections (Cross & 
Jones, 1991) (Hamers etal. 1984).
During the production of superoxide anions, there is an increase in oxygen uptake 
followed by the passing of two electrons from reduced nicotinamide adenine 
dinucleotide phosphate (NADPH), formed by the hexose monophosphate pathway, 
down two redox active components, namely a flavin adenine dinucleotide (FAD)- 
containing protein, and cytochrome b-245. This results in the eventual reduction of 
oxygen to produce superoxide (Cross & Jones, 1991). This system is known as 
NADPH oxidase. It becomes activated upon stimulation of the monocytes and the 
superoxide produced is released onto the outer face of the cell (Jones etal. 1993). 
The presence of superoxide dismutase (SOD) in the cells converts the superoxide 
ions into hydrogen peroxide (Root & Metcalfe, 1977).
Apart from the adhesion molecules that are upregulated on the surface of monocytes 
following stimulation there is another cell surface molecule which has been found to 
be upregulated on the surface of monocytes, namely CD23 (Vercelli etal. 1988). 
CD23 was first identified as a B cell activation marker and is a low affinity receptor for 
immunoglobulin E (IgE). It is also known as FCeRII (review (Delespesse etal. 1991)). 
CD23 is an integral type II membrane glycoprotein and several cytokines, including 
interleukin-4 (IL-4) (Vercelli etal. 1988), IL-3 (Alderson etal. 1992), GM-CSF and 
interferon-a (IFN-a) (Williams etal. 1992) stimulate its upregulation on monocytes. 
There are two isoforms of CD23, namely CD23a and b, that differ in their cytoplasmic 
domain and they have been shown to perform distinct functions (Yokota etal. 1988).
It is the type b CD23 which is expressed on monocytes.
When CD23 expression is increased on the cell surface it can be cleaved into 
biologically active soluble fragments and this cleavage process has been
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demonstrated to be involved in the differentiation of the myelomonocytic leukaemia 
cell line U937 into mature monocyte/macrophage cells (Ouaaz etal. 1993). CD23 
upregulation has also been identified in phagocytosis of IgE-coated particles by 
monocytes (Boltz-Nitulescu etal. 1988).
The upregulation of this cell surface CD23 molecule appears to be important in the 
monocytes regulation in IgE -dependent diseases and its upregulation on monocytes 
from patients suffering from allergic asthma has already been confirmed (Demoly et 
al. 1994).
Due to the difficulty in obtaining large numbers of blood-derived monocytes, the 
monocytic cell line THP-1 was utilised in this study. THP-1 cells were originally 
derived from a patient suffering from acute monocytic leukaemia (Tsuchiya etal. 
1980). They are a pre-monocytic cell line but, like monocytes, they possess Fc and 
C3b receptors. However, they lack surface and cytoplasmic immunoglobulins. They 
are a phagocytic cell line and can be differentiated into macrophage-like cells by 
factors such as phorbol ester (Tsuchiya etal. 1982).
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1.8 Aims of study
1. To determine the binding of MCP-1 to the human monocytic cell line THP-1 and to 
human embryonic kidney (HEK) 293 cells stably transfected with the CC CKR 2 A 
or B, using both radioligand binding studies and biotinylated MCP-1 and FACS 
analysis.
2. To examine the increase in intracellular calcium in response to MCP-1 using fura-2 
labelled cells and to explore the source of this calcium rise with the aid of various 
calcium influx and calcium mobilisation inhibitors in THP-1 cells compared to the 
transfected cells and human blood derived monocytes and to identify the possible 
role for PLC by studying IP3 generation.
3. To demonstrate the activation of PI 3-kinase by MCP-1 in THP-1 cells compared 
with the transfected cells by monitoring the production of PI 3-kinase products and 
to identify whether the PTK/SH2 -coupled PI 3-kinase and/or the G-protein -coupled 
PI 3-kinase are activated following MCP-1 stimulation using both a whole cell assay 
and an in vitro lipid kinase assay.
4. To determine whether MCP-1 induces tyrosine phosphorylation of proteins in THP- 
1 cells and the MCP-1 receptor transfected cells and to identify the role of these 
proteins in PI 3-kinase activation using Western blotting techniques.
5. To study the activation of various functional responses in monocytes following 
MCP-1 stimulation including chemotaxis, adhesion molecule upregulation, 
superoxide release and low affinity IgE receptor expression and to try to identify a 
possible role for the signal transduction pathways activated by MCP-1.
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SECTIO N 2 : M A TER IA LS  AND M ETHO DS
2.1 Materials
Material Source
p-glycerophosphate Sigma, Poole, U.K.
[,1BI]-MCP-1 Gift from Dr. M. Needham, Zeneca, 
U.K.
[33P]-yATP Dupont NEN, U.S.A.
[33P]-orthophosphoric acid Dupont NEN, U.S.A.
[aH] Ptdlns(4)P Amersham International, Amersham, 
U.K.
[3H] Ptdlns(4,5)P2 Amersham International, Amersham, 
U.K.
[3H]-thymidine Amersham International, Amersham, 
U.K.
‘Immunolyse’ blood lysing kit Coulter, U.S.A.
2-mercaptoethanol Sigma, Poole, U.K.
5/8pm PVPF chemotaxis membrane Costar, High Wycombe, U.K.
Adenosine triphosphate Sigma, Poole, U.K.
Ammonium persulphate BDH, Poole, U.K.
anti-CD11b-FITC Sigma, Poole, U.K.
anti-CD11c-FITC Sigma, Poole, U.K.
anti-CD14-FITC Sigma, Poole, U.K.
anti-CD23-FITC Biosource International,
anti-lgGi-FITC Sigma, Poole, U.K.
anti-lgG2A-FITC Sigma, Poole, U.K.
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anti-lgG-FITC Sigma, Poole, U.K.
anti-VLA-4-FITC Sigma, Poole, U.K.
Biorad protein reagent Biorad, U.K.
Bisacrylamide solid Sigma, Poole, U.K.
Bovine serum albumin Sigma, Poole, U.K.
Bromophenol blue BDH, Poole, U.K.
C5a Sigma, Poole, U.K.
Calcium chloride Sigma, Poole, U.K.
Chloroform Fisons, Loughborough, U.K.
Coomassie blue Sigma, Poole, U.K.




Diff-Quik stain Browne, Newbury, U.K.
Digitonin BDH, Poole, U.K.
Dimethyl sulphoxide Sigma, Poole, U.K.
Durapore filter plates Millipore, Watford, U.K.
Econazole Sigma, Poole, U.K.
EDTA Sigma, Poole, U.K.
EGTA Sigma, Poole, U.K.
Enhanced Chemiluminescence 
reagent
Amersham International, Amersham, 
U.K.
Eotaxin Peprotech, Rocky Hill, USA.
Epidermal growth factor Sigma, Poole, U.K.
Ethyl formate Fisons, Loughborough, U.K.
Ferricytochrome C Sigma, Poole, U.K.
Flo-scint IV scintillation fluid Canberra Packard, U.K.
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fMLP Sigma, Poole, U.K.
Foetal bovine serum Gibco BRL, Paisley, U.K.
Folch Lipids Sigma, Poole, U.K.
Fura-2/AM Calbiochem, U.K.
Geneticin (G418) Gibco BRL, Paisley, U.K.
GF/A filter paper Whatman, U.K.
Glacial acetic acid Fisons, Loughborough, U.K.
Glutamine Gibco BRL, Paisley, U.K.
Glycerol Sigma, Poole, U.K.
Goat anti-mouse peroxidase conjugate Gift from Dr. M. Welham, Bath, U.K.
Goat anti-rabbit peroxidase conjugate Gift from Dr. M. Welham, Bath, U.K.
Hank’s balanced salt solution Gibco BRL, Paisley, U.K.
HEK 293 CC CKR 2A and 2B 
transfected cells
Gift from Dr. V. Schweickart, ICOS 
Corp., Washington, USA.
Heparin C.P. Pharmaceuticals Ltd., Wrexham, 
U.K.
Hepes (1M liquid) Gibco BRL, Paisley, U.K.
Hepes solid Sigma, Poole, U.K.
Horseradish peroxidase Sigma, Poole, U.K.
Hydrochloric acid BDH, Poole, U.K.
Hydrogen peroxide Sigma, Poole, U.K.
IL-3 R+D Systems, Abingdon, U.K.
IL-8 Gift from Dr. I. J. D. Lindley, Sandoz 
Research Institute, Austria.
Iodine Sigma, Poole, U.K.
lodoacetamide Sigma, Poole, U.K.
lonomycin Sigma, Poole, U.K.
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IP3 assay kit Amersham International, Amersham, 
U.K.
Leupeptin Sigma, Poole, U.K.
Lithium chloride Sigma, Poole, U.K.
Lymphoprep Nycomed, Birmingham, U.K.
Magnesium chloride Sigma, Poole, U.K.
Manganese chloride Sigma, Poole, U.K.
MCP-1 Peprotech, Rocky Hill, USA.
MCP-1 Fluorkine kit R+D Systems, Abingdon, U.K.
MCP-3 Peprotech, Rocky Hill. USA.
MEM medium Gibco BRL, Paisley, U.K.
MEM non-essential amino acids Gibco BRL, Paisley, U.K.
Methanol Fisons, Poole, U.K.
Methylamine Fisons, Loughborough, U.K.
MIP-1a Peprotech, Rocky Hill, USA.
Molecular weight markers Gibco BRL, Paisley, U.K.
Monoclonal MCP-1 antibody R+D systems, Abingdon, U.K.
N-butanol BDH, Poole, U.K.
Nickel chloride Sigma, Poole, U.K.
NP40 Fisons, Poole, U.K.
Optiphase Scintillation fluid Canberra Packard, U.K.
Orthophosphoric acid Fisons, Loughborough, U.K.
Ovalbumin Sigma, Poole, U.K.
p70 S6 kinase antibody Santa Cruz, U.S.A.
p85 (a-isoform) antibody Gift from Dr. D. Cantrell, I.C.R.F., U.K.
Penicillin / Streptomycin Gibco BRL, Paisley, U.K.
Pepstatin Sigma, Poole, U.K.
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Perchloric acid Fisons, Loughborough, U.K.
Pertussis Toxin Gibco BRL, Paisley, U.K.
Petroleum Ether BDH, Poole, U.K.
Phosphate buffered saline Gibco BRL, Paisley, U.K.
Phosphate free DMEM Gibco BRL, Paisley, U.K.
Phosphatidylinositol Sigma, Poole, U.K.
Phosphatidylserine Sigma, Poole, U.K.
Phosphotyrosine antibody (4G10) Gift from Dr. M. Welham, Bath, U.K.
Phosphotyrosine antibody (PY20) Sigma, Poole, U.K.
Plasticware (tissue culture grade) Nunc, U.K.
PMA Sigma, Poole, U.K.
PMSF Sigma, Poole, U.K.
Potassium hydroxide Fisons, Poole, U.K.
Potassium oxalate Sigma, Poole, U.K.
Propan-1 -ol Fisons, Loughborough, U.K.
Propridium Iodide Sigma, Poole, U.K.
Protein G beads Sigma, Poole, U.K.
RANTES Gift from Dr. T. Wells, GIMB, Geneva, 
Switzerland.
Ro31 -8220-002 Gift from Dr. J.S. Nixon, Roche, U.K.
RPMI 1640 Gibco BRL, Paisley, U.K.
Scopoletin Sigma, Poole, U.K.
Sodium azide Sigma, Poole, U.K.
Sodium chloride Sigma, Poole, U.K.
Sodium citrate BDH, Poole, U.K.
Sodium dodecyl sulphate Sigma, Poole, U.K.
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Sodium fluoride Sigma, Poole, U.K.
Sodium hydroxide Fisons, Loughborough. U.K.
Sodium orthovanadate Sigma, Poole, U.K.
Sodium pyruvate Gibco BRL, Paisley, U.K.
Sulphuric acid Fisons, Loughbrough, U.K.
Superoxide dismutase Sigma, Poole, U.K.
TCA Sigma, Poole, U.K.




THP-1 cells ECCAC, Salisbury, U.K.
Tris base Sigma, Poole, U.K.
Tris HCI Sigma, Poole, U.K.
Tween 20 Sigma, Poole, U.K.
U73122/U73343 Affinity Laboratories,
Universal Indicator Sigma, Poole, U.K.
Untransfected HEK 293 cells ECACC, Salisbury, U.K.
Uridine triphosphate Sigma, Poole, U.K.
Versene Gibco BRL, Paisley, U.K.
Versene Gibco BRL, Paisley, U.K.
Wortmannin Sigma, Poole, U.K.






THP-1 cells were cultured in RPMI 1640 medium (appendix 1). They were 
maintained at 37°C in 95% 0 2 / 5% C02 and passaged when they reached a 
concentration of between 5x105 - 1x106 cells/ml.
2.2.1.2 HEK 293 cells
HEK 293 cells transfected with either the MCP-1 type A or the MCP-1 type B receptor 
were obtained from ICOS Corp., USA.
The transfected/untransfected control cells were cultured in T75 Nunc flasks in 
Modified Eagles medium (MEM) (appendix 1). The cells were dissociated from the 
flask using 3ml Versene (buffered EDTA solution) and washed in medium prior to 
passaging. The cells were passaged when confluent, i.e. 1 : 5 every seven days.
Prior to all experiments the HEK 293 cells were dissociated from the flask using 3 ml 
of Versene.
2.2.1.3 Monocyte preparation
Human venous blood from healthy individuals was collected into either 10 Units of 
heparin/ml blood or 3.8% citrate at 1 ml per 9ml of blood. This was centrifuged at 800g 
for 6 minutes and the plasma aspirated off. The packed cell volume was diluted 1:1 
with RPM11640 and layered 2:1 onto Lymphoprep (specific gravity 1.077). This was 




Photograph 2.1 - Cytospin preparations of monocyte populations a) before and 
b) after plastic adherence. The PBMC’s were purified as given in section 2.2.1.3 and 
then the monocytes isolated by plastic adherence. Samples of the preparations before 
and after this adherence step were prepared using a Shandon cytospin 3 and the 
slides stained with Diff-Quick stain. A large number of the cells in photograph a) can 
be seen as lymphocytes, small cells with a large dense nucleus and scanty 
surrounding cytoplasm. In photograph b) there are very few lymphocytes with the 
majority of the cells being monocytes, with horse-shoe shaped nuclei and an abundant 
cytoplasm (Magnification x 40).
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The peripheral blood mononuclear cell (PBMC) layer between the RPMI and the 
Lymphoprep was removed and washed with a three fold excess of RPM11640 and 
centrifuged at 500g for 10 minutes. The PBMC’s were then plated out into petri 
dishes in RPM11640 with 10% foetal calf serum (FCS) a t» 2x107 cells/dish and left at 
37°C for one hour in 95% 0 2/ 5%C02. The non-adherent cells were removed and 
discarded and the adhered monocytes were gently scraped off the petri dish using a 
plastic cell scraper and washed once with RPM11640 and used in the experiment. A 
cytospin of the cell suspension was carried out to determine the purity of the 
population (Photograph 2.1a and b). Purity was always between 90-95%.
2.2.2 Radioligand binding
A 96 well Durapore filter plate (0.65|im pore size) was washed with 200pl of 
phosphate buffered saline (PBS) containing 10mg/ml bovine serum albumin (BSA) 
and dried at 37°C to reduce non-specific binding to the filters. The HEK 293 cells and 
the THP-1 cells were washed twice and resuspended in binding buffer (appendix 2) at 
5x106 cells/ml and 1x107 cells/ml respectively. 50pl of the competing ligand (0.1- 
30nM) or binding buffer was added to the appropriate wells followed by 50|il of 400pM 
125I-MCP-1 (total counts » 55 OOOcpm, stock specific activity 2000Ci/mmol, 100Ci/ml). 
The incubation was started by the addition of 100jil of THP-1 cells (1x106/well) or 
HEK 293 cells (5x105 /well) and left at 4°C for 90 minutes. Following incubation, the 
plate was washed twice with ice cold binding buffer containing 0.5M NaCI using a 
Multiscreen vacuum manifold for 96 well Durapore plates from Millipore. The plate was 
blotted on paper towel and the filters punched out using Multiscreen multiple punch 
apparatus and disposable punch tips. Each filter was then counted for two minutes on 
an LKB Wallac 1277 Gammamaster automatic gamma counter.
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Non-specific binding to the filters was determined by incubating 125I-MCP-1 in the 
absence of cells. This value was then subtracted from the binding data obtained in 
the presence of cells. All the binding data was normalised by expressing it as a 
percentage of the total binding. The total binding was defined as the radioactivity 
bound to the cells in the absence of any competing ligand.
In order to be able to calculate the dissociation constant for MCP-1 binding (Kd) and 
the number of receptors per cell (B m a x ), a  Scatchard transformation was performed, in 
which the ratio of the number of moles of bound ligand/free ligand was plotted against 
the number of moles of bound ligand (Scatchard, 1949). This transformation was 
carried out using the Grafit binding program (Leatherbarrow, 1992). This Scatchard 
plot also determined the number of receptor types present on the cell. A straight line 
indicates a single receptor type. This straight line has a slope of 1/Kd and an intercept 
with the x-axis of Bm ax- The number of receptors per cell can be directly calculated 
from the B m ax using equation 1.
Equation 1
Number of receptors = (B m a x  / 5000) x NA
per cell cell number
Where B Ma x  = intercept with the x-axis
5000 = dilution factor (B m a x  is given as moles/l but only 200jil/well used in the
assay)
Na = Avogadro’s number = 6.02x1023 moles’1
In some cases the Scatchard plot departs significantly from linearity. A curvilinear 
plot indicates the presence of more than one receptor type, each with differing Kd 
values.
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2.2.3 Binding bv FACS analysis
Recently, R+D Systems have developed a binding assay for MCP-1 which utilises 
biotinylated MCP-1. Biotinylated MCP-1 is incubated with the cells and binds to 
receptors on the cell surface. The cells are then directly incubated with 
fluoresceinated-avidin which attaches to the receptor-bound biotinylated MCP-1. Cells 
expressing the receptors become fluorescently labelled and the intensity of this 
fluorescence staining is directly proportional to the density of receptors present on the 
cell surface. The fluorescence is then determined using a fluorescence activated cell 
sorter (FACS).
FACS is a technique in which cells flow in single file in the centre of a fluid stream 
through a fine orifice at rates of up to 2-3 thousand cells per second (Watson, 1991).
A light source illuminates the particle stream and detectors measure both the light 
scattered by the cell, giving an indication of cell size and the fluorescence intensity 
emitted from the fluorescent probe with which the cells have been labelled. The 
FACS is also able to separate, or sort, the cells into distinct sub-populations using 
various parameters such as fluorescence intensity or size. FACS analysis of binding 
has one main advantage and that is its sensitivity. This makes it possible to detect 
very low numbers of receptors i.e. a few thousand per cell.
2.2.3.1 Assay procedure
HEK 293 cells and THP-1 cells were washed twice and resuspended at a 
concentration of 4x106 cells/ml in PBS. 25^1 of the cell suspension was added to 
polypropylene FACS tubes and incubated with 10jxl of biotinylated MCP-1 (stock = 
224nM) or negative control for 60 minutes at 4°C.
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To check the specificity of the MCP-1 binding, both non-biotinyiated MCP-1 and an 
anti-MCP-1 antibody were used. The non-biotinylated MCP-1 was added at a final 
concentration of 1 jiM, prior to the biotinylated MCP-1 and the samples were 
incubated for 60 minutes at 4°C.
For the anti-MCP-1 antibody samples, 10^ 1 of the biotinylated MCP-1 was incubated 
with 20\i\ of the 2mg/ml stock anti-MCP-1 antibody for 15 minutes at room 
temperature prior to its addition to the cell suspensions. Also, to block Fc-mediated 
reactions, the cell suspensions were incubated with 0.1 mg/ml anti-mouse IgG 
antibody at room temperature for 15 minutes prior to the addition of the biotinylated 
MCP-1/anti-MCP-1 antibody complex. The samples were incubated for 60 minutes at 
4°C.
Following the 60 minute incubation at 4°C, 10|J of avidin-fluoroscein isothiocyanate 
(FITC) conjugate (f:p ratio 5:1) was added to the suspensions and incubated for a 
further 30 minutes at 4°C. After the second incubation, the cell suspensions were 
washed twice with a working solution of the RDF1 wash buffer provided with the kit 
containing 0.5M NaCI and then resuspended in RDF1 wash buffer without NaCI. The 
amount of binding to the live cells (as defined by the lack of uptake of propridium 
iodide) was analysed using a Becton Dickinson FACS Vantage fluorescence activated 
cell sorter, collecting 10 000 events for each sample.
2.2.4 Measurement of rCa2*!
The measurement of [Ca2+J has been made possible by the development of a number 
of calcium sensitive dyes including fura-2 (review (Walt et al. 1987)). Fura-2 can be 
non-disruptively loaded into the cells as the acetoxymethyl ester (AM) since the 
esterified fura-2 is uncharged and hydrophobic and can cross the plasma membrane.
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Once in the cells, endogenous esterases release the free fura-2 which cannot 
permeate out of the cell. The fluorescence excitation maximum of fura-2 shifts to a 
lower wavelength upon calcium binding, without any change in the emission 
maximum. Thus, fura-2 can be used as a dual excitation indicator. The excitation 
maximum for calcium-free and calcium-bound fura-2 are monitored at 380nm and 
340nm respectively. The emission maximum is monitored at 510nm. Fura-2 also has 
an isofluorescence, or isobestic, point at 360nm which can be used to monitor 
calcium-independent fluorescence. For example, manganese can be used to monitor 
influx pathways as it binds to fura-2 causing a quenching of the fluorescence at 
360nm.
2.2.4.1 [Ca2+]i measurements in a cell population
2.2.4.1.1 Loading cells with fura-2/AM
The cells were pelleted by centrifugation and resuspended in Hanks balanced salt 
solution (HBSS) (without calcium (Ca2+)/magnesium (Mg2+)) containing 0.1% BSA 
(HBSS/BSA) at between 1x106 - 1x107 cells/ml. The HEK 293 cells and THP-1 cells 
were then incubated with 5jiM fura-2/AM at 37°C for 40 minutes and 30 minutes 
respectively. Subsequently, the cells were washed twice and resuspended at 1x106 
cells/ml in HBSS/BSA. Human monocytes were purified as given in section 2.2.1.3 
and loaded with fura-2/AM as described for HEK 293 cells.
2.2.4.1.2 fCa2+li measurement
The cells were aliquoted into a 2ml quartz cuvette at a final concentration of 3x105 
cells/ml for the THP-1 cells and 1x106 cells/ml for the HEK 293 cells and for the 
human monocytes, if enough were obtained from the purification procedure. 1mM 
Ca2+ and 1 mM Mg2+ was added to the cell suspension in the cuvette and equilibrated 
in the 37°C chamber in the spectrofluorimeter for 4 minutes. The cell suspensions 
were constantly stirred using a small magnetic stirrer bar. A basal intracellular
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calcium measurement was taken for 40 seconds prior to the addition of the agonist. 
The response was monitored for at least 60 seconds and detected using dual 
excitation wavelengths of 340nm and 380nm and a single emission wavelength of 
510nm on a dual excitation/dual emission spectrofluorimeter from Photon Technology 
International.
For the manganese influx experiments, the cells were loaded and maintained in 
HBSS/BSA with 100j^M Ca2+ and then pelleted immediately prior to use and 
resuspended and treated as given above. The changes were then monitored at an 
excitation wavelength of 360nM and an emission wavelength of 510nm.
The administration time of any compounds used was as given in the appropriate figure 
legends during the 4 minutes pre-incubation period.
2.2.4.1.3 Fluorimeter calibration
Calibration of the system was achieved by monitoring the fluorescence changes in the 
cell suspensions after the addition of 0.16ng/ml digitonin followed by the addition of 
40mM sodium hydroxide (NaOH) and 4mM [ethylenebis(oxyethylenenitrilo)tetra- 
acetic] acid (EGTA) 30 seconds later. Conversion of the change in intracellular 
calcium from the ratio of the fluorescence at the two wavelengths to a nM calcium 
concentration was then determined as defined by Grynkiewicz et. al. (Grynkiewicz et 
al. 1985). In brief, the equation is as follows:
Equation 2
[Ca2+]j = Kd R-Rmin S,2 
Rmax"R Sb2
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Where, Kd = effective dissociation constant for fura-2 (2.24 x 10'7 M)
R = Ca2+ bound / Ca2+ free fluorescence ratio 
Rmjn = fluorescence ratio with zero calcium 
Rmax = fluorescence ratio under saturating calcium conditions 
Sf2/Sb2 = ratio of fluorescence values for Ca2+ bound / Ca2+ free indicator 
measured at the wavelength used to monitor Ca2+ - free indicator (denominator 
wavelength of R) i.e. at 380nm.
2.2.4.2 [Ca2+]i measurements on a small population of adherent cells
The [Ca2+]i changes in HEK 293 cells were also studied at the single cell level. This 
was performed by growing the cells on 22mm diameter glass cover slips. When sub­
confluent, the cells were loaded with 5jiM fura-2/AM at 37°C for 40minutes in HBSS 
(with 1 mM Ca2+/Mg2+) / BSA. The adherent cells were then washed twice and placed 
in a 37°C chamber with 1ml HBSS (with Ca2+/Mg2+)/ BSA. This chamber was 
positioned on a fluorescence microscope from Photon Technology International and a 
population of approximately 30 cells was selected by adjusting the field of view. Using 
a x 40 oil immersion objective, the fluorescence changes were monitored for 40 
seconds before and 60 seconds after agonist addition. The results were expressed as 
the fluorescence ratio at 340/380nm wavelengths.
2.2.5 Inositol (1.4.5) trisphosohate (IP*) measurement
The measurement of IP3 can be performed by two different techniques. The first 
relies on the labelling of cells with [3H]-inositol and the separation of IP3 isomers by 
HPLC (Meek, 1986). The main drawback with this method is the assumption that all 
the phosphoinositide pools have been labelled to equilibrium, but this is rarely
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achieved. The second method was first developed by Challiss et al. in 1988 (Challiss 
et al. 1988) and has subsequently been optimised and marketed by Amersham 
International. This assay is a competition assay using a bovine adrenal cortex 
membrane preparation as a binding protein. [3H]-IP3 is incubated with this binding 
protein in the presence of non-labelled I Pa/samples and the IP3 concentration in the 
samples calculated from a standard curve. The radioreceptor approach is both faster 
and more suitable for analysis of large sample numbers than the isotopic method.
Also, because it does not rely on cell labelling, it is both more accurate and more 
sensitive as possible agonist-induced changes in the specific radioactivity of IP3, which 
can occur in the isotopic method, do not apply.
2.2.5.1 Sample preparation
The HEK 293 cells and the THP-1 cells were washed once in HBSS with 0.1% BSA 
and resuspended at a concentration of 2x107 cells/ml in HBSS / BSA containing 1mM 
Ca2+ and 1mM Mg2+. 500pl aliquots were put into 1.5ml Eppendorf tubes and, 
following 10 minutes equilibration at 37°C, were stimulated with 50jLtl of agonist for 
various times. The reaction was quenched by the addition of 0.22 volumes of ice cold 
20% (v/v) perchloric acid. After 20 minutes incubation on ice, the proteins were 
pelleted at 10 OOOg for 5 minutes. The supernatants were titrated to pH 7.5 with 1.5M 
potassium hydroxide (KOH) containing 60mM N-[2-hydroxyethyl] piperazine-N’-[2- 
ethanesulphonic acid] (Hepes) buffer in the presence of 1pl universal indicator.
2.2.5.2 Detection of IP3
The IP3 levels in these supernatants were assayed immediately, using the IP3 
detection kit from Amersham International. In brief, the sample was incubated with 
0.07nCi/ml [3H]-IP3 and bovine adrenal membrane binding protein for 15 minutes on 
ice in parallel with IP3 standards ranging from 0.19-25pmol / tube in H20  (assay 
sensitivity 0.1 pmol/tube). The samples were then centrifuged and the pellets
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resuspended in 0.15M sodium hydroxide to release the all of the IP3 bound to the 
receptor. After 10 minutes incubation at room temperature the samples were 
decanted into scintillation vials and 4ml of scintillation fluid was added. The tubes 
were read on an LKB Wallac 1215 Rackbeta liquid scintillation counter for 4 minutes 
each. The results were calculated using linear regression from the standard curve, 
performed in parallel with the samples. A typical standard curve is shown in figure 
2.1.
2.2.6 PI 3-kinase activity
There are two separate methods for measuring the agonist-induced activation of PI 3- 
kinase. These are the measurement of the accumulation of D-3 phosphatidylinositol 
lipids in intact cells and the immunoprecipitation of PI 3-kinase using an antibody to 
the p85 subunit followed by an in vitro lipid kinase assay of the immunoprecipitated PI 
3-kinase. These two assays differ in the PI 3-kinase activity they measure. The 
former accounts for all the PI 3-kinase activities that are activated in the cells. In 
contrast, the in vitro lipid kinase assay only measures the activation of the PTK/SH2 - 
coupled PI 3-kinase, immunoprecipitated by the p85 antibody.
2.2.6.1 Accumulation of D-3 phosphatidylinositol lipids in intact cells
2.2.6.1.1 Sample preparation
The cells were washed three times in phosphate-free Dulbeccos Modified Eagles 
medium (DMEM) with 10 minute incubations at 37°C before each spin of 400g for 5 
minutes. The cells were subsequently resuspended in 10ml phosphate-free DMEM 
containing 10% dialysed foetal calf serum and 20mM HEPES at 1x107 cells/ml. THP- 
1 cells were incubated with 1mCi of [32P]-orthophosphoric acid (100nCi/ml, 185MBq) 
at 37°C for 4 hours. The HEK 293 cells were incubated with 0.5mCi [32P]- 























Figure 2.1 - A typical standard curve for the measurement of IP3.
Non-specific binding was defined as the total binding in the presence 
of excess unlabelled IP3 (0.1 nmoles). This was subtracted from the
binding data and the percentage of bound/total binding was plotted against 
l°9 [IP3]- The total binding was defined as the amount of radioactivity in
the absence of any competing ligand. Data is mean of duplicate samples.
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After incubation, the ceils were washed three times in phosphate-free DMEM and 
resuspended in RPM11640. 1x107 [32P]-labelled cells were aliquoted in a volume of 
120jLtl into 1.5ml Eppendorf tubes and equilibrated at 37°C for 10 minutes. The cells 
were stimulated with 12pl of agonist or vehicle for the appropriate times and the 
reaction quenched by the addition of 700jnl of ice cold chloroform/methanol/water 
(32.6%/65.3%/2.1%) according to the method described by Jackson etal. (Jackson et 
al. 1992). The samples were immediately put on ice. 600^1 of chloroform containing 
10pg of Folch lipids as a carrier protein were then added along with 100^1 of 2.4M 
hydrochloric acid (HCI), 5mM tetrabutylammoniumhydrogen sulphate. The extraction 
mixtures were vortexed and centrifuged at 3 OOOg for 5 minutes. The lower phase of 
the extraction mixture was subsequently removed and added to 400pl of 1M HCL, 
5mM ethylenediaminetetraacetic acid (EDTA). The mixtures were again vortexed and 
centrifuged at 3000g for 5 minutes. The lower phase was removed and dried in vacuo 
using a Savant SpeediVac . When dried down, 1 ml of 25% (w/v) 
methylamine/methanol/N-butanol (4/4/1) was added to the residue and, after 
vortexing, the samples were incubated in a 53°C water bath for 40minutes. This 
deacylation procedure renders the glycerophosphorylinositol derivatives of Ptdlns(3)P 
(GroPlns(3)P), Ptdlns (3,4)P2 (GroPlns(3,4)P2) and Ptdlns(3,4,5)P3 
(GroPlns(3,4,5)P3) water soluble. The samples were then cooled for 1 minute on ice 
and dried in vacuo. Finally, 500pl of water and 600pil of N-butanol/40-60% petroleum 
ether/ethyl formate (20/4/1) were added. The samples were vortexed and centrifuged 
at 750g for 30 seconds. The upper phase was removed and discarded and the lower 
phase was dried in vacuo. The samples were then stored at -20°C until analysis.
2.2.6.1.2 HPLC analysis of samples
Anion exchange high performance liquid chromatography (HPLC) was used to 
analyse the lipid content of the samples using a water and phosphate buffer gradient 
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Figure 2.2 - An example of a trace showing the retention times
of the [3H]Ptdlns(4)P and [3H]Ptdlns(4,5)P2 standards used in the analysis
of PI 3-kinase products. The elution times of the 3-phosphorylated 
were compared to previous results obtained by Dr. Stephen Ward and 
previously published data (Stephens etal. 1991).
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orthophosphate ((NH4)2HP04) with the pH adjusted to 3.8 using orthophosphoric acid. 
The samples were resuspended in 120pl of water and injected onto a Partisphere SAX 
column. The eluant was detected using a Canberra Packard A-500 Fio-One on-line 
beta radiodetector where it was mixed in a ratio of 1:3 with Flo-Scint IV scintillation 
cocktail, according to manufacturers specifications. The results were analysed on a 
FLO-one data program. The retention times were compared to standards of 
[H3]Ptdlns(4)P and [H3]Ptdlns(4,5)P2. An example of the standards trace is seen in 
figure 2.2. The identity of the various peaks obtained using this separation technique 
has been defined previously (Stephens etal. 1991). The Ptdlns(3)P elution time was 
compared to that determined by Dr. Stephen Ward by immunoprecipitating PI 3- 
kinase using an anti-p85 antibody and performing an in vitro lipid kinase assay. The 
Ptdlns(3)P was isolated by TLC and then extracted from the TLC plate and its elution 
time on the HPLC monitored (personal communication) (Ward etal. 1995). The 
elution times of the other 3-phosphorylated lipids were compared to those quoted in 
the literature (Stephens etal. 1991) (Traynor-Kaplan etal. 1988) (Cheatham etal.
1994). The levels of Ptdlns were used as an internal standard to confirm that each 
sample contained a similar amount of radioactivity as the Ptdlns pool should not vary 
upon agonist stimulation.
2.2.6.2 Immunoprecipitation and in vitro lipid kinase assay
2.2.6.2.1 Coupling the antibody to protein G sepharose beads 
The protein G sepharose beads from Sigma were provided in methanol and were 
therefore washed three times with 1 ml of PBS and then resuspended as a 50% 
suspension in PBS. 500pl aliquots were stored at 4°C until required.
50jnl of anti-p85 antibody was added to 500jj.I of 50% bead suspension and the volume 
increased to 1ml with PBS. The suspension was rotated for two hours at room 
temperature. Following rotation, the bead suspension was washed three times with
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1 ml of PBS and again resuspended as a 50% suspension by the addition of 250jil of 
PBS and stored at 4°C until required.
To confirm that the antibody had coupled to the beads, 10^ 1 of the beads were 
denatured by heating to 90°C for 10 minutes in reducing sample buffer (appendix 5). 
The samples were then separated by a 10% sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis (SDS-PAGE) gel (appendix 5), along with molecular weight 
markers, using Biorad Mini Protean II gel running apparatus. The gel was run at 75 
volts whilst the samples traversed through the stacking gel and 175 volts whilst they 
traversed through the resolving gel. The gel was stained with Coomassie blue stain 
for 6 hours and subsequently destained for 24 hours (appendix 5) to detect the heavy 
and light chains of the antibody. See figure 2.3 for an example of the gel.
2.2.6.2.2 Immunoprecipitation of the PI 3-kinase.
This was performed as described by Ward et al. (Ward et al. 1992). HEK 293 cells 
and THP-1 cells were pelleted by centrifugation and washed twice with RPM11640 
and resuspended in RPM11640 + 20mM Hepes at a concentration of 2x107 cells/ml. 
500fil aliquots of the cells were allowed to equilibrate at 37°C for 10 minutes and then 
stimulated with 50pl of agonist for the appropriate times. The reaction was stopped by 
the addition of equal volumes of ice cold lysis buffer ( appendix 3). The samples were 
then rotated at 4°C for 15 minutes and the cell debris pelleted at 10 OOOg for 15 
minutes at 4°C. 20pl of lysate was kept for a total kinase sample and the rest of the 
lysates were removed and added to 1.5ml Eppendorf tubes containing 20ja.l of protein 
G sepharose beads. The samples were then pre-cleared by rotating at 4°C for 60 
minutes to remove any non-specific proteins that may bind to protein G-sepharose. 
The pre-cleared samples were spun at 10 OOOg for 5 minutes and the supernatants 
removed and added to 1.5ml Eppendorf tubes containing 20jil of the antibody-coupled 
protein G beads. These suspensions were rotated for 120 minutes at 4°C.
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Subsequently, the immunoprecipitates were washed 3 times with lysis buffer, once 
with PBS, twice with 500mM lithium chloride (LiCI) (pH 7.4), once with water and once 
with lipid kinase buffer ( appendix 4), spinning at 10 OOOg between each wash. After 
the final wash all the surplus kinase buffer was removed using a Hamilton syringe.
2.2.6.2.3 In vitro lipid kinase assay.
Each of the samples, including the total lysate sample, were resuspended in 40|J of 
lipid kinase buffer. 50pl of a lipid substrate mixture (1 mg of Ptdlns and 1 mg of 
phosphatidylserine (PtdS) made up in 2ml of 25mM Hepes/1mM EDTA and dispersed 
by sonication in three 15 second bursts on ice) was added to the immunoprecipitates. 
The reaction was initiated by the addition of 5 pCi of [y-32P]-ATP (S.A. 3000Ci/mmol, 
0.5mCi/ml, 18.5MBq) and 100 i^M ATP. The samples were incubated in a 25°C water 
bath for 15 minutes and the reaction quenched using 100^11M HCL and 200jx\ 1:1 
chloroform:methanol. The samples were spun for 30 seconds at 10 OOOg and then 
the lower chloroform layer removed and dried in vacuo.
The dried samples were resuspended in 50jxl chloroform and applied to a 1% oxalate 
sprayed thin layer chromatography (TLC) plate. The plate was placed in a TLC tank 
that had been equilibrated for at least 6 hours with propan-1-ol:2N glacial acetic acid 
(65:35 (v/v)) and lined with filter paper to ensure adequate vapour equilibration. The 
TLC was run for 15 hours.
Subsequently, the plate was air dried and exposed to iodine to detect the substrates 
and finally exposed to a film for 1-12 hours at -70°C. The film was developed using an 
RGII Fuji X-ray film processor. The total lysate sample contained not only PI 3-kinase 
but also other kinases such as PI 4-kinase. This provided a positive control for the in 








Figure 2.3 - Example of an SDS-PAGE gel to show 
coupling of the p85-antibody to the protein G 
sepharose beads. Lane 1 shows the p85 antibody 
coupled beads and lane 2 shows the control, 
uncoupled beads. The molecular weight markers 
are indicated by the arrows as are the heavy and 
light chains of the antibody.
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Figure 2.4 - Diagram to show the reaction which takes place in the in 





The Ptdlns(3)P product visualised by autoradiography was confirmed from previous 
experiments performed by Dr. Stephen Ward, in which the product was extracted from 
the TLC plate and analysed by HPLC (personal communication).
2.2.7 Detection of tyrosine phosohorvlated proteins
2.2.7.1 Sample preparation
THP-1 cells and HEK 293 cells were washed twice with RPM11640 and resuspended 
at 2x107 cells/ml in RPM11640 with 20mM Hepes. 500^1 aliquots of cells were 
equilibrated at 37°C for 10 minutes prior to stimulation with 50^1 of agonist for various 
times. The reaction was quenched by the addition of an equal volume of ice cold lysis 
buffer (appendix 3). The samples were rotated for 15 minutes at 4°C and then the cell 
debris pelleted at 10 OOOg for 15 minutes at 4°C. The supernatant was pre-cleared for 
1 hour by rotating with 20jil of a 50% suspension of protein G-sepharose beads at 
4°C. This removed any non-specific proteins which may have bound to protein G- 
sepharose.
The beads were spun down at 10 OOOg for 5 minutes at 4°C and then the tyrosine 
phosphorylated proteins in the supernatants were immunoprecipitated by rotating with 
20jul of a 50% suspension of protein G beads coupled to PY20 anti-phosphotyrosine
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antibody (coupling method as given for p85 antibody coupling in section 2.2.6.2.1) for 
2 hours at 4°C. The immunoprecipitates were washed 5 times with lysis buffer and 
denatured by heating to 90°C for 10 minutes with 15^ 1 reducing sample buffer 
(appendix 5).
The proteins were separated on a 7.5% SDS gel using Biorad Mini Protean II gel 
running apparatus, Western blotted and detected as given in section 2.2.9.
2.2.8 Phosphorylation of p70 S6 kinase
2.2.8.1 Sample preparation
THP-1 cells were depleted of serum in the culture medium for 24 hours prior to the 
sample preparation. The cells were then washed once and resuspended at 2x107 
cells/ml in RPM11640 with 20mM Hepes. 500pl aliquots of cells were equilibrated to 
37°C for 10 minutes and then stimulated with 50jxl of agonist for various times. The 
reaction was quenched by the addition of an equal volume of ice cold lysis buffer 
(appendix 3). The cell lysates were rotated for 15 minutes at 4°C and then the cell 
debris pelleted by centrifugation at 10 OOOg for 15 minutes at 4°C. The proteins were 
precipitated by the addition of 700jil of ice cold acetone to 500pl of the cell 
supernatant. The samples were left on ice for 15 minutes and then the proteins 
pelleted by centrifugation at 10 OOOg for 15 minutes at 4°C. The acetone was dried off 
in vacuo and the concentrated proteins denatured in 100^1 of sample buffer (appendix 
5) by heating to 90°C for 10 minutes.
The proteins were separated on a 15% SDS gel, containing an 
acrylamide/bisacrylamide mixture of 30%/0.08% respectively instead of 30%/0.8%, 
using the Hoefer SE400 ‘Sturdier’ vertical slab gel unit. The proteins were Western 
blotted and detected as given in section 2.2.9.
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2.2.9 SDS-PAGE and Western blotting
2.2.9.1 Separation of proteins
The proteins were separated on an SDS gel of the percentage specified in the sample 
preparation (sections 2.2.7 and 2.2.8)(appendix 5) in parallel with molecular weight 
markers following a method adapted from Laemmli (Laemmli, 1970). The gels were 
run at 75 volts whilst the samples traversed through the stacking gel and then 180 
volts to the bottom of the resolving gel.
The separated proteins were transferred onto a nitrocellulose membrane by semi-dry 
transfer. This involved wetting the electrodes in semi-dry transfer buffer (appendix 5) 
and making a sandwich of 4 pieces of filter paper, membrane, gel and a further 4 
pieces of filter paper, all soaked in semi-dry transfer buffer. The transfer was run at 
0.8mA/cm2 of membrane for 1 hour on Pharmacia-Biotech Multiphor II semi-dry 
transfer apparatus. The membrane was then stained with Ponceau S to check for 
transfer / even loading of the samples and the stain removed by washing the 
membrane for 2 minutes with water and for 10 minutes with Tyrodes buffered saline 
(TBS).
2.2.9.2 Development of the blot
The non-specific protein binding was blocked by overnight incubation of the 
membrane with blocking buffer (appendix 5) at room temperature. The membrane 
was washed once for 10 minutes with TBS and then incubated for 3 hours at room 
temperature with primary antibody specified in table 2.1, made up in 1:5 diluted 
blocking buffer.
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Table 2.1 - Primary and secondary antibodies used for the development 
of tyrosine phosphorylation and p70 S6 kinase 
phosphorylation Western blots
Assay Primary antibody Secondary antibody
Protein tyrosine 
phosphorylation
0.1ng/ml 4G10 anti- 
phosphotyrosine 
antibody
1/10 000 goat anti­
mouse horseradish 
peroxidase conjugate
p70 S6k phosphorylation 0.1 fig/ml p70 S6k 
antibody
1/10 000 goat anti-rabbit 
horseradish peroxidase 
conjugate
The membrane was washed once with TBS (appendix 5), 3 times with TBS/NP40 and 
finally once with TBS, each for 10 minutes. The membrane was subsequently 
incubated for a further 90 minutes with 1/10 000 horseradish peroxidase conjugated 
secondary antibody specified in table 2.1, diluted in TBS/NP40. Again, the membrane 
was washed as given for the primary antibody with an extra TBS wash at the end and 
finally incubated with 10ml Enhanced Chemiluminescence (ECL) reagent for 1 minute. 
The membrane was exposed to a film for 30seconds - 30 minutes and the film 
developed using an RGII Fuji X-ray film developer.
2.2.10 Proliferation assay
The proliferation rate of cells can be determined by monitoring the incorporation of 
[3H]-thymidine into the cell’s DNA.
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The HEK 293 cells were plated out in 96 well plates at 5x104 cells/ml with 100^1 per 
well and incubated at 37°C in 95% 0 2 / 5% C02 for 40 hours. The cells were then 
serum starved for 4 hours prior to the reintroduction of serum at varying percentages 
(0,1, 5 and 10%). Also, the effects of 1% FCS in the presence of varying 
concentrations of MCP-1 (1.25-60nM) or 60nM MCP-1 pre-incubated with 0.3mg/ml 
neutralising anti-MCP-1 antibody were tested. The cells were subsequently incubated 
for 48 hours, pulsing each well with 1pCi [3H]-thymidine (S.A. 5Ci/mmol, 1mCi/ml, 
37MBq) for the final 18 hours. The cells were harvested by washing with 5% TCA, 
water and finally methanol using a Skatron Combi cell harvester. The cells were 
collected onto Whatman GF/A filter paper and the filters were then submerged in 4ml 
of Optiphase scintillant and the samples counted on an LKB Wallac 1215 Betarack 
liquid scintillation counter for 1 minute per sample.
2.2.11 Chemotaxis
This method was modified from that described by Falk et al. (Falk et al. 1980). The 
monocytes were prepared as given in section 2.2.1.3 and resuspended in RPMI 
containing 0.1% BSA at a final concentration of 1.75x106cells/ml. THP-1 cells were 
used at a concentration of 4x106 cells/ml. 27pl of agonist was placed in the lower 
wells of the Boyden chamber (figure 2.5). The two chambers were then separated by 
a 5 or 8|xm polyvinlypyrolidine-free (PVPF) membrane, orientated with the shiny side 
upwards, which was secured in place by a silicon gasket and the upper chamber.
Prior to the addition of the cells, the chamber was incubated at 37°C for 10 minutes 
and then 40pl of the cell suspension was added to the upper wells.
For chemokinesis experiments the agonist was placed in both the lower and the upper 
wells. The chamber was then incubated at 37°C with 5% C02 for 90-120 minutes. 






Figure 2.5 - Diagram of the Boyden Chamber set-up.
The agonist was placed in the lower chamber and the membrane 
and gasket were placed ontop. The upper chamber was secured 
in place and then after a 10 minute incubation period 7x104-1.6x105 
cells were placed in the upper chamber. Following incubation for 90-120 
minutes the filter was washed, stained and counted as given in section 
2 .2 .11.
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thoroughly in PBS and the cells fixed in methanol and stained with Diff-Quick stain. 
The number of cells per 5 high power fields of view were counted.
2.2.12 Adhesion molecule expression
Human venous blood from healthy individuals was collected into 3.8% sodium citrate 
at 1 ml per 9ml of blood. 1OOpI aliquots were stimulated with MCP-1 (1.25-60nM) for 
30 minutes at 37°C. For the last 10 minutes the samples were incubated with 10pl 
FITC-labelled antibodies against CD11b, CD11c, VLA-4, IgG control and CD14 at 
room temperature and then washed twice in PBS containing 2% FCS and 0.05% 
azide ( FACS buffer). The red blood cells were subsequently lysed using a red blood 
cell lysing solution (‘Immunolyse’) from Coulter. Briefly, 1 ml of 1:25 diluted working 
solution of the lysis buffer was added and the samples vortexed vigorously. Then, 
between 30 seconds to 2 minutes later 250pl of fixative was added. Again, the 
samples were vortexed vigorously and 2ml of FACS buffer was added. The cells were 
pelleted by centrifugation and washed twice with FACS buffer. The samples were 
resuspended in 500pl of FACS buffer and analysed on a Becton Dickinson FACScan, 
collecting 10 000 events per sample, the monocyte population being selected from 
both the scatter pattern and the CD14 positive staining.
2.2.13 Measurement of superoxide release from monocytes.
There are a number of ways in which the generation of superoxide from cells can be 
measured (Jones & Hancock, 1994). The two methods utilised in this study were the 
oxidation of scopoletin to a non-fluorescent product by H20 2, which is the product of 
the spontaneous breakdown of superoxide and the direct reduction of ferricytochrome 
C by superoxide.
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2.2.13.1 Scopoletin assay (De La Harpe & Nathan, 1985)
Monocytes were purified as given in section 2.2.1.3 and resuspended in HBSS 
containing 0.1% BSA and 1.5mM Ca2+ and Mg2+ at a concentration of 2x106 cells/ml. 
For the standard curve, 10|il of H20 2 standards (0.5-6nmol), diluted in H20, were 
added followed by 100^1 of HBSS alone and finally 10jaI of the reaction mixture 
(appendix 6). For the samples, 1 0jj,I of reaction mixture was added followed by the 
addition of 10Ojul of cell suspension. A zero reading of the plate was taken 
immediately prior to the reaction being started by the addition of the agonist or vehicle. 
The plate was read on a Titretek Fluoroskan II fluorescent plate reader at an excitation 
wavelength of 355nm and an emission wavelength of 460nm at 10 minute intervals for 
up to 120 minutes. The results were then calculated from the standard curve using 
equation 3. A typical standard curve is shown in figure 2.6.
Equation 3
The equation of the line for the standard curve is>
y = y0 + A e where y0, A and t are constants obtained from the graph.
Therefore, solving for x:-
y - y0 = A e t  




2.2.13.2 Ferricytochrome C assay (Pick & Mizel, 1981)
The monocytes were purified in a slightly different manner for this assay. The 
PBMC’s obtained from the Lymphoprep separation given in section 2.2.1.3 were 
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Figure 2.6 - A typical standard curve for the measurement of hydrogen 
peroxide generation using scopoletin. Data is mean +/- s.d. of triplicate 
samples.
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After 11/2 hours adherence at 37°C the non adherent cells were washed off and the 
adherent cells covered with 50^ 1 HBSS with 1mM Ca2+/Mg2+ and 0.1% BSA. 50^ 1 of 
320fxM ferricytochrome C solution was added to each well either with or without 
300U/ml SOD. The reaction was started by the addition of 10jil agonist or vehicle 
(made up in 160jiM ferricytochrome C solution) and the plate was read at 550nm on a 
Dynatech MR5000 plate reader at 10 minute intervals for up to 120 minutes.
The background values of the wells containing no agonist plus SOD were subtracted 
from the values of the sample wells and the nmole concentration of superoxide 
present per well was calculated using the extinction coefficient of reduced 
ferricytochrome C, 21x103M*1cm'1 (see equation 4). A protein assay (section 
2.2.13.2.1) was then carried out to determine the amount of protein per well and if the 
protein concentrations were significantly variable then the values adjusted to nmoles 
superoxide / mg protein.
Equation 4
Extinction coefficient of reduced cytochrome C (O.D.) = 21 x 103 M'1 cm'1 
However, the light path was not 1cm but 0.3cm.
Therefore, extinction coefficient (O.D.) = 6.3 x 103 M'1 0.3cm'1




The cells were digested for 18 hours with 100fil 1M NaOH at 4°C. 50jxl of each 
sample was then diluted by 1:2 with water to reduce the effects of the NaOH on the 
assay. The BSA standards (3.125-1 OO^g/ml) were also made up in 0.5M NaOH. 20jil 
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Figure 2.7 - A typical standard curve for the measurement of protein content 
in the samples used in the ferricytochrome C assay. Data is mean +/- s.d. of 
triplicate samples.
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The plate was read at 595nm on a Dynatech MR5000 plate reader. The protein 
concentrations were calculated by linear regression from the standard curve (see 
figure 2.7 for an example) and then if significantly variable, the superoxide results 
were adjusted.
2.2.14 CD23 uoreaulation on human monocvtes
The PBMC’s were purified as given in section 2.2.1.3. These were put into Petri 
dishes at between 2x106-5x106 cells/ml and incubated with the agonists for 44 hours. 
After incubation, the cells were washed and aliquoted into separate tubes. The 
samples were incubated with 10pl of anti-CD14-, -IgG i-, -lgG2A- or -CD23-FITC 
antibody for 10 minutes at room temperature in FACS buffer (see section 2.2.12).
The cells were subsequently washed three times in PBS and resuspended in 500jil of 
FACS buffer. The samples were analysed using a Beckton Dickinson FACScan, 
collecting 10 000 events per sample, selecting the monocyte population by scatter 
properties and CD14 positive staining.
2.2.15 Statistical analysis
Unless otherwise stated in the text, where appropriate, statistical analysis was 
performed on the raw data from ‘n’ experiments using 2-way Analysis of Variance 
(ANOVA) and Dunnet’s T-test. P<0.05, P<0.01 and P<0.001 are represented by *,** 
and *** respectively.
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SECTION 3 : MCP-1 BINDING STUDIES
3.1 r125Il-MCP-1 hinding
The initiation of any MCP-1-induced responses must be preceded by the binding of 
MCP-1 to its receptor. To study this interaction initially, the classical radioligand 
binding study was employed. The optimal concentration of [125I]-MCP-1 was 
determined by Dr. M. Needham at Zeneca, U.K. by incubating cells with increasing 
concentrations of [125I]-MCP-1 (-0.01 -10nM). The time taken for equilibrium to be 
reached was also determined by incubating cells with [125I]-MCP-1 for various times 
(-10-120 minutes). The optimal [125I]-MCP-1 concentration was observed to be 
100pM with equilibrium being reached between 45-90minutes (Dr. M. Needham, 
Zeneca, U.K., personal communication).
3.1.1 THP-1 cells
[125I]-MCP-1 was observed to bind to THP-1 cells. Figure 3.1a shows the competition 
curve obtained for THP-1 cells with increasing concentrations of competing MCP-1 
(0.01-30nM). The Scatchard analysis of this saturation binding curve is shown in 
figure 3.1b. The Scatchard plot was a straight line from which the Kd was determined 
as 4.71 ± 0.91 nM (n=4). These results together indicate the presence of a single 
group of high affinity MCP-1 receptors. The number of these receptors per cell was 
calculated from the B Ma x  to be 19 979 ± 3 508 receptors per cell (n=4).
3.1.2 CC CKR 2A and 2B transfected cells
There was a complete absence of [125I]-MCP-1 binding to the CC CKR 2A transfected 
cells. This is demonstrated in figure 3.2a, in which the radioactivity bound to the CC 
CKR 2A cells is plotted alongside the radioactivity bound to the CC CKR 2B cells. The 
maximum binding detected in the CC CKR 2A cells was only 118.6 ± 24.5 cpm (n=4),
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compared to the maximum binding detected in the CC CKR 2B transfected cells which 
was 1 256.7 ± 41.7 cpm (n=4).
The [125I]-MCP-1 binding detected in the CC CKR 2B cells was very similar to that 
observed with THP-1 cells. Figure 3.2b shows the competition curve with increasing 
concentrations of unlabelled MCP-1. Scatchard analysis of this data also 
demonstrated a straight line with a Kd of 2.69 ± 0.28nM (figure 3.2c). The number of 
receptors per cell was calculated to be 22 618 ± 7 593 (n=4).
3.2 Biotinylated MCP-1 binding
Due to the lack of [125I]-MCP-1 binding detected to the CC CKR 2A transfected cells, a 
relatively new technique was employed. This utilised biotinylated MCP-1 which bound 
to the receptor and this was detected by using an avidin-FITC conjugate, allowing 
MCP-1 binding to individual cells to be analysed using the FACS.
3.2.1 THP-1 cells
Figure 3.3a shows the changes in fluorescence detected in the presence or absence 
of biotinylated MCP-1 as well as the effects of an anti-MCP-1 antibody. In the 
presence of biotinylated MCP-1 there was an increase in the mean fluorescence 
intensity above that of control, demonstrating MCP-1 binding (mean fluorescence 
intensity for the control=11.79 ± 0.91, mean fluorescence intensity for biotinylated 
MCP-1 =29.9 ± 3.1; P<0.05). This MCP-1 binding was completely abrogated in the 
presence of anti-MCP-1 antibody demonstrating that the binding was specific. A 
similar inhibition was also observed with the non-biotinylated MCP-1 (figure 3.3b) 
confirming the specificity of the MCP-1 binding.
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3.2.2 CC CKR 2A and 2B transfected cells
Figure 3.4a shows the increase in fluorescence detected with the CC CKR 2A cells.
In contrast to the results observed with the radioligand binding, MCP-1 was 
demonstrated to bind to the CC CKR 2A transfected cells (control=18.93 ± 1.42, 
biotinylated MCP-1 =36.0 ± 4.0; P<0.05). The complete inhibition of this binding by 
both the anti-MCP-1 antibody and the non-biotinylated MCP-1 established that this 
binding was specific (figure 3.4a and b).
The CC CKR 2B cells also demonstrated specific MCP-1 binding as shown in figures 
3.4c and d (mean fluorescence intensities, control=25.22 ± 3.2, biotinylated MCP- 
1=57.65 ± 12.4; P<0.05). The increase in fluorescence was completely inhibited by 
both the anti-MCP-1 antibody and non-biotinylated MCP-1. One noticeable difference 
observed between the CC CKR 2A and 2B transfected cells was the pattern of the 
fluorescence increases. The CC CKR 2B cells demonstrated similar results to those 
observed in the THP-1 cells. A single peak was observed to shift to the right in the 
presence of biotinylated MCP-1. In contrast, the CC CKR 2A transfected cells 
demonstrated two populations of cells, indicated by the split peak in the presence of 
biotinylated MCP-1. The first peak was not noticeably different from the control but 
the second peak was much higher than that of the control.
There was no increase in MCP-1 binding above that of control in the untransfected 
HEK 293 cells (figure 3.5).
3.3 Summary
1. MCP-1 bound to a single group of high affinity receptors on THP-1 cells with a Kd 
of 4.71 ± 0.91 nM (n=4). The number of these high affinity receptors per cell was 
determined from the Scatchard plot as 19 979 ± 3 508 (n=4). This binding was
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confirmed by the significant increase in fluorescence observed in these cells in the 
presence of biotinylated MCP-1. The specificity of this binding was demonstrated 
by the reduction in the fluorescence by anti-MCP-1 antibody and non-biotinylated 
MCP-1.
2. No detectable [125I]-MCP-1 binding was observed to the CC CKR 2A transfected 
cells. In contrast, biotinylated MCP-1 was observed to specifically bind to a 
population of these cells. The specificity was again determined by the reduction in 
fluorescence by both anti-MCP-1 antibody and non-biotinylated MCP-1. Two 
populations of cells, one showing MCP-1 binding and the other not, were 
demonstrated by the two peaks observed in the FACS data in the presence of 
biotinylated MCP-1.
3. CC CKR 2B cells demonstrated similar binding characteristics to those observed in 
THP-1 cells. The Kd and the number of receptors per cell were calculated from the 
Scatchard plot as 2.69 ± 0.28nM and 22 618 ± 7 593 respectively. Specific binding 
was confirmed by biotinylated MCP-1 binding and its inhibition by anti-MCP-1 
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Figure 3.1 - [126I]-MCP-1 binding to THP-1 cells.
a) 1x106 THP-1 cells were incubated with 100pM [125I]-MCP-1 
and increasing concentrations of competing MCP-1 as given
in section 2.2.2. The results are shown as mean +/- s.e.m. (n=4).
b) Scatchard analysis of the competition data. This data is 
representative of four separate experiments. Analysis of the 
data was performed using the Grafit binding program.
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CC CKR 2A and 2B - comparison of binding
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Figure 3.2 - [125I]-MCP-1 binding to CC CKR 2A and 2B 
transfected cells, a) 5x105 CC CKR 2A or 2B cells were 
incubated with 100pM [125I]-MCP-1 and increasing concentrations 
of competing MCP-1 as given in section 2.2.2. The results are 
shown as mean CPM +/- s.d. and are representative of four 
separate experiments, b) Competition curve in the CC KR 
2B cells. The results are expressed as percentage binding 
and are shown as mean +/- s.e.m. (n=4). c) Scatchard analysis 
of the competition data in the CC CKR 2B cells. This data 
is representative of four separate experiments. Analysis of the 
data was performed using the Grafit binding program.
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Figure 3.3 - Binding of biotinylated MCP-1 to THP-1 cells. 1x105 cells 
were incubated with biotinylated MCP-1 for 60 minutes followed by 
an avidin-FITC conjugate for the next 30 minutes as given in section 
2.2.3. The samples were analysed by FACS. The data is representative 
of three separate experiments and shows the increase in fluorescence 
in the presence of biotinylated MCP-1 ( —), biotinylated MCP-1 with 
anti-MCP-1 antibody ( —), biotinylated MCP-1 with non-biotinylated 
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Figure 3.4 - Binding of biotinylated MCP-1 to a) and b) CC CKR 2A and
c) and d) CC CKR 2B transfected cells. 1x105 cells were incubated with 
biotinylated MCP-1 for 60 minutes followed by an avidin-FITC conjugate 
for the next 30 minutes as given in section 2.2.3. The samples were 
analysed by FACS. The data is representative of three separate experiments 
and shows the increase in fluorescence in the presence of biotinylated MCP-1 
( — ), biotinylated MCP-1 with anti-MCP-1 antibody ( — ), biotinylated MCP-1 
with non-biotinylated MCP-1 ( ) or control ( — ).
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Figure 3.5 - Binding of biotinylated MCP-1 to untransfected 
HEK 293 cells. 1x105 cells were incubated with biotinylated 
MCP-1 for 60 minutes followed by an avidin-FITC conjugate 
for the next 30 minutes as given in section 2.2.3. The samples 
were analysed by FACS. The data is representative of three 
separate experiments and shows the increase in fluorescence 
in the presence of biotinylated MCP-1 ( — ), biotinylated MCP-1 
with anti-MCP-1 antibody (— ) or control ( — ).
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SECTION 4 : CHARACTERISATION OF THE MCP-1-INDUCED
RISE IN rCa2+lt
4.1 Measurement of rCa2+l; in THP-1 cells
4.1.1 Elevation of TCa2*! by MCP-1
One of the most well documented chemokine responses is the increase in [Ca2+]j 
(Oppenheim etal. 1991). Figure 4.1a demonstrates the increase in [Ca2+]j observed in 
THP-1 cells following MCP-1 stimulation. This rise was dose-dependent and transient 
in nature, reaching a maximum by 10 seconds and returning to almost basal levels by 
60 seconds. Figure 4.1 b shows the dose-response curve for the MCP-1 -induced 
increase in [Ca2+]j. The EC5o for MCP-1 was 2.13 ± 0.2nM (n=6) and the maximal 
change in [Ca2+]j following 12.5nM MCP-1 stimulation was 230.14 ± 45.66nM (n=6).
4.1.2 Desensitisation of the MCP-1-induced calcium response
The calcium response detected following MCP-1 stimulation can be used as a method 
for identifying the receptors expressed by THP-1 cells. Repeated stimulation of a 
chemokine receptor with the same chemokine, or another chemokine acting at the 
same receptor, leads to desensitisation of the second response (Sozzani et al. 
1993)(Dahinden etal. 1994)(Combadiere etal. 1995). This is a well reported 
chemokine receptor characteristic and provides a useful method for identifying the 
receptors present on the cells by sequential stimulation with a selection of 
chemokines. Figures 4.2, 4.3 and table 4.1 summarise the results seen following 
repeated stimulation of THP-1 cells by a variety of different chemokines. Stimulation 
with 12.5nM MCP-1 almost completely abrogated the calcium response to a second 








































Figure 4.1 - Dose-dependent effects of MCP-1 on the [Ca2+]j response 
in THP-1 celis. 106-107 THP-1 cells/ml were loaded with 5pM fura-2/AM 
as given in section 2.2.4. a) The increases in [Ca2+]j in response to 
three concentrations of MCP-1. The data is representative of at least five 
separate experiments, b) The dose-response curve for MCP-1-induced [Ca2*], 
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Figure 4.2 - Desensitisation effects of repeated chemokine stimulation.
106-107 THP-1 cells/ml were loaded with 5jJVI fura-2/AM as given in section 2.2.4. 
Stimulation with the first chemokine was at 40 seconds followed by the second 
chemokine 80 seconds later. All chemokines were used at a concentration of 12.5nM. 
a) shows the effects of repeated doses of MCP-1. b) and c) show the effects of MCP-1 
and MCP-3 and d) and e) show the effects of MCP-1 and eotaxin. The traces are 
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Figure 4.3 - Desensitisation effects of repeated chemokine stimulation.
106-107 THP-1 cells/ml were loaded with 5(iM fura-2/AM as given in section 2.2.4. 
Stimulation with the first chemokine was at 40 seconds and with the second chemokine 
stimulation 80 seconds later. All the chemokines were used at a concentration of 12.5nM. 
a) and b) show the effects of MCP-1 and MIP-1a, c) and d) show the effects of MCP-1 and 
RANTES and e) and f) show the effects of MCP-1 and IL-8. The traces are representative 
of three separate experiments.
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MCP-1 also significantly reduced the calcium responses to sequential MCP-3, 
RANTES, MIP-1a and IL-8 stimulation. However, only MCP-3 could significantly 
inhibit the subsequent MCP-1-induced calcium response.
4.1.3 Identification of the source of calcium responsible for the MCP-1- 
induced fCa2+li elevation
4.1.3.1 Role of calcium influx in the MCP-1-induced rise in [Ca2+]i
In order to be able to study the role of both calcium influx and calcium mobilisation in 
the MCP-1-induced calcium response, a positive control for both of these calcium 
sources was required. ATP has already been reported to induced a biphasic calcium 
response, involving both calcium influx and calcium mobilisation, in macrophages 
(Greenberg etal. 1988). When applied to THP-1 cells, ATP did induce a dose- 
dependent increase in [Ca2+]j (figure 4.4a and b). The response was very different to 
that observed following MCP-1 stimulation. Although the increase was very rapid, it 
remained maximally elevated for more than 60 seconds.
To be able to identify the source of the [Ca2+]j rise in response to MCP-1 and compare 
it to the ATP response, a number of inhibitors were utilised. These included the 
calcium chelator EGTA (Hagiwara & Nakajima, 1966), the calcium channel blocker 
Ni2+ (Hagiwara & Takahashi, 1967) and the calcium influx inhibitor econazole (Alvarez 
etal. 1991).
Figures 4.5a and b show the effects of EGTA on the MCP-1-induced increase in 
[Ca2+]j. EGTA had no obvious effects on the peak height of the response, although 
the T1/2 was reduced. The Ti/2 is defined as the time taken for the response to fall to 
half of the maximum height. In contrast to the effects of EGTA, addition of 1 mM Ni2+ 
prior to MCP-1 addition inhibited the MCP-1-induced calcium response by
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Table 4.1 - Effects of repeated chemokine addition on the [Ca2+]i in THP-1 cells.
The cells were loaded as given in section 2.2.4. Addition of the first agonist was at 40 
seconds followed by the addition of the second agonist at 120 seconds, a) This 
shows the effects of initial stimulation with MCP-1 on the subsequent responses to 
various chemokines and b) shows the effects of the various chemokines on the 
subsequent MCP-1 response. All agonists were added at a concentration of 12.5nM. 
The results are expressed as a percentage of the control response generated by the 
second agonist when the first agonist was only HBSS (mean ± s.e.m, n=3).
a) _________________________________________________________
Agonist (12.5nM) Percentage of control 
response
First Second
MCP-1 MCP-1 12.47 ±2.7 **
MCP-1 MCP-3 22.1 ± 4.6 **
MCP-1 RANTES 39.3 ±7.4 **
MCP-1 MIP-1a 39.5 ±4.8 **
MCP-1 Eotaxin No response
MCP-1 IL-8 52.05 ±14.73 **
b)
Agonist (12.5nM) Percentage of control 
response
First Second
MCP-1 MCP-1 12.47 ±2.7 **
MCP-3 MCP-1 48.3 ±4.4 **
RANTES MCP-1 86.7 ± 6.9



















Figure 4.4 - Dose-dependent effects of ATP on [Ca2+]j in THP-1 cells.
106-107 THP-1 cells were loaded with 5pM fura-2/AM as given in section 
2.2.4. a) The increases in [Ca2+]j in response to three concentrations of ATP. 
The data is representative of at least five separate experiments, b) The dose- 
response curve for ATP-induced [Ca2+]j changes (mean +/- s.e.m., n=5)
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Figure 4.5 - Effects of calcium influx inhibitors on the MCP-1-induced increase in
[Ca2+]j. 106-107 THP-1 cells/ml were loaded with 5(iM fura-2/AM as given in section 
2.2.4. a) 1mM EGTA was added at 40 seconds (1) followed by 12.5nM MCP-1 (2) 40 
seconds later. 1mM Ca2+ was readded at 100seconds (3). b) Graphical representation 
of the effects of EGTA on the peak height and the T1/2 of the MCP-1 response. c)1mM
Ni2+ was added to the cells at 40 seconds and the MCP-1-induced calcium response 
in the presence or absence of Ni2+ was monitored, d) Graphical representation of 
the effects of Ni2+ on the MCP-1-induced calcium response e) 30fiM econazole 
was added at 10 seconds (1) and then 12.5nM MCP-1 was added after a 2 minute 
incubation period (2). f) Graphical representation of the effects of econazole on the 
peak height and the T1/2 of the MCP-1 response. The traces are all representative













68.9 ± 11.7% (n=5) (figure 4.5c and d). Figures 4.5e and f show the effects of 
econazole on the MCP-1-induced response. A 2 minute pre-treatment of the cells 
with 30pM econazole had no significant effect on either the peak height or the Jy2 of 
the MCP-1 -induced increase in [Ca2+]j.
These results are in stark contrast to the results obtained with ATP. Figures 4.6a and 
b demonstrate that EGTA almost completely abrogated the prolonged phase of the 
ATP-induced calcium response. Inhibition of the response 40 seconds after ATP 
addition was 60.6 ± 1.2% (n=5) in the presence of EGTA. The readdition of 1mM Ca2+ 
returned the response to a level similar to that seen in the absence of EGTA. Similar 
results were also observed in the presence of Ni2+ and econazole. Both of these 
compounds greatly reduced the prolonged phase of the response (figure 4.6 c, d, e 
and f) (53.75 ± 13.9% (n=5) and 67.45 ± 8.99% (n=5) inhibition of the response 40 
seconds after ATP administration respectively). None of these inhibitors had any 
effect on the initial peak of the ATP response.
Calcium influx can be further demonstrated by the use of Mn2+ as a surrogate Ca2+ 
ion. When Mn2+ enters the cell it binds to fura-2 and quenches the fluorescence 
signal. By monitoring at the isobestic point of fura-2, influx of Mn2+ can be directly 
monitored.
Figures 4.7a and b show the influx of Mn2+ in response to various concentrations of 
MCP-1 compared to buffer control and ionomycin as a positive control. There was no 
significant difference in the influx detected in response to any concentration of MCP-1 
or buffer control. In contrast, figures 4.7c and d show the effects of increasing 
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Figure 4.6 - Effects of calcium influx inhibitors on the ATP-induced increase in [Ca2*^.
106-107 THP-1 cells/ml were loaded with 5|iM fura-2/AM as given in section 2.2.4.
a) 1mM EGTA was added at 40 seconds (1) followed by 3^M ATP (2) 40 seconds later.
1mM Ca2+ was readded (3) at 100 seconds, b) Graphical representation of the effects of EGTA 
The measurements were taken either 40 seconds after ATP addition for the control, 20 seconds 
after ATP and 40 seconds after Ca2+ readdition in the presence of EGTA. c) Either 3jiM ATP 
alone (2) or 1 mM Ni2+ (1) followed by ATP (2) 30 seconds later were added to the cells, 
d) Graphical representation of the effects of Ni2+. The measurements were taken 40 seconds 
after ATP addition, e) 30|aM econazole was added at 10 seconds (1) and 3^M ATP was 
added 2 minutes later (2). f) Graphical representation of the effects of econazole. The 
measurements were taken 40 seconds after ATP addition. The traces are all representative 
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Figure 4.7 - Mn2+ influx in THP-1 cells in response to MCP-1 and ATP.
106-107 THP-1 cells/ml were loaded with 5^M fura-2/AM as given 
in section 2.2.4. They were also maintained in 100^iM Ca2+ containing 
medium and pelleted and resuspended immediately prior to use. For all 
traces, buffer, ionomycin or agonist was added at 40 seconds (1) and 
300|aM Mn2+ was added 40 seconds later (2). The changes were 
studied at an excitation wavelength of 360nm. All traces are representative 
of five separate experiments. On the right hand side are the graphical 
representations of the Mn2+ influx (mean +/- s.e.m., n=5). The results 
are expressed as a percentage of the ionomycin influx, with the buffer 
control taken as zero.
4.1.3.2 Involvement of PLC in the MCP-1-induced elevation in [Ca2+]j
Figure 4.8 shows the effects of the PLC inhibitor U73122 (Smith etal. 1990) on the 
MCP-1-induced calcium response. U73122 completely inhibited the MCP-1-induced 
[Ca2+]i elevation with an IC5o of 3.0 ± 0.34jaM (n=3-5). 5 minute pre-treatment of the 
cells with the inactive isomer of U73122, namely U73343, had no effect on the calcium 
response following MCP-1 stimulation.
To prove that MCP-1 activated PLC, the effects of 12.5nM MCP-1 on IP3 levels were 
investigated. The basal IP3 levels of 8.0 ± 4.25pmol IP3 /1 07 cells (n=3) was 
significantly increased at 2 seconds post MCP-1 stimulation to 17.45 ± 4.3 pmol IP3 / 
107 cells (n=3) (figure 4.9b). This increase in IP3 was at a maximum of 29.25 ± 7.3 
pmol IP3 / 107 cells (n=3) at 5 seconds post MCP-1 stimulation. By 60 seconds the 
IP3 levels were not significantly different from the basal level. These increases in IP3 
preceded the increase in [Ca2+]j detected following MCP-1 stimulation (figure 4.9a).
4.1.3.3 Role for PKC in the MCP-1-induced elevation in [Ca2+]i
To examine the role of PKC in the MCP-1-induced calcium response, the actions of 
the PKC activator PMA and the PKC inhibitor Ro31-8220-002 were investigated on the 
MCP-1-induced [Ca2+]j rise. Figures 4.10a and b show the effects of PMA on the 
MCP-1-induced calcium response. 30nM PMA inhibited the calcium response by 68 ± 
13.7% (n=5). In contrast, Ro31 -8220-002 dose-dependently potentiated the MCP-1- 
induced calcium response (figure 4.10c and d). A 2 minute pre-treatment of the cells 
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Figure 4.8 - Role of phospholipase C in the MCP-1-induced increase in [Ca2+]j.
106-107 THP-1 cells/ml were loaded with 5fiM fura-2/AM as given in section 2.2.4. 
They were then pre-incubated with various doses of U73122/U73343 for 5 minutes 
prior to the addition of 12.5nM MCP-1. a) This data shows the effects of 0.1 (iM and 
10^M U73122 on the 12.5nM MCP-1-induced increase in [Ca2+]j and is representative
of three to five experiments, b) The percentage inhibition of the MCP-1 response by 
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Figure 4.9 - [Ca2+]j and IP3 levels in THP-1 cells following 12.5nM MCP-1
stimulation, a) 106-107 THP-1 cells/ml were loaded with 5jiM fura-2/AM as given 
in section 2.2.4. The cells were then stimulated with 12.5nM MCP-1. The mean [Ca2+]j
values +/- s.e.m. from six separate experiments have been plotted b)1x107 THP-1 
cells were stimulated with 12.5nM MCP-1 and IP3 extracted using 20% perchloric acid.
The IP3 levels were detected using a [3H]-IP3 competition assay as given in section 
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Figure 4.10 - Role of PKC in the MCP-1-induced increase in [Ca2+]j.
106-107 THP-1 cells/ml were loaded with 5^iM fura-2/AM as given in section 
2.2.4. a) 30nM PMA was incubated with the cells for 5 minutes prior to the 
addition of 12.5nM MCP-1. b) Graphical representation of the effects of 30nM 
PMA (mean+/- s.e.m., n=5). c) Various concentrations of Ro31-8220-002 
were incubated with the cells for 2 minutes (1) prior to the addition of 12.5nM 
MCP-1 (2). d) Graphical representation to show the percentage potentiation of 
the MCP-1-induced calcium response in the presence of increasing concentrations 
of Ro31 -8220-002 (mean +/- s.e.m., n=5). The calcium traces are all representative 
of five separate experiments.
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Interestingly, the ATP-induced calcium response was also modified by the PLC 
inhibitor. Pre-treatment of the cells with IOjaM U73122 inhibited the calcium response, 
although, unlike the complete inhibition observed with the MCP-1 response, only a 
65.16 ± 10.8% (n=5) inhibition of the ATP response was observed (figure 4.11a and 
b). A role for PKC in the ATP response was also identified. Figures 4.11c and d show 
the effects of 30nM PMA on the ATP-induced [Ca2+]j elevation. Both the initial peak 
and the prolonged phase of the response were inhibited by 58 ± 14.75 % (n=5) 
following PMA pre-treatment. Ro31 -8220-002 further identified a role for PKC in the 
ATP-induced calcium response. The initial peak of the response was significantly 
increased following 20pM Ro31-8220-002 pre-incubation (figure 4.11e and f). All 
three compounds which appeared to affect the initial phase of the ATP response, also 
modified the prolonged ATP response.
4.1.3.4 Coupling of the MCP-1-induced elevation of [Ca2+]i in THP-1 cells 
to G-proteins
Since, to date, all of the chemokine receptors have been identified as 7 
transmembrane spanning, G-protein -coupled receptors, the effects of the G/G0 G- 
protein inhibitor pertussis toxin was investigated. Figure 4.12 demonstrates that 
pertussis toxin pre-treatment inhibited the MCP-1 -induced [Ca2+]j elevation in a dose- 
dependent manner. The IC5o for this inhibition was 0.58 ± 0.05ng/ml (n=3). 
Interestingly, pertussis toxin pre-treatment of the cells had no significant effect on the 
ATP-induced calcium response (figure 4.13).
Figure 4.14 demonstrates that the THP-1 cells also responded to another purinergic 
agonist, namely UTP. This calcium response was very comparable with the response 
observed upon ATP stimulation of these cells. The maximum change in [Ca2+]j in 
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Figure 4.11 - Role of PLC and PKC in the ATP-induced rise in [Ca2+]j.
106107 THP-1 cells/ml were loaded with 5|iM fura-2/AM as given in section 2.2.4.
a) The cells were incubated with 10|tM U73122 for 5 minutes prior to the addition 
of 3|tM ATP. b) Graphical representation of the effects of U73122 c) 30nM PMA 
was incubated with the cells for 5 minutes prior to the addition of 3^M ATP. 
d) Graphical representation of the effects of PMA. e) Ro31-8220-002 was incubated 
with the cells for 2 minutes (1) prior to the addition of 3(iM ATP (2). f) Graphical 
representation of the effects of Ro31-8220-002 on the ATP response. The 
measurements were taken 5 seconds after ATP addition. The traces are all 
representative of five separate experiments. The graphs are all expressed as 
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Figure 4.12 - Effects of pertussis toxin on the MCP-1-induced increase in [Ca2+]j.
The cells were pre-treated for 16 hours with various concentrations of pertussis 
toxin and then 106-107 THP-1 cells/ml were loaded with 5pM fura-2/AM as given 
in section 2.2.4. a) This data shows the 12.5nM MCP-1-induced increases in 
[Ca2+]j in the presence/absence of pertussis toxin. The traces are representative
of three separate experiments, b) The percentage inhibition after four separate 
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Figure 4.13 - Effects of pertussis toxin on the ATP-induced rise in [Ca2+]j.
THP-1 cells were pre-treated with various concentrations of pertussis toxin for 
16 hours and then 106-107 cells/ml were loaded with 5pM fura-2/AM as given 
in section 2.2.4. a) This data shows the 3jiM ATP [Ca2+]j responses in the
presence/absence of pertussis toxin. The traces are representative of five separate 
experiments, b) The percentage inhibition after three separate concentrations of 
pertussis toxin (n=3, mean +/- s.e.m.)
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Figure 4.14 - Effects of UTP on the [Ca2+], in THP-1 cells.
106-107 THP-1 cells/ml were loaded with 5(iM fura-2/AM as given in 
section 2.2.4. The traces are representative of three separate experiments.
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4.2 Detection of MCP-l-induced fCa2+1{ elevations in CC CKR 2A and 
2B transfectants and human monocytes
4.2.1 Comparison of MCP-1-induced calcium responses
Figure 4.15a shows the effects of MCP-1 on the [Ca2+]j levels in CC CKR 2A 
transfected cells. MCP-1 did not induce a rise in [Ca2+]j at any of the concentrations 
tested (0.125-60nM); nor was there a calcium response induced by any other 
chemokines tested (n=3-5). These cells were also examined at the single cell level as 
well as in suspension. Again, no [Ca2+]j response was detected in response to MCP-1 
(n=3) (figure 4.15b). As a positive control, the effects of EGF were examined on the 
[Ca2+]j levels. EGF has already been reported to induce increases in [Ca2+]j in 
epithelial cells (Wahl & Carpenter, 1988). Figure 4.15c demonstrates that the CC 
CKR 2A transfected cells responded in a dose-dependent manner following EGF 
stimulation (n=3).
In contrast to the results observed with the CC CKR 2A transfected cells, the CC CKR 
2B transfected cells demonstrated a dose-dependent rise in [Ca2+]j in response to 
MCP-1 (figure 4.16). This increase in [Ca2+]j was observed both with cells in 
suspension and at the single cell level (figure 4.16 a and b). The rise in [Ca2+]j in 
response to other chemokines was also examined. Figure 4.16c shows that CC CKR 
2B transfected cells did not respond to 60nM MIP-1a, MIP-1(3, RANTES or IL-8. They 
did demonstrate a calcium rise in response to 60nM MCP-3, although the response 
was only 25.0 ± 1.6% (n=3) of that observed with 60nM MCP-1.
The untransfected HEK 293 cells responded to stimulation by 100ng/ml EGF, 
demonstrating an increase in [Ca2+]j (figure 4.17). In contrast, MCP-1 did not produce 
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Figure 4.15 - Effects of MCP-1, related chemokines and EGF on the [Ca2+]j elevation
in CC CKR 2A transfected cells. 106-107 cells/ml were loaded with 5^M fura-2/AM as 
given in section 2.2.4. a) The effect of MCP-1 and related chemokines on the CC CKR 2A 
transfected cells in suspension, b) The effects of MCP-1 in a small population of cells 
adhered onto a glass coverslip. c) The EGF responses in CC CKR 2A transfected cells 
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Figure 4.16 - Dose-dependent effects of MCP-1 and related chemokines on 
the[Ca2+]j in CC CKR 2B transfected cells. 106-107 cells/ml were loaded
with 5^M fura-2/AM as given in section 2.2.4. a) The effect of MCP-1 on the CC 
CKR 2B transfected cells in suspension, b) The MCP-1 responses in a small 
population of cells adhered to a glass coverslip. c) The effects of 60nM MCP-1 
compared to 60nM MCP-3, MIP-1a, MIP-1 p, RANTES and IL-8 on cells in 




















0 20 40 60 80 100
Time (secs)
Figure 4.17 - [Ca2+]j responses in untransfected HEK 293 cells in response
to MCP-1 and EGF. 106-107 cells/ml were loaded with 5fiM fura-2/AM as 
given in section 2.2.4 and then stimulated with either 12.5nM MCP-1 or 
100ng/ml EGF. The traces are representative often separate experiments.
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The effect of MCP-1 on the [Ca2+]j levels in human blood derived monocytes was also 
investigated. MCP-1 induced very similar increases in [Ca2+]j in human monocytes as 
observed in THP-1 cells and CC CKR 2B transfected cells (figure 4.18), although, 
unlike the other two cell types, the MCP-1 response in human monocytes appeared to 
remain elevated for a longer time period (n=10). The traces observed with human 
monocytes demonstrated more background noise due to the number of cells used.
As a result of the limited number of monocytes obtained for each experiment, only half 
the number of monocytes required (1x106 instead of 2x106) could be used for each 
trace to allow a complete experiment to be performed.
4.2.2 Comparison of the source of the MCP-1-induced fCa2*1i elevation 
in CC CKR 2B transfected cells and human monocytes
4.2.2.1 Role for calcium influx in the increase in [Ca2+]i
Pre-incubation of CC CKR 2B transfectants with 1mM EGTA inhibited the [Ca2+]j rise 
in response to MCP-1 by 53.66 ± 4.6% (n=3). The readdition of 1mM Ca2+ returned 
the response to a level observed in the absence of EGTA (figure 4.19). Figure 4.20 
demonstrates the Mn2+ influx observed in the CC CKR 2B transfected cells following 
stimulation by various concentrations of MCP-1. MCP-1 induced a dose-dependent 
influx of Mn2+ in these cells. 12.5nM MCP-1 induced a Mn2+ influx response which 
was 34.03 ± 5.79% (n=3) of the response observed in the presence of digitonin 
(figure 4.20b).
The effects of EGTA on the MCP-1-induced [Ca2+]i elevation in the human monocytes 
was very similar to that observed in the CC CKR 2B transfectants. 1 mM EGTA 
inhibited this calcium response by 62.1 ± 7.2% (n=7) in human monocytes (figure 
4.21). The readdition of 1mM Ca2+ increased the response to a similar level observed 


























Figure 4.18 - MCP-1-induced increase in [Ca2+]j in human blood-derived
monocytes. The cells were purified as given in section 2.2.1.3 and 106-107 
cells/ml were loaded with 5|iM fura-2/AM as given in section 2.2.4. a) The 
increases in [Ca2+]j in response to three concentrations of MCP-1. The traces are 
representative often separate experiments, b) The dose-response curve for MCP-1- 
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Figure 4.19 - Effects of EGTA on the MCP-1-induced increase in [Ca2+]j in
CC CKR 2B transfected cells. 106-107 cells/ml were loaded with 5jtM fura-2/AM 
as given in section 2.2.4. a) 1 mM EGTA was added first (1) followed by 12.5nM 
MCP-1 (2) 40 seconds later. The responses were subsequently followed either 
with or without the readdition of 1 mM Ca2+ (3). The data is representative of three 
separate experiments, b) Graphical representation of the effects of EGTA. The 
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Figure 4.20 - Mn2+ influx in CC CKR 2B transfected cells in response to MCP-1.
106-107 cells/ml were loaded with 5j^M fura-2/AM as given in section 2.2.4.
They were also maintained in 100j^M Ca2+ containing medium and pelleted and 
resuspended immediately prior to use. a) The buffer, ionomycin or agonist was addec 
at 40 seconds (1) and 300j^M Mn2+ was added 40 seconds later (2). The changes 
were studied at an excitation wavelength of 360nm. The data is representative of five 
separate experiments, b) Graphical representation of the Mn2+ influx (mean +/- s.e.m 
n=5). The results are expressed as a percentage of the ionomycin influx, with the 
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Figure 4.21 - Effects of EGTA and calcium readdition on the MCP-1-induced 
[Ca2+]j changes in human monocytes. The cells were purified as given in
section 2.2.1.3 and 106-107 cells/ml were loaded with 5^M fura-2/AM as 
given in section 2.2.4. a) 1mM EGTA was added at 40 seconds (1) followed by 
12.5nM MCP-1 (2) 40 seconds later. 1mM Ca2+ was readded 20 seconds later 
(3). The traces are representative of seven separate experiments, b) Graphical 
representation of the effects of EGTA. The measurements were taken at the peak 
of the control response or 20 seconds after the addition of MCP-1 in the presence 
of EGTA, immediately prior to Ca2+ readdition. The results are expressed as the 
mean [Ca2+l  change +/- s.e.m. from seven separate experiments.
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4.2.2.2 Determination of the role of PLC in the MCP-1-induced calcium 
responses
The PLC inhibitor U73122 inhibited the MCP-1 -induced [Ca2+], rise in the CC CKR 2B 
transfectants (figure 4.22a). Pre-treatment of the cells for 5 minutes with 10|iM 
U73122 completely abrogated the calcium response. The inactive isomer of U73122, 
U73343, had no effect on the calcium response.
10pM U73122 also completely abrogated the calcium response induced by MCP-1 in 
the human monocytes (figure 4.22b). Again, U73343 demonstrated no effect.
To prove that MCP-1 activates PLC, the IP3 levels were investigated in both the CC 
CKR 2A and CC CKR 2B transfected cells as well as the untransfected cells. The CC 
CKR 2B transfectants demonstrated a rapid and transient increase in IP3 levels 
(figure 4.23b). The maximal increase from the basal level of 40.4 ± 8.3 pmol IP3 / 107 
cells (n=4) to 79.7 ± 15.6 pmol IP3 /107 cells (n=4) was 2 seconds after 12.5nM MCP- 
1 stimulation. The IP3 levels returned to basal levels by 15 seconds.
Since the CC CKR 2A transfectants did not demonstrate any calcium response to 
MCP-1, it was surprising to note that they demonstrated a significant increase in IP3 
levels from 51.8 ± 9.8 pmol IP3 /1 07 cells (n=4) to 99.3 ± 31.6 pmol IP3 /1 07 cells 
(n=4), 2 seconds after MCP-1 stimulation (figure 2.23a). This increase in IP3 was 
very transient and by 5 seconds after MCP-1 stimulation, the levels had returned to 
basal.
The untransfected cells demonstrated no significant increase in IP3 in response to 
MCP-1 at any timepoint monitored (n=4) (figure 4.23c).
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Figure 4.22 - Effects of PLC inhibition on the MCP-1-induced increases in [Ca2+]j
in a) and b) CC CKR 2B transfected cells and c) and d) human monocytes. The monocytes
were purified as given in section 2.2.1.3. 106-107 CC CKR 2B cells or monocytes/ml were
loaded with 5(iM fura-2/AM as given in section 2.2.4. They were then pre-treated
with either U73122 or U73343 for 5 minutes prior to 12.5nM MCP-1 addition. The
traces are representative of four separate experiments. The graphical representations
of the results are expressed as [Ca2*], levels in cells either unstimulated (basal), stimulated
with 12.5nM MCP-1 alone or stimulated with 12.5nM MCP-1 in the presence of 10[iM 
U73122 or U73343 (mean +/- s.e.m., n=4).
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Figure 4.23 - IP3 levels in HEK 293 cells transfected with a) the CC CKR 2A,
b) the CC CKR 2B and c) untransfected cells following 12.5nM MCP-1 stimulation.
1x107 cells were stimulated with 12.5nM MCP-1 and the IP3 extracted using 20% 
perchloric acid. The IP3 levels were detected using a [3H]-IP3 competition 
assay as given in section 2.2.5. (Mean +/- s.e.m., n=4)
134
300
12.5nM MCP-1 minus P.T.
250
200








_  160 -
i  140-
0)  1 2 0 -  D)
n  1 0 0 -








Figure 4.24 - Effects of pertussis toxin on the MCP-1-induced increase in [Ca2+]j 
in CC CKR 2B transfected cells, a) The cells were pre-treated with 250ng/ml pertussis 
toxin for 16 hours and then 106-107 cells/ml were loaded with 5|aM fura-2/AM as given 
in section 2.2.4 and stimulated with 12.5nM MCP-1. The data is representative of three 
separate experiments, b) Graphical representation of the effects of 250ng/ml pertussis 






4.2.2.3 Coupling of the MCP-1-induced [Ca2+]j response in CC CKR 2B 
transfectants to G-proteins
Pertussis toxin pre-treatment was used to investigate the role of Gj or G0 G-proteins 
in the [Ca2+]j rise observed upon MCP-1 stimulation of CC CKR 2B transfected cells. 
The calcium response to MCP-1 in the CC CKR 2B transfectants was sensitive to 
pertussis toxin, as seen in figure 4.24. However, unlike the 100% inhibition observed 
in THP-1 cells, 250ng/ml pertussis toxin only produced a 73.9 ± 8.7% (n=3) inhibition 
of the calcium response.
4.3 Summary 
THP-1 cells
1. During the desensitisation experiments, the loss of the [Ca2+]j responses to both 
MCP-1 and MCP-3, no matter which of these two chemokines were administered 
first, demonstrated that MCP-1 and MCP-3 both bind to the same receptor. In 
addition, MCP-1 also produced a significant inhibition of the responses elicited by 
RANTES, MIP-1 a and IL-8, indicating that these agonists activate a receptor also 
utilised by MCP-1. However, prior treatment with either RANTES, MIP-1 a or IL-8 
did not affect the subsequent MCP-1 response, indicating that these agonists also 
interact with receptors distinct from that activated by MCP-1.
2. The [Ca2+]j elevation induced by MCP-1 in THP-1 cells did not require the presence 
of calcium in the extracellular medium, since neither EGTA nor econazole greatly 
inhibited the calcium response, although inhibition was observed following pre­
treatment with 1 mM Ni2+. The lack of Mn2+ influx detected in these cells in 
response to MCP-1 further demonstrated that extracellular calcium and calcium 
influx are not required for the MCP-1-induced calcium response in THP-1 cells.
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3. These results were in stark contrast to those observed with the ATP- induced 
[Ca2+]j elevation. EGTA, Ni2+ and econazole all inhibited the prolonged phase of 
the ATP-induced calcium response, demonstrating the role of extracellular calcium 
in the maintenance of the calcium response.
4. The inhibition of the MCP-1-induced calcium response by U73122 identified the 
activation of PLC and its role in the elevation of [Ca2+]j. Proof of the activation of 
PLC was obtained by the time-dependent increase in the levels of IP3 following 
MCP-1 stimulation, which preceded the increase in intracellular calcium.
5. A role for PLC in the initial peak of the ATP-induced calcium response was 
identified as U73122 inhibited this phase of the calcium response in a similar 
manner to that observed with the MCP-1-induced calcium response.
6. The role of PKC in the MCP-1-induced calcium response was demonstrated by 
both the inhibitory effects of the PKC activator PMA and the dose-dependent 
potentiating effects of the PKC inhibitor Ro31-8220-002.
7. PKC was also observed to play a role in the initial phase of the ATP-induced 
calcium response, with PMA and Ro31-8220-002 inhibiting and potentiating the 
initial peak of the calcium response respectively.
8. Pertussis toxin identified the activation of a Gj or G0 G-protein prior to the MCP-1- 
induced increase in [Ca2+]j, as demonstrated by the dose-dependent abrogation of 
the response.
9. In contrast, these G-proteins were not involved in the ATP-induced calcium 
response as pertussis toxin pre-treatment had no effect. Interestingly, the THP-1 
cells also responded to another purinergic agonist, namely UTP, in a similar 
manner to that observed with ATP.
Monocytes
10. MCP-1 also induced a rise in [Ca2+]j in human monocytes. The presence of 
extracellular calcium was required for this response as demonstrated by the
inhibition of the response by EGTA. This is in contrast to the results obtained with 
THP-1 cells.
11. However, the dependence of the calcium response on PLC activation was also 
demonstrated by the complete inhibition of the response by pre-treatment of the 
cells with U73122.
CC CKR 2A and 2B transfectants
12. CC CKR 2A transfectants did not demonstrate any detectable increase in [Ca2+]j 
in response to MCP-1. In contrast, the CC CKR 2B transfectants showed a dose- 
dependent increase in [Ca2+]j.
13. The requirement of extracellular calcium for the calcium response in the CC CKR 
2B transfectants was demonstrated by the inhibition of the calcium response by 
EGTA. Also, in CC CKR 2B transfected cells, a dose-dependent Mn2+ influx was 
detected. These were similar to the results obtained in the human monocytes
14. The calcium response in CC CKR 2B transfectants also required the activation of 
PLC, demonstrated by the complete abrogation of the MCP-1-induced calcium 
response in the presence of U73122, similar to the situation in the human 
monocytes.
15. The rapid increase in IP3 in CC CKR 2B cells in response to MCP-1 proved the 
role for PLC in the calcium response, although, interestingly, the CC CKR 2A 
transfected cells also showed a small increase in IP3 even though no calcium 
response was detected. The untransfected cells demonstrated no increase in 
either IP3 or [Ca2+]j.
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SECTION 5 : MCP-1-INDUCED ACTIVATION OF PI 3-KINASE
5.1 PI 3-kinase activation by MCP-1 in THP-1 cells
5.1.1 Accumulation of D-3 phosphatidvlinositol lipids
Following recent publications on the activation of phosphatidylinositol 3-kinase (PI 3- 
kinase) in various myeloid cells such as platelets, U937 cells and neutrophils after 
stimulation by thrombin, ATP and fMLP respectively (Thomason etal. 1994)(Stephens 
etal. 1993) (Stephens etal. 1991), the activation of this novel pathway by MCP-1 was 
examined in THP-1 cells. The initial method utilised was the measurement of the 
accumulation of D-3 Ptdlns lipids from [32P]-labelled cells. Hence, after activation of 
the cells, lipids were extracted, deacylated and the glycerophosphoinositol derivatives 
of the D-3 Ptdlns lipids were separated by HPLC and detected by an on-line 
radiodetector. Figure 5.1 shows representative HPLC traces of unstimulated and 
stimulated cells. In figure 5.1a, the positions of the main phospholipid products in 
unstimulated cells are marked by the arrows. In figure 5.1b, the cells have been 
stimulated with 180nM MCP-1 for 30 seconds and the position of the three PI 3-kinase 
products, namely Ptdlns(3)P, Ptdlns(3,4)P2 and Ptdlns(3,4,5)P3 are indicated by 
arrows. The positions of the various phospholipid products were compared to 
standards analysed at the same time, the results obtained by Dr. Stephen Ward using 
the same equipment and published data (Stephens etal. 1991) (Traynor-Kaplan etal. 
1988) (Cheatham etal. 1994). The stimulation of THP-1 cells by MCP-1 induced an 
increase in both Ptdlns(3,4)P2 and Ptdlns(3,4,5)P3 but no notable increases in 
Ptdlns(3)P. Figure 5.2b and c shows the time-dependent increases in Ptdlns(3,4)P2 
and Ptdlns(3,4,5)P3. 180nM MCP-1 was used to study the activation kinetics of PI 3- 
kinase by MCP-1. The increase in Ptdlns(3,4,5)P3 was fairly rapid but transient when 
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Figure 5.1 - Typical HLPC traces obtained from a) unstimulated 
cells and b) cells stimulated with 180nM MCP-1 for 30 seconds 
following phospholipid extraction and deacylation. The sample 
preparation was as given in section 2.2.6. The positions of the 
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Figure 5.2 - Timecourse of a) Ptdlns(3)P, b) Ptdlns(3,4)P2 and 
c) Ptdlns(3,4,5)P3 changes in THP-1 cells in response to 180nM
MCP-1 stimulation. 1x107 [32P] labelled cells were stimulated for various 
times with either vehicle or 180nM MCP-1 and then extracted, deacylated 
and analysed as given in section 2.2.6. The data is representative of at 
least three separate experiments.
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Since the accumulation of Ptdlns(3,4,5)P3 was optimal at 30 seconds, this timepoint 
was chosen for the studies on Ptdlns(3)P, Ptdlns(3,4)P2 and Ptdlns(3,4,5)P3 
accumulation following three concentrations of MCP-1. The MCP-1-induced 
accumulation of Ptdlns(3,4l5)P3 exhibited bell-shaped characteristics with the 
maximum being at 60nM MCP-1 (figure 5,3a). In contrast, the increase in 
Ptdlns(3,4)P2 was maximum at 180nM MCP-1 (figure 5.3b). Only a very small 
increase in Ptdlns(3)P was observed following 12.5nM MCP-1 stimulation of these 
cells (figure 5.3a).
5.1.1.1 Identification of the PI 3-kinase sub-type activated by MCP-1
Since several isoforms of PI 3-kinase have been identified, it was necessary to 
determine which isoform is activated following MCP-1 stimulation. Hence, the 
pharmacological agents pertussis toxin and wortmannin were employed. Figure 5.4a 
shows the effects of 16 hours pre-treatment with pertussis toxin on the accumulation 
of Ptdlns(3,4,5)P3. Pertussis toxin almost completely abrogated the MCP-1-induced 
increase in Ptdlns(3,4,5)P3. In contrast, pre-incubation of the cells for 5 minutes with 
100nM wortmannin had no effect on the MCP-1-induced accumulation of 
Ptdlns(3,4,5)P3 (figure 5.4b).
5.1.2 Determination of in vitro lipid kinase activity after MCP-1 
stimulation
The second method of determining PI 3-kinase activation following MCP-1 stimulation 
was using an antibody to the regulatory p85 subunit of the PTK/SH2-coupled PI 3- 
kinase which was coupled to protein G sepharose beads. These immunoprecipitates 
were then incubated with a Ptdlns substrate in the presence of [y-32P]-ATP. This in 
vitro activity resulted in the formation of radiolabelled Ptdlns(3)P which was detected 
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Figure 5.3 - Concentration dependent changes in a) Ptd!ns(3)P, b) Ptdlns(3,4)P2
and c) Ptdlns(3,4,5)P3 in THP-1 cells following a 30 second incubation with
various concentrations of MCP-1. 1x107 [32P] labelled cells were stimulated 
for 30 seconds and then the samples extracted, deacylated and analysed 
















































Figure 5.4 - Effects of pertussis toxin and wortmannin on the MCP-1-induced 
changes in Ptdlns(3l4,5)P3 in THP-1 cells, a) The cells were pre-treated with vehicle
( or 100ng/ml pertussis toxind® for 16 hours prior to the labelling of the cells 
as given in section 2.2.6. 1x107 [32P] labelled cells were then stimulated with 
three concentrations of MCP-1 for 30 seconds and extracted, deacylated and analysed 
by HPLC as given. The data is representative of at least four separate experiments 
and is presented as the percentage of unstimulated control, b) 1x107[32P] labelled 
cells were pre-treated with 100nM wortmannin for 5 minutes prior to stimulation by 
180nM MCP-1 for 30 seconds. The samples were then extracted and deacylated as 
given. The data is representative of at least three separate experiments and 
is shown as actual CPM values.
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Figure 5.5 shows the time-course of effects of 180nM MCP-1 on the generation of 
Ptdlns(3)P from the immunoprecipitated PI 3-kinase activity. There was a time- 
dependent increase in this product which became notable at 60 seconds and 
increased up to 300 seconds. This increase in immunoprecipitated PI 3-kinase 
activity was also dose-dependent, as demonstrated in figure 5.6, in which the cells 
were stimulated with various concentrations of MCP-1 for 120 seconds. This dose- 
dependent increase was maximal at 300nM MCP-1, although there was a notable 
increase at concentrations as low as 1.25nM. Some basal activity of this enzyme was 
also observed.
5.1.2.1 Further characterisation of the immunoprecipitated PI 3-kinase 
activity stimulated by MCP-1
To further determine the nature of the lipid kinase activity in the p85 
immunoprecipitates after MCP-1 stimulation, the PI 3-kinase inhibitor wortmannin, or 
pertussis toxin were employed. Figure 5.7 demonstrates that wortmannin produced a 
dose-dependent inhibition of the immunoprecipitated PI 3-kinase activity stimulated by 
MCP-1. The IC5o for this inhibition was between 0.1-1 nM.
In contrast to the results obtained with wortmannin, pre-treatment of the cells for 16 
hours with various concentrations of pertussis toxin (0.1-100ng/ml) had no effect on 
the immunoprecipitated PI 3-kinase activity stimulated by MCP-1 (figure 5.8).
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Figure 5.5 - In vitro lipid kinase assay of THP-1 cells stimulated 
for various times with MCP-1. 1x107 cells were stimulated for 
various times with 180nM MCP-1 and then the PI 3-kinase activity 
was immunoprecipitated from the cell lysates using anti-p85 
antibody coupled protein G beads and subjected to an in vitro 
lipid kinase assay as given in section 2.2.6.2. This figure shows 
the scanned image of the autoradiograph as well as the densitometric 
analysis, expressing the results as PI kinase activity as a percentage 
of the maximum. The results are representative of at least three 
separate experiments.
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Figure 5.6 - In vitro lipid kinase assay of THP-1 cells stimulated 
with various concentrations of MCP-1. 1x107 cells were stimulated 
with various concentrations of MCP-1 for 120 seconds and then the 
PI 3-kinase activity was immunoprecipitated from the cell lysates 
using anti-p85 antibody coupled protein G beads and subjected to 
an in vitro lipid kinase assay as given in section 2.2.6.2. This figure 
shows the scanned Image of the autoradiograph as well as the 
densitometric analysis expressing the results as PI kinase activity as a 
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Figure 5.7 - In vitro lipid kinase assay of MCP-1 stimulated THP-1 
cells in the presence or absence of various concentrations of 
wortmannin. 1x107cells were pre-incubated with various concentrations of 
wortmannin for 5 minutes and then stimulated with 180nM MCP-1 for 120 
seconds. The PI 3-kinase activity was then immunoprecipitated from the 
cell lysates using anti-p85 coupled protein G beads and subjected to an in 
vitro lipid kinase assay as given in section 2.2.6.2. This figure shows the 
scanned image of the autoradiograph as well as the densitometric analysis. 
The results are expressed as PI kinase activity as a percentage of the 
maximum. The data is representative of at least three separate 
experiments.
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Figure 5.8 - In vitro lipid kinase assay of MCP-1 stimulated 
THP-1 cells in the presence or absence of various concentrations 
of pertussis toxin. The cells were pre-treated with pertussis toxin 
for 16 hours and then 1x107 cells were stimulated with 180nM 
MCP-1 for 120 seconds. Cell lysates were then prepared, 
immunoprecipitated using anti-p85 coupled protein G beads and 
subjected to an in vitro lipid kinase assay as given in section 
2.2.6.2. This figure shows the scanned image of the autoradiograph 
as well as the densitometric analysis. The results are expressed as 
PI kinase activity as a percentage of the maximum. The data is 
representative of at least three separate experiments.
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5.2 MCP-l-induced activation of PI 3-kinase in CC CKR 2A and 2B
transfected cells
5.2.1 MCP-1-induced accumulation of D-3 phosphatidvlinositol lipids
Using the 30 second time-point observed to be maximal for MCP-1-induced 
Ptdlns(3,4)P2 and Ptdlns(3,4,5)P3 accumulation in THP-1 cells, the effects of MCP-1 
on PI 3-kinase product levels in the CC CKR 2A and 2B transfectants were examined. 
EGF has already been reported to induce activation of PI 3-kinase in epithelial cells 
and was used as a positive control (Soltoff et al 1994) (Carter and Downes, 1992).
Ptdlns(3)P, Ptdlns(3,4)P2 and Ptdlns(3,4,5)P3 all demonstrated dose-dependent 
increases upon MCP-1 stimulation in the CC CKR 2A transfected cells (figure 5.9). 
The increases in Ptdlns(3,4,5)P3 demonstrated bell-shaped characteristics, with 60nM 
MCP-1 inducing a maximal increase. In contrast, the MCP-1-induced increases in 
Ptdlns(3)P and Ptdlns(3,4)P2 were both maximal at 180nM MCP-1. The elevation of 
Ptdlns(3,4)P2 and Ptdlns(3,4,5)P3 in these cells was very similar to those observed in 
the THP-1 cells following MCP-1 stimulation. In contrast, the MCP-1-induced 
increase in Ptdlns(3)P was not detected in THP-1 cells. Stimulation with 100ng/ml 
EGF produced a 2-fold increase in the levels of Ptdlns(3)P, Ptdlns(3,4)P2 and 
Ptdlns(3,4,5)P3 in these cells.
In stark contrast to the results obtained with the CC CKR 2A transfectants, the CC 
CKR 2B transfected cells demonstrated a very different pattern of PI 3-kinase product 






9 0 0 0
8 0 0 0
7 0 0 0
o  ^  6 0 0 0  
|  O  5 0 0 0  
o  > 4 0 0 0
S  >  3 0 0 0
e- -o 2000
£ 1000
con 1 2 .5  6 0  180  100ng /m l
 —  [M C P -1 ]  (n M ) ------------------^ E G F


















I  ^</) CL
|  £  
O  CD 
SZ >  
CL ~
co co o >




[M C P -1 ]  (n M )
100ng/m l
E G F
Figure 5.9 - Changes in a) Ptdlns(3)P, b) Ptdlns(3,4)P2 and c) Ptdlns(3,4,5)P3
in CC CKR 2A transfected cells. 1x107 [32P] labelled cells were stimulated 
with either vehicle ( WM ), MCP-1 (mg ) or EGF ( ■  ) at the given concentrations 
for 30 seconds and then extracted, deacylated and analysed as given in section
2.2.6. The data is representative of four separate experiments.
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following MCP-1 stimulation. An increase in the Ptdlns(3>4)P2 levels was also 
detected in response to MCP-1, with a maximal 3-fold increase following 12.5nM 
MCP-1 stimulation, but there was a very high basal level of Ptdlns(3,4,5)P3 present in 
these cells (figure 5.10). This basal level of Ptdlns(3,4,5)P3 was at least 7-fold higher 
than that observed in the CC CKR 2A transfected cells and was not increased upon 
MCP-1 stimulation and in some cases the Ptdlns(3,4,5)P3 levels were reduced by 
MCP-1. Stimulation of the cells with 100ng/ml EGF did not produce any increase in 
the levels of Ptdlns(3)P, Ptd!ns(3,4)P2 or Ptd!ns(3,4,5)P3 above basal levels.
Stimulation of the untransfected cells with 100ng/ml EGF induced a 10-fold and 2-fold 
increase in Ptdlns(3,4)P2 and Ptdlns(3,4,5)P3 respectively but no change in the 
Ptdlns(3)P levels (figure 5.11). Stimulation with 12.5-180nM MCP-1 did not induce an 
increase in PI 3-kinase products in these untransfected cells.
5.2.2 Immunoprecipitation of MCP-1-induced PI 3-kinase in CC CKR 2A 
and 2B transfectants
The effects of MCP-1 on the in vitro lipid kinase activity in the CC CKR 2A and 2B 
transfected cells were investigated using the 120 second time-point optimal for the 
THP-1 cells.
In contrast to the marked increases in the levels of Ptdlns(3)P, Ptdlns(3,4)P2 and 
Ptdlns(3,4,5)P3 observed in the CC CKR 2A transfectants following MCP-1 
stimulation, no increase in the immunoprecipitated PI 3-kinase activity was detected in 
these cells (figure 5.12). Similar results were also observed with EGF. Stimulation of 
the cells with 100ng/ml EGF produced no increase in the immunoprecipitated PI 3- 
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Figure 5.10 - Changes in a) Ptdlns(3)P, b) Ptdlns(3,4)P2 and c) Ptdlns(3,4,5)P3
in CC CKR 2B transfected cells. 1x107 [32P] labelled cells were stimulated 
with either vehicle ( WM), MCP-1 ( g i ] ) or EGF ( ■  ) for 30 seconds at the given 
concentrations and then extracted, deacylated and analysed as given in section
2.2.6. The data is representative of four separate experiments.
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Figure 5.11 - Changes in a) PI(3)P, b) PI(3,4)P2 and c) PI(3,4,5)P3
in untransfected HEK 293 cells. 1x107 [32P] labelled cells were 
stimulated with either vehicle (■§ ). MCP-1 ( f  ) or EGF ( H i  ) at the 
given concentrations for 30 seconds and then extracted, deacylated 
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Figure 5.12 - In vitro lipid kinase assay of CC CKR 2A cells 
stimulated with various concentrations of MCP-1 or 100ng/ml EGF.
1x107 cells were stimulated with various concentrations of MCP-1 or 
100ng/ml EGF for 120 seconds and then the PI 3-kinase activity was 
immunoprecipitated from the cell lysates using anti-p85 antibody 
coupled protein G beads and subjected to an in vitro lipid kinase assay 
as given in section 2.2.6.2. This figure shows the scanned image of 
the autoradiograph as well as the densitometric analysis expressing 
the results as PI kinase activity as a percentage of the maximum.
The data is representative of at least three separate experiments.
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Figure 5.13 shows the effects of MCP-1 and EGF on the immunoprecipitated PI 3- 
kinase activity from the CC CKR 2B transfected cells. Stimulation of these cells with 
various concentrations of MCP-1 resulted in an increase in the immunoprecipitated PI 
3-kinase activity. The concentrations of MCP-1 required for the maximal activation of 
this immunoprecipitated PI 3-kinase activity in the CC CKR 2B transfectants were 
lower than required in THP-1 cells. These results in the CC CKR 2B transfectants are 
in contrast to the results obtained studying the accumulation of D-3 Ptdlns lipids, in 
which there was a very high basal Ptdlns(3,4,5)P3 level which was not increased by 
MCP-1 stimulation. Also, stimulation of the cells with 100ng/ml EGF, which did not 
induce an increase in Ptdlns(3)P, Ptdlns(3,4)P2 or Ptdlns(3,4,5)P3, induced a 4-fold 
increase in the immunoprecipitated PI 3-kinase activity.
5.3 Determination of protein tyrosine kinase coupling to MCP-1
receptors in THP-1 cells and CC CKR 2A and 2B transfectants
The activation of the PTK-coupled PI 3-kinase is thought to be through the interaction 
of tyrosine phosphorylated proteins with the SH2 domains of the p85 regulatory 
subunit (Carpenter etal. 1993). Following the identification of MCP-1-induced 
activation of the PTK/SH2-coupled PI 3-kinase by immunoprecipitation and in vitro 
lipid kinase assay, it was important to investigate 1) whether MCP-1 induced tyrosine 
phosphorylation of cellular proteins, 2) whether these tyrosine phosphorylated proteins 
interacted with the p85 subunit of PI 3-kinase and 3) whether PI 3-kinase was 
phosphorylated on tyrosine.
This was performed by activating the cells and subsequently immunoprecipitating 
either the tyrosine phosphorylated proteins using the anti-phosphotyrosine antibody 
coupled to protein G sepharose beads or immunoprecipitating the p85 subunit using
156
an anti-p85 antibody coupled to proteins G beads. The proteins were separated by 
SDS-PAGE, Western blotted and developed using the anti-phosphotyrosine antibody, 
4G10.
Attempts to detect tyrosine phosphorylation in whole cell lysates were unsuccessful 
due to the amount of background making any potential small increases impossible to 
detect.
Figure 5.14a shows the three proteins which were tyrosine phosphorylated in a time- 
dependent manner following 180nM MCP-1 stimulation of THP-1 cells. These 
proteins had molecular weights of 120, 80 and 50kDa. The 80 kDa and the 50kDa 
proteins demonstrated similar phosphorylation kinetics. They were maximally 
phosphorylated at 30 seconds and the levels of phosphorylation had declined back to 
basal levels by 120 seconds. The 120kDa band exhibited more rapid phosphorylation 
kinetics than the other two proteins. Phosphorylation of the 120kDa protein was only 
clearly observed at 30 seconds and by 120 seconds its phosphorylation level was 
reduced to control.
To further characterise the protein tyrosine kinase activity stimulated by MCP-1 in 
THP-1 cells, both pertussis toxin and wortmannin were employed. Figure 5.14b 
demonstrates that the MCP-1 -induced tyrosine phosphorylation was completely 
abrogated by the pre-incubation of the cells for 16 hours with 100ng/ml pertussis 
toxin. In contrast, pre-treatment of the cells for 5 minutes with 100nM wortmannin 
had no effect on the tyrosine phosphorylation stimulated by MCP-1.
Figure 5.15 shows preliminary data demonstrating the tyrosine phosphorylated 
protein which was co-precipitated with the p85 subunit of PI 3-kinase in the THP-1
157
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Figure 5.13 - In vitro lipid kinase assay of CC CKR 2B cells 
stimulated with various concentrations of MCP-1 or 100ng/ml 
EGF. 1x107 cells were stimulated with various concentrations of 
MCP-1 or 100ng/ml EGF for 120seconds and then the PI 3-kinase 
activity immunoprecipitated from the cell lysates using anti-p85 
antibody coupled protein G beads and subjected to an in vitro lipid 
kinase assay as given in section 2.2.6.2. This figure shows the 
scanned image of the autoradiograph as well as the densitometric 
analysis expressing the results as PI kinase activity as a percentage 
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Figure 5.14 - Tyrosine phosphorylation of proteins following 
MCP-1 stimulation of THP-1 cells 1x107 THP-1 cells were stimulated 
and cell lysates prepared. These were then immunoprecipitated with 
PY20-coupled protein G beads and the proteins separated by 
SDS-PAGE, Western blotted and developed with 4G10 antibody, as 
given in section 2.2.7. a) This figure shows a photograph of an 
autoradiograph following 180nM MCP-1 stimulation for various times 
and is representative of three separate experiments, b) This figure 
shows the effects of 16 hour pre-treatment of the cells with 100ng/ml 
pertussis toxin and c) shows the effects of 100nM wortmannin pre­
treatment for 5 mins prior to MCP-1 stimulation. These photographs 
are represenative of two separate experiments. The molecular weight 
markers and the heavy and light chains of the antibody used for immuno- 
precipitation are indicated by arrows. A, B and C indicate the proteins 
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Figure 5.15 - Tyrosine phosphorylated proteins associated 
with the p85 subunit of PI 3-kinase in THP-1 cells. 1x107 THP-1 
cells were stimulated with 180nM MCP-1 for various times 
and then cell lysates prepared. In this experiment the lysates 
were incubated for 1 hour with the anti-p85 antibody at 4°C 
and then rotated for 1 hour with 30ptl of a 50% suspension of 
protein G sepharose beads at 4°C. The proteins were separated 
by SDS-PAGE, Western blotted and developed with 4G10 antibody, 
as given in section 2.2.7. This figure shows a photograph of the 
autoradiograph and is preliminary data from one experiment. The 
molecular weight markers are indicated by the arrows. A indicates 
the phosphorylated protein associated with p85 and its molecular 
weight is 55kDa.
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cells. This band had a molecular weight of approximately 55 kDa and its 
phosphorylation was delayed. The protein was only just visible at 30 and 60 seconds 
but was greatly increased by 120 seconds and was maximally phosphorylated by 300 
seconds. This was comparable with the kinetics of the immunoprecipitated PI 3- 
kinase activity activated by MCP-1 in these THP-1 cells. However, the time-course of 
phosphorylation of this 55kDa band was different to the time-course of 
phosphorylation observed for the other proteins present in the anti-phosphotyrosine 
immunoprecipitates. There was no evidence that the p85 subunit itself was tyrosine 
phosphorylated.
Given the results obtained in the THP-1 cells following MCP-1 stimulation, the ability 
of MCP-1 to activate protein tyrosine kinase activity in the CC CKR 2A and 2B 
transfected cells was investigated. The preliminary data shown in figure 5.16a 
demonstrates that very little protein phosphorylation was detected in the CC CKR 2A 
transfectants following MCP-1 stimulation. The 80kDa protein, observed to be 
phosphorylated by MCP-1 in the THP-1 cells, demonstrated a very small increase in 
the level of phosphorylation at 60 seconds after MCP-1 stimulation of these CC CKR 
2A transfectants. However, no other proteins were observed to be phosphorylated 
following MCP-1 stimulation of the CC CKR 2A transfected cells.
In contrast, preliminary data indicates that MCP-1 induced a time-dependent increase 
in the tyrosine phosphorylation of three proteins in the CC CKR 2B transfected cells 
(figure 5.16b). These phosphorylated proteins demonstrate the same molecular 
weights as the phosphorylated proteins detected following MCP-1 stimulation of the 
THP-1 cells. The 120, 80 and 50kDa proteins phosphorylated upon MCP-1 
stimulation of the CC CKR 2B transfectants were maximally phosphorylated 60 
seconds after MCP-1 stimulation and had declined to basal levels by 300 seconds. 
This time-course of phosphorylation of these proteins in the CC CKR 2B transfectants
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was slightly delayed compared to the tyrosine phosphorylation observed in the THP-1 
cells, which was maximal 30 seconds after MCP-1 stimulation.
5.4 Determination of potential downstream effectors of PI 3-kinase 
activated by MCP-1
The number of downstream targets of PI 3-kinase is now increasing very rapidly and, 
to date, includes PKCs s, 5, r\ and £, PKB and p70 S6 kinase (reviewed (Ward et at. 
1996)). One method of investigating the possible activation of p70 S6 kinase is using 
a so-called ‘band shift’ assay. The cells are stimulated and lysed and the reduced 
cell lysates separated on an SDS-PAGE gel. The proteins are transferred onto a 
nitrocellulose membrane and the p70 S6 kinase is detected by immunoblotting using 
a specific monoclonal antibody. This antibody recognises two isoforms of p70 S6 
kinase, namely the al and the all isoform. In the course of activation, the enzyme 
becomes phosphorylation and has reduced gel mobility. Thus, the p70 S6 kinase 
band detected by immunoblotting appears to shift upwards. As PI 3-kinase activation 
has already been identified in THP-1 cells following MCP-1 stimulation, the 
phosphorylation of the downstream target p70 S6 kinase was investigated using the 
‘band shift’ assay.
Figure 5.17 shows that MCP-1 induced a time-dependent increase in the number of 
p70 S6 kinase bands appearing in THP-1 cells. Only the all isoform of p70 S6 kinase 
demonstrated any MCP-1-induced band shift. The increase in the number of bands, 
from three to four, was notable 2 minutes after 180nM MCP-1 stimulation and was 
maximal 15 minutes after stimulation. The all band appeared to be declining to basal 
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Figure 5.16 - Tyrosine phosphorylation of proteins following 
MCP-1 stimulation of CC CKR 2A and 2B transfected cells.
1x107 cells were stimulated and cell lysates prepared. These were 
then immunoprecipitated with PY20-coupled protein G beads and the 
proteins separated by SDS-PAGE, Western blotted and developed 
with 4G10 antibody, as given in section 2.2.7. a) This figure shows 
a photograph of an autoradiograph following stimulation of CC CKR 2A 
cells with 180nM MCP-1 for various times, b) This shows a photograph 
of an autoradiograph following stimulation of CC CKR 2B cells with 
180nM MCP-1 for various times. This is preliminary data from one 
experiment. The molecular weight markers are indicated by the arrows. 
A, B and C indicate the proteins phosphorylated by MCP-1 The 
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Figure 5.17 - Effects of MCP-1 on p70 S6 kinase phosphorylation 
in THP-1 cells. 1x107 cells were stimulated with 180nM MCP-1 for 
various times and cell lysates prepared. The proteins were then 
acetone precipitated and separated using SDS-PAGE, Western 
blotted and developed using an anti-p70 S6 kinase antibody as 
given in section 2.2.8. This figure is a photograph of an auto­
radiograph and is representative of three separate experiments.
The molecular weight marker is indicated by the arrow. The a1 
and a2 marked by the arrows are the two isoforms of p70 S6 
kinase recognised by the antibody.
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5.5 Role of MCP-1 in the proliferation rate of the CC CKR 2A  and 2B
transfected cells
During routine culture it was observed that the CC CKR 2B transfectants appeared to 
grow at a faster rate than the CC CKR 2A transfectants. One possible explanation 
was that the HEK 293 cells could be producing MCP-1 that was acting on the 
receptors transfected into these cells and inducing differences in growth rates. The 
variation in MCP-1 receptor expression could explain the differences between the two 
transfectants. Also, the very high basal levels of Ptdlns(3,4,5)P3 may play an 
important role in these growth differences, as Ptdlns(3,4,5)P3 has already been linked 
to cell growth and differentiation (Coughlin etal. 1989). Thus, the incorporation of 
[3H]-thymidine into these cells was investigated in the presence of increasing 
concentrations of FCS. The role of MCP-1 in these incorporation experiments was 
also investigated.
In the presence of increasing concentrations of FCS, [3H]-thymidine incorporation in 
the CC CKR 2B transfected cells was greater than that in the CC CKR 2A transfected 
cells (figure 5.18a). In the presence of 1% FCS, there was a 3-fold difference 
between the CC CKR 2A and 2B transfectants. Interestingly, the untransfected cells 
demonstrated a much more rapid rate of [3H]-thymidine incorporation than both of the 
transfectants (figure 5.18b).
The effects of MCP-1 on the rate of [3H]-thymidine incorporation into the CC CKR 2A, 
CC CKR 2B and untransfected cells were also investigated. The cells were grown in 
the presence of 1% FCS with increasing concentrations of MCP-1 (1.25-60nM).
60nM MCP-1 was also pre-incubated with a neutralising anti-MCP-1 antibody prior to 
addition to the cells.
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Figure 5.18 - [3H]-thymidine incorporation into a) CC CKR 2A transfectants 
( ■ )  and CC CKR 2B transfectants ( □  ) and b) untransfected HEK cells.
5x103 cells/well were plated out into 96 well plates and after 40 hours incubation 
they were depleted of serum for 4 hours and then grown in the presence of increasing 
concentrations of serum for 44 hours as given in section 2.2.10. The cells were pulsed 
with [3H]-thymidine for the final 18 hours and then harvested and counted. The 
results are expressed as the mean +/- s.d. of from one experiment representative of 
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Figure 5.19 - ^HJ-thymidine incorporation into a) CC CKR 2A transfectants 
b) CC CKR 2B transfectants and c) untransfected HEK cells in response 
to MCP-1. 5x103 cells/well were plated out into 96 well plates and after 40 
hours incubation they were depleted of serum for 4 hours and then grown in the 
presence of 1% FCS plus various concentrations of MCP-1 or 60nM MCP-1 plus a 
neutralising monoclonal MCP-1 antibody. The cells were pulsed with [3H]-thymidine 
for the final 18 hours and then harvested and counted as given in section 2.2.10. 
The results are expressed as the mean +/-s.d. of one experiment representative 
of three other separate experiments.
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Figure 5.19 demonstrates that there was no significant difference in the [3H]- 
thymidine incorporation in either the CC CKR 2A or 2B transfectants in the presence 
of MCP-1 or the MCP-1/anti-MCP-1 antibody complex. No significant difference in 
[3H]-thymidine incorporation was observed in the untransfected cells following MCP-1 
stimulation either.
5.6 Summary
1. MCP-1 induced the accumulation of both Ptdlns(3,4)P2 and Ptdlns(3,4,5)P3 but 
not Ptdlns(3)P in THP-1 cells in both a dose- and time-dependent manner. The 
accumulation of Ptdlns(3,4,5)P3 was almost completely inhibited by 100ng/ml 
pertussis toxin but was insensitive to wortmannin pre-treatment.
2. MCP-1 also activated the PTK/SH2-coupled PI 3-kinase, specifically 
immunoprecipitated using anti-p85 antibody coupled protein G beads, in THP-1 
cells. This activation was also both dose-and time-dependent. 100nM 
wortmannin completely abolished the immunoprecipitated PI 3-kinase activity 
activated by MCP-1. In contrast, pertussis toxin pre-treatment had no effect.
3. The CC CKR 2A transfectants demonstrated an MCP-1-induced increase in the 
levels of Ptdlns(3)P, Ptdlns(3,4)P2 and Ptdlns(3,4,5)P3. EGF, used as a positive 
control for these epithelial cells, also induced an increase in these PI 3-kinase 
products. In contrast, the CC CKR 2B transfected cells demonstrated very high 
basal levels of Ptdlns(3,4,5)P3 which were not increased by MCP-1 or EGF 
stimulation.
4. Immunoprecipitation of the PTK/SH2-coupled PI 3-kinase from MCP-1 stimulated 
CC CKR 2A cells revealed that MCP-1 did not increase the PTK/SH2-coupled PI 3- 
kinase activity in these cells. The positive control, EGF, also induced no increase 
in PI 3-kinase activity in these immunoprecipitates. In contrast, CC CKR 2B 
transfectants exhibited an MCP-1 -induced dose-dependent increase in the
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PTK/SH2-coupled PI 3-kinase activity present in the immunoprecipitates. EGF 
also produced a 4-fold increase in the immunoprecipitated PI 3-kinase activity.
5. Investigation into the activation of protein tyrosine kinases following MCP-1 
stimulation demonstrated that three proteins, of molecular weights 120, 80 and 
50kDa, were phosphorylated in a time-dependent manner in THP-1 cells. The 
maximal phosphorylation time was 30 seconds. The phosphorylation of these 
proteins was inhibited by 100ng/ml pertussis toxin pre-treatment but was 
unaffected by wortmannin.
6. Immunoprecipitation of the p85 subunit of PI 3-kinase from THP-1 cells and 
determination of the phosphorylated proteins which co-precipitated with this 
subunit identified a single protein of approximately 55kDa. The phosphorylation 
kinetics of this protein were delayed with notable phosphorylation only occurring 
from 120 seconds post MCP-1 stimulation. These kinetics were similar to the 
kinetics observed with the immunoprecipitated PTK/SH2-coupled PI 3-kinase 
activation.
7. No notable protein tyrosine phosphorylation was detected in the CC CKR 2A 
transfected cells following MCP-1 stimulation. In contrast, proteins of molecular 
weight 120, 80 and 50 kDa were phosphorylated in a time-dependent manner in 
the CC CKR 2B transfectants upon MCP-1 stimulation.
8. MCP-1 appeared to induce a time-dependent phosphorylation of the potential 
downstream effector of PI 3-kinase, p70 S6 kinase, as demonstrated by the 
increase in the number of bands detected in the so-called ‘band shift’ assay. This 
phosphorylation was maximal at 15 minutes and returning to basal levels by 30 
minutes.
9. There was a marked difference between the [3H]-thymidine incorporation in the CC 
CKR 2A and 2B transfectants but MCP-1 did not affect this incorporation in either 
CC CKR 2A, CC CKR 2B or untransfected cells.
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SECTION 6 : FUNCTIONAL RESPONSES ACTIVATED BY MCP-1
IN HUMAN MONOCYTES AND MONOCYTIC CELL LINES
In order to try and investigate the potential roles of the signalling pathways, 
demonstrated in this study to be activated by MCP-1, a number of functional 
responses were investigated in both human monocytes and THP-1 cells. These 
included chemotaxis, adhesion molecule upregulation, superoxide release and low 
affinity IgE receptor (CD23) upregulation.
6.1 MCP-l-induced chemotaxis in human monocytes and THP-1 cells
The movement of monocytes down a chemotactic gradient can be monitored in vitro 
using a Boyden chamber in which MCP-1 is placed in the lower well and the cells in 
the upper well. The two chambers are separated by a membrane with pores of 
diameter 5 or 8j^m. The number of cells which have moved towards the stimulus is 
identified by staining and counting the cells on the lower side of the membrane (Falk 
etal. 1980).
Human monocytes demonstrated a dose-dependent chemotactic response to MCP-1 
(figure 6.1a). The EC5o for this response was around 1nM. THP-1 cells also 
demonstrated a dose-dependent chemotactic response to MCP-1 (figure 6.1b). The 
EC5o for these cells was between 0.1 and 1 nM, slightly lower than observed for human 
monocytes. Due to the donor variation of the monocytes and the small responses 
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Figure 6.1 - Chemotactic response to MCP-1 in human blood derived monocytes and 
THP-1 cells, a) Monocytes were purified as given in section 2.2.1.3. Various concentrations 
of MCP-1 were placed in the lower wells and 7x104 monocytes were placed in the upper 
wells of the Boyden chamber. The two chambers were separated by an 8|im pore size filter 
and incubated at 37°C for 90 minutes, b) 1.6x105 THP-1 cells were placed in the upper 
wells separated from various concentrations of MCP-1 in the lower wells by a 5^m pore 
size filter and incubated at 37°C for 120 minutes. The filters were stained with Diff-Quick 
stain and the average number of cells from five high power fields of view calculated. The 
results are expressed as the mean chemotactic index from one experiment representative 
of six separate experiments (data +/- s.d.) for the monocytes and the mean chemotactic index 
from six separate experiments (mean +/- s.e.m.) for the THP-1 cells.
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6.2 Upregulation of various adhesion molecules on human monocytes
following MCP-1 stimulation
Adhesion molecule upregulation is important for monocyte transmigration and these 
cell surface molecules can be labelled with a fluoresceinated antibody and detected 
using the FACS. The upregulation of CD11b/CD18, CD11c/CD18 and VLA-4, upon 
MCP-1 stimulation was investigated in human blood derived monocytes. Although 
MCP-1 has already been demonstrated to induce adhesion molecule upregulation 
(Jiang etal. 1992), the signalling pathways involved in this upregulation have not been 
well characterised.
Following the recent publications on MCP-1-induced adhesion molecule upregulation, 
a 30 minute timepoint was chosen (Jiang etal. 1992)(Vaddi & Newton, 1994). Also, 
due to the upregulation of adhesion molecules upon monocyte purification, whole 
blood was incubated with MCP-1 and the CD14 positive monocyte population was 
identified in the whole blood preparation during the FACS analysis.
Figure 6.2a shows the dose-dependent increase in CD11b expression following MCP- 
1 stimulation, demonstrated by the increase in the relative fluorescence intensity. 
Maximum CD11 b expression above basal levels was observed following 60nM MCP-1 
stimulation. Stimulation by 1.25nM MCP-1 produced CD11b expression not markedly 
above unstimulated CD11 b expression. The lack of fluorescence demonstrated by 


















Figure 6.2 - Effects of MCP-1 on a) CD11b and b) CD11c 
expression on human monocytes. 100pl of whole blood was 
stimulated with various concentrations of MCP-1 for 30 minutes 
and then labelled with anti-CD11b- or CD11c-FITC antibodies as 
given in section 2.2.12. The data is representative of four separate 
experiments and is shown as the change in fluorescence after 60nM
MCP-1 (-------) or 1.25nM ( ----- ) compared to unstimulated ( — )
or IgG control ( ------ ).
1 7 3
Similar dose-dependent effects were observed upon investigation of the MCP-1 - 
induced CD11c upregulation. Figure 6.2b shows that 60nM MCP-1 induced a 
maximal upregulation of CD11c above basal levels. 1.25nM MCP-1 did not induce 
any notable CD11c upregulation compared to control. Again, the IgG control was very 
low. Interestingly, the basal level of CD11 b expression was higher than the basal 
CD11c expression.
VLA-4 was not upregulated on human monocytes in response to 60nM MCP-1 
stimulation for 30 minutes, as demonstrated by figure 6.3 (n=3).
To further characterise the MCP-1-induced monocyte adhesion molecule upregulation 
the effects of wortmannin and pertussis toxin were studied on the MCP-1-induced 
CD11b and CD11c upregulation.
Figure 6.4 shows the effects of 100nM wortmannin pre-treatment on the upregulation 
of CD11 b and CD11c. Preliminary data indicates that wortmannin had no marked 
effect on the upregulation of either CD11b or CD11c following MCP-1 stimulation. 
Unfortunately, pre-treatment of the whole blood for 2 hours with 10Ong/ml pertussis 
toxin induced activation of the monocytes and thus, a very high basal expression of 
both CD11b and CD11c. This made it was impossible to study the effects of MCP-1 





Figure 6.3 - Effects of MCP-1 on VLA-4 expression on human monocytes.
100fil of whole blood was stimulated with 60nM MCP-1 for 30 minutes 
and then labelled with a VLA-4-FITC antibody as given in section 2.2.12. 
The samples were then analysed using a FACScan. The results are 
expressed as the mean fluorescence intensity and are representative 
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Figure 6.4 - Upregulation of a) CD11b and b) CD11c by MCP-1 on 
human monocytes in the a b s e n c e (^ ) or presence (IWI) of 100 nM 
wortmannin. Whole blood was pre-treated with 100nM wortmannin or 
vehicle control for 5 minutes at 37°C prior to stimulation of 100|il 
aliquots with various concentrations of MCP-1 for 30 minutes at 37°C.
The cells were then labelled with either anti-CD11b-FITC or anti-CD11c-FITC 
antibodies as given in section 2.2.12. The results are preliminary data from 
one experiment (mean +/- s.d.). Where error bars are not visible they are 
smaller than the lines.
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6.3 Superoxide generation in response to MCP-1 stimulation
of human monocytes
One of the functional responses of human monocytes to agonist stimulation is 
superoxide release. There are many ways in which the generation of superoxide can 
be measured from cells (Jones & Hancock, 1994). Two of these methods are the 
oxidation of scopoletin and the reduction of ferricytochrome C. The first method 
measures the oxidation of scopoletin to a non-fluorescent product by H20 2> which is 
the product of the spontaneous breakdown of superoxide. The second method is a 
more direct method which involves the reduction of ferricytochrome C by the 
superoxide produced by the cells. Both of these methods were used to look at the 
production of superoxide from purified human blood derived monocytes in response to 
MCP-1 as well as C5a, fMLP and PMA as positive controls.
Figure 6.5 shows the generation of H20 2 in purified human monocytes following MCP- 
1, C5a, fMLP and PMA stimulation. Although the positive controls, C5a, fMLP and 
PMA all produced dose-dependent increases in H20 2 concentrations, MCP-1 did not 
induce any notable increases in H20 2 concentrations at any of the concentrations 
tested.
Due to the lack of H20 2 detected following MCP-1 stimulation of human monocytes 
using the scopoletin assay the more direct reduction of ferricytochrome C was 
monitored. Figure 6.6a demonstrates that MCP-1 did induce a dose-dependent 
increase in superoxide generation in these purified monocytes. The MCP-1-induced 
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Figure 6.5 - Generation of hydrogen peroxide in purified human monocytes 
following stimulation by a) MCP-1, b) C5a, c) fMLP and d) PMA. The monocytes 
were purified as given in section 2.2.1.3. 2x105 cells/well were stimulated 
with various concentrations of the given agonists and the reaction started as 
given in section 2.2.13.1. The fluorescence readings were then taken using a 
fluorescent plate reader and the results calculated from the standard curve.
The results are expressed as mean +/- s.d. from the readings taken at 120 
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Figure 6.6 - Generation of superoxide by purified human monocytes following 
stimulation by a) MCP-1, b) C5a, c) fMLP and d) PMA. 1x106 PBMC's well 
were plated out into 96 well plates and after 90 minutes incubation the non­
adherent cells were washed off. The adherent monocytes were then stimulated 
with various concentrations of the given agonists and the reaction started as 
given in section 2.2.13.2. The O.D. readings were taken using a plate reader and 
converted into [O2-] using the extinction coefficient for reduced ferricytochrome C. 
The results are expressed as mean +/- s.d. from the readings taken at 120 minutes. 
The data is expressed as [O2 ] (nmole/well) as the amount of protein per well did 
not vary significantly from 3mg/ml. The data is from one experiment representative 
of four other separate experiments.
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6.4 Low affinity IgE receptor expression on human monocytes
following MCP-1 stimulation
Following a number of reports of CD23 upregulation on monocytes and monocytic cell 
lines (Gessl etal. 1993)(Ouaaz etal. 1993), the effects of its cleavage product soluble 
CD23 (Paul-Eugene etal. 1993) as well as its increased expression on monocytes of 
asthmatic patients (Williams etal. 1992)(Demoly etal. 1994), the effects of MCP-1 on 
monocyte CD23 expression was studied. A fluoresceinated CD23 antibody was used 
to detect cell surface expressed CD23 using the FACS. As a positive control, IL-3 
was administered in parallel as it has already been identified as a potent inducer of 
CD23 upregulation (Alderson etal. 1992).
Figure 6.7 shows that the percentage of unstimulated cells expressing CD23 was 
10.72 ± 2.99% (n=3). Upon stimulation of these cells with 100ng/ml IL-3, the 
percentage positive cells increased to 44.64 ± 0.93% (n=3). In contrast, stimulation of 
these cells with 12.5nM MCP-1 did not increase the percentage of cells expressing 
CD23 (5.68 ± 0.77, n=3).
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Figure 6.7 - Effects of MCP-1 on the upregulation of CD23 on human monocytes.
The PBMC's were prepared as given in section 2.2.1.3 and 2-5x106 cells/ml 
were plated out into Petri dishes and treated with either vehicle ( H i  )> 12.5nM MCP-1 
( G 3 ) or 100ng/ml IL-3 ( M ) for 44 hours. The cells were then labelled with anti- 
CD23-FITC antibody as given in section 2.2.14. The expression of CD23 on the CD14 
positive monocytes was analysed by FACS. The data is representative of three separate 
experiments and is expressed as the percentage positive cells (data +/- s.d.).
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6.5 Summary
1. MCP-1 induces a chemotactic response in both human monocytes and THP-1 
cells. This response is dose-dependent with an EC50 value of around 1nM.
2. The expression of both CD11b and CD11c on human monocytes was greatly 
increased upon MCP-1 stimulation, in a dose-dependent manner. VLA-4 was not 
upregulated by MCP-1. 10OnM wortmannin pre-treatment of the cells did not 
appear to have any marked effect on the expression of either CD11b or CD11c.
3. MCP-1 induced the production of superoxide by purified human monocytes, as 
detected by the dose-dependent reduction of ferricytochrome C. This response 
was similar to that induced by C5a but smaller than that observed following fMLP or 
PMA stimulation.
4. IL-3 induced a 4-fold increase in the expression of CD23 on human monocytes. In 
contrast, MCP-1 did not have any effect on the expression of this low affinity IgE 
receptor.
5. Although MCP-1-induced chemotaxis and superoxide release were detected, large 
donor variations and very small responses made investigations into the roles of 
PLC and PI 3-kinase in these functional responses very difficult. Also, as 
demonstrated in the adhesion molecule experiments, pre-treatment of the cells with 
pharmacological agents such as pertussis toxin was very difficult due to the ease 
with which human monocytes become activated.
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SECTION 7: DISCUSSION
7.1 The binding of MCP-1 to its receptors
The results presented in this thesis identified a single, high affinity group of MCP-1 
receptors on THP-1 cells with a Kd of 4.71 nM and 20 000 receptors per cell. These 
results are comparable with those already reported. The published Kd values for 
MCP-1 binding to THP-1 cells vary from 0.44nM to 25.7nM and the number of high 
affinity receptors per cell range from 5 000 to 18 000 (Van Riper et al. 1993) (Wang et 
al. 1993). Both of these reports identified a single receptor type on THP-1 cells, as 
demonstrated by a straight line on the Scatchard plot.
Receptor desensitisation is a phenomenon that has been observed by a number of G- 
protein -coupled receptors (Hausdorff et al. 1990) and it provides a method of 
observing which agonists bind to the same receptors. There are a number of possible 
explanations for receptor desensitisation, including receptor phosphorylation 
(Hausdorff etal. 1990), alteration of sensitivity of G-proteins to guanine nucleotides 
(Small etal. 1987) and receptordownregulation (Samanta etal. 1990). Interestingly, 
the IL-8 B receptor becomes phosphorylated upon the binding of MGSA and the 
receptor is subsequently degraded (Mueller etal. 1995). Also, chemokine receptor 
internalisation and subsequent degradation has already been reported for both IL-8 
and MCP-1 receptors at 37°C following agonist binding (Samanta etal. 1990) (Wang 
etal. 1993). Therefore, it is likely that both receptor phosphorylation and receptor 
internalisation play a role in the MCP-1-induced desensitisation detected in THP-1 
cells in this study.
In the results presented in this thesis, stimulation of THP-1 cells with various 
combinations of chemokines demonstrated heterologous desensitisation, with prior
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stimulation of the cells with MCP-1 inhibiting the subsequent MIP-1a, RANTES, MCP- 
3 and IL-8 responses. In contrast, only MCP-3 could desensitise the MCP-1-induced 
calcium response. These results indicate the presence of at least two, if not three, 
separate MCP-1 receptors on THP-1 cells, one binding MCP-1 and MCP-3 only, one 
binding MCP-1, MIP-1a and RANTES and possibly a third which binds MCP-1 and IL- 
8. The first two receptors are most likely to be the CC CKR 2 and CC CKR 1 
respectively, both of which have been identified on THP-1 cells (Charo etal. 1994) 
(Neote et al. 1993). The third is possibly a promiscuous receptor which binds both C- 
C and C-X-C chemokines. An example is the DARC, although the DARC has not yet 
been identified as a biologically active receptor (Horuk etal. 1996). Therefore, it is 
possible that there is another, as yet unidentified promiscuous chemokine receptor 
also present on THP-1 cells.
These results are in contrast to the desensitisation results published by Vaddi and 
Newton (Vaddi & Newton, 1994a). They studied the cross-desensitisation between 
MCP-1, RANTES and MIP-1a in THP-1 cells and found that only readdition of the 
same agonist could cause desensitisation, thus indicating that none of the 
chemokines applied interacted with the same receptor. Variations in the clone of 
THP-1 used and the culture conditions may explain the disparity between these 
results.
In contrast to the radioligand binding studies presented in this thesis, which identified 
a single receptor group, the calcium desensitisation results show the presence of 
more than one MCP-1 receptor type. The CC CKR 2 is a high affinity MCP-1 receptor 
and is the most likely candidate for the receptor identified in the radioligand binding 
study. The other receptors identified by the calcium desensitisation experiments, 
namely the CC CKR 1 and the promiscuous receptor, are likely to be low affinity MCP- 
1 receptors, which are not expressed at such a high level as the CC CKR 2 and are
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not detected in the radioligand binding studies performed either in this study or in 
other published studies.
The binding data obtained with the CC CKR 2B transfected cells was also comparable 
to the published data. The Kd for MCP-1 binding to these cells was calculated from 
the Scatchard plot presented in this thesis to be 2.69nM with the number of receptors 
per cell calculated at 22 500. MCP-1 binding to the CC CKR 2B transfected into HEK 
293 cells has been reported by other groups, although the Kd values obtained were 
slightly lower than observed in my study (0.26nM and 0.166nM) (Myers etal. 1995) 
(Franci et al. 1995). However, no Bmax values have been published for these cells.
Although no radioligand binding was detected in the CC CKR 2A transfected cells, the 
data from this study using biotinylated MCP-1 demonstrated that the CC CKR 2A is 
expressed at the cell surface, but the pattern was very unlike that seen with either 
THP-1 cells or the CC CKR 2B transfected cells. The CC CKR 2A transfected cells 
fell into two categories, those expressing MCP-1 receptors and those not expressing 
MCP-1 receptors. This biphasic response might be explained by the following three 
factors; 1) the receptor may only be transiently expressed on the cell surface and thus 
only a percentage and not all of the cells express the receptor at any one time 2) an 
inadequate receptor transfection and 3) low affinity binding interactions. Addressing 
the first point, transient receptor expression could explain the two populations of cells 
detected, as not all of cells may express the receptor at any one time. This might also 
explain why no radioligand binding was detected. As only a percentage of the cells 
express the receptor, this population may not be large enough to be detected by the 
radioligand binding assay. The second point is unlikely as the clone used was chosen 
due to its high expression of CC CKR 2A mRNA and as the cells are maintained in 
G418 selection medium it is unlikely that a population of non-receptor expressing cells 
would develop. With regard to the low affinity binding interaction between the agonist
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and its receptor, the equal shifts in the fluorescence detected in the THP-1 cells, the 
CC CKR 2B and the positive population of the CC CKR 2A transfected cells makes 
this an unlikely theory for the lack of radioligand binding and, again, would not 
adequately explain the presence of two cell populations.
No reports of MCP-1 binding to the CC CKR 2A transfected cells have, to date, been 
published. However, it is very interesting to note that there have been a number of 
radioligand binding studies performed using various chemokines and their receptors 
which have demonstrated results not representative of the biological responses. This 
was first demonstrated by Neote etal. with the CC CKR 1, the MIP-1a and RANTES 
receptor, in which the Kd values obtained with MCP-1 and MIP-1 p were lower than for 
RANTES. However, a 10-fold excess of MCP-1 and MIP-1 p were required to produce 
a calcium response and even then it was only 20% of the RANTES response (Neote 
et at. 1993). Similar anomalies have been observed by a number of groups during the 
characterisation of new members of the CC chemokine receptor group. For example, 
two independent groups have transfected CC CKR 3 into HEK 293 cells and, although 
they have found differences in the agonist specificity’s, neither group can detect 
significant ligand binding by agonists which produce potent calcium responses 
(Combadiere etal. 1995) (Kitaura etal. 1996). Similar results have also been 
observed in HL60 cells transfected with the CC CKR 4 and in Chinese hamster ovary 
K1 (CHO K1) cells transfected with the proposed CC CKR 5 (Hoogewerf etal. 1996) 
(Samson et al. 1996). In both of these studies no significant radioligand binding could 
be detected in these cells using agonists which produced biological responses. These 
groups concluded that there must be either very low affinity binding interactions 
between the agonist and its receptor or inadequate receptor expression in the 
transfected cells.
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Similar discrepancies between radioligand binding data and biological responses have 
been observed in the results presented in this thesis with the CC CKR 2A transfected 
cells. Although biological responses were detected in these cells, such as PI 3-kinase 
activation, no radioligand binding was observed. Interestingly, Charo presented some 
data at the 4th International Chemokine Symposium in which he showed that the CC 
CKR 2A was expressed within the transfected cells but was not translocated and 
subsequently expressed at the surface of the cells. He proposed that the alternatively 
spliced C-terminal tail prevented the appearance of the receptor at the cell surface. 
The biotinylated MCP-1 binding presented in this thesis has demonstrated that the CC 
CKR 2A is expressed at the surface of a small population of these cells.
7.2 Generation of calcium transients in response to MCP-1
7.2.1 MCP-1 induces a rise in TCa2+1i in THP-1 cells and human monocytes
The use of factors affecting both calcium influx and calcium mobilisation identified the 
source of calcium utilised in the MCP-1-induced [Ca2+]j elevations in THP-1 cells. 
EGTA and the calcium influx inhibitor econazole (Mason etal. 1993) (Vostal & 
Fratantoni, 1993) had no effect on the peak height of the MCP-1-induced calcium 
transient, although EGTA did reduce the Jy2 of the response. A possible explanation 
for the reduction in Ti/2 is that although the extracellular calcium does not play a role in 
the peak height of the calcium response, it may be involved in the refilling of the 
calcium stores and the maintenance of the calcium response. The lack of calcium 
influx in response to MCP-1 was confirmed by the lack of Mn2+ influx. 1 mM Ni2+ did 
inhibit the MCP-1-induced calcium response but this concentration of Ni2+ has been 
reported to inhibit PLC activity (Azula et al. 1993) and so its effects as a selective 
calcium channel blocker may be confused with its PLC inhibitory activity. These 
results collectively indicate that there is no role for calcium influx in the MCP-1 - 
induced calcium response in THP-1 cells.
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The effects of the PKC inhibitor Ro31 -8220-002 and the PKC activator PMA were also 
investigated in this thesis. These compounds were observed to potentiate and inhibit 
the calcium response in THP-1 cells respectively, indicating some form of negative 
feedback mechanism. Similar results have also been observed with PKC activators 
and inhibitors on thrombin-induced [Ca2+]j elevations in platelets (Poll & Westwick, 
1986) (Murphy & Westwick, 1992). Pre-treatment of platelets with PMA inhibited the 
thrombin-induced calcium response. However, administration of the PKC inhibitor 
Ro31 -8220-002 to the platelets prior to thrombin stimulation had no effect on the peak 
height of the response but significantly increased the duration of the calcium 
response. PKC has been found to have two roles which directly affect the mobilisation 
of calcium from intracellular stores by IP3. 1) PKC activates the IP3 5-phosphatase 
which induces the breakdown of IP3 to IP2, thus reducing calcium mobilisation 
(Connolly etal. 1986). 2) PKC inhibits PLC thus preventing the generation of the 
calcium mobiliser IP3 (Smith etal. 1987). These effects might explain the results 
obtained with the MCP-1 response and indicate a role for both PKC and PLC in the 
induction and maintenance of the MCP-1-induced calcium response in these cells. 
However, as well as having a direct effect on calcium mobilisation, PKC could also 
phosphorylate the IP3 receptor itself or the CRAC channel, explaining the results 
obtained by some groups in which PKC inhibits capacitative calcium entry (Montero et 
al. 1993) (Petersen & Berridge, 1994). This may explain the results observed in 
platelets, in which the PKC inhibitor prolonged the calcium response, perhaps 
prolonging calcium influx. However, the lack of any detectable calcium influx in 
response to MCP-1 makes the latter effect of PKC less applicable to the MCP-1 
response.
188
The role of PLC in the MCP-1-induced elevations in [Ca2+]i was further confirmed in 
my study by the dose-dependent abrogation of the calcium response by the PLC 
inhibitor U73122.
However, the use of inhibitors to study the signal transduction pathways utilised by an 
agonist must always be interpreted cautiously, particularly in the case of U73122 
which has been found to have effects other than inhibition of PLC (Alter etal. 1994) 
(Abayasekara & Flint, 1993). Therefore, the most accurate method of studying PLC 
activation is through the generation of IP3. Results presented in this thesis 
demonstrated significant increases in IP3 following MCP-1 stimulation. These 
increases preceded the calcium response proving the role of PLC in the induction of 
calcium transients by MCP-1.
The roles of calcium influx and calcium mobilisation in the MCP-1-induced elevations 
in [Ca2+]j in THP-1 cells, observed in this thesis, are in stark contrast to those 
demonstrated by Sozzani etal. in human monocytes (Sozzani etal. 1993). This 
group first demonstrated in 1993 that the rise in intracellular calcium in human blood 
derived monocytes was dependent on the influx of calcium from the extracellular 
medium. This was deduced following the complete inhibition of the calcium transients 
by the calcium chelator EGTA and the calcium channel blocker Ni2+ as well as a 
significant dose-dependent quench of the fluorescence signal when Mn2+ was used as 
a surrogate calcium ion. They also investigated the effects of MCP-1 on the levels of 
IP3 and found no agonist-induced increase in IP3.
The main difference between my study and that carried out by Sozzani et al. was the 
time points at which the IP3 levels were measured following MCP-1 stimulation. The 
first timepoint taken by Sozzani et al. during the IP3 measurements was at 15 seconds 
which, in my study, was after the peak of the MCP-1-induced IP3 response. Although
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they performed the experiment in the presence of LiCI to try to prevent IP3 
metabolism, LiCI only inhibits IP phosphatase and inositol polyphosphate-1 - 
phosphatase (Berridge & Irvine, 1989). Thus, although LiCI prevents inositol 
formation, a precursor lipid required for IP3 generation, it does not inhibit IP3 5- 
phosphatase which metabolises IP3. Therefore, it is possible that the MCP-1-induced 
increase in IP3 in human monocytes was missed.
Interestingly, Sozzani etal. extended their study of monocyte calcium transients in 
response to MCP-1 to include adherent monocytes and found that there was a 
significant role for calcium mobilisation as well as calcium influx (Bizzarri etal. 1995). 
The results from this latter study were very similar to the results obtained in my study 
with blood derived monocytes in suspension. The results presented in this thesis 
demonstrated that EGTA inhibited the calcium response but that this calcium influx 
was dependent on the initial calcium mobilisation, as indicated by the complete 
abrogation of the response by U73122. This demonstrates the possible activation of a 
capacitative calcium entry pathway in these monocytes by MCP-1, explaining why the 
influx is dependent upon the initial mobilisation of calcium.
Another member of the CC chemokine family, namely RANTES, has also been 
demonstrated to induce a calcium release activated calcium current. Bacon et al. 
observed that with very high concentrations of RANTES i.e. 1^M, a biphasic calcium 
response was obtained in human clonal T cells with the second phase being due to 
calcium influx (Bacon et al. 1995). Using patch clamp experiments they found that the 
properties of this phase were identical to those of the Ic r a c  observed in Jurkat T cells 
following TCR activation. This is another demonstration of the link between calcium 
mobilisation and calcium influx following chemokine stimulation.
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Unfortunately, due to the small numbers of monocytes that were obtained from each 
blood preparation, it was not possible to measure IP3 levels following MCP-1 
stimulation. It is also for this reason that the calcium traces using blood derived 
monocytes were more noisy.
The results from human monocytes presented in this thesis have demonstrated 
marked differences from those observed by Sozzani etal. (Sozzani etal. 1993). 
Differences in the monocyte preparation procedures might explain these variations in 
monocyte responses. With regard to this monocyte preparation question, it is 
interesting to note that the monocytes in this study were purified by adherence and the 
results obtained were similar to those observed for adherent monocytes by Sozzani 
and his co-workers (Bizzarri et al. 1995). In the previous study published by Sozzani 
et al., the suspension monocytes were purified by Percoll gradient. Therefore, there is 
a possible effect of monocyte adherence which interferes with the calcium transients 
in response to MCP-1, perhaps involving integrin upregulation.
The results in this thesis have also detected a difference in the source of the calcium 
for the MCP-1-induced calcium transients in THP-1 cells and monocytes. This 
variation in the results between THP-1 cells and monocytes may be explained by the 
fact that THP-1 cells are a pro-monocytic cell line and may lack important signal 
transduction pathways vital for MCP-1-induced calcium influx. To examine this 
possibility, the biphasic response of ATP was observed in parallel with the MCP-1 
response to confirm that THP-1 cells do possess an agonist induced calcium influx 
pathway.
The ATP-induced stimulation of THP-1 cells demonstrated in this thesis was 
demonstrated to induce a biphasic increase in [Ca2+]j. The factors affecting calcium 
influx, namely EGTA and econazole, almost completely abrogated the prolonged
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calcium response, demonstrating calcium influx as a prerequisite for this secondary 
response. Calcium influx was further confirmed by the use of Mn2+ as a surrogate 
calcium ion, which demonstrated an ATP-induced dose-dependent Mn2+ influx 
response. The initial mobilisation of calcium in response to ATP was confirmed by the 
inhibition of the peak ATP response by the PLC inhibitor, U73122. The inhibition and 
potentiation of the initial peak of the ATP response by the PKC activator and inhibitor 
respectively, indicated a similar negative feedback effect of PKC on PLC as 
suggested for the MCP-1 response and thus further indicated the mobilisation of 
intracellular calcium.
Previous studies have demonstrated that, in macrophages, the initial phase of the 
ATP-induced calcium response is as a result of calcium mobilisation. The influx of 
calcium from the extracellular medium is responsible for the maintenance of the 
calcium response (Greenberg etal. 1988). These results relate well to the results 
presented in this thesis. The exact mechanism of calcium influx induced by purinergic 
receptor stimulation is not known (Alonso-Torre & Trautmann, 1993). It has been 
proposed to involve capacitative calcium entry although a role for receptor operated 
calcium channels cannot be ruled out. Interestingly, the observation in this thesis that 
inhibition of PLC reduced the subsequent calcium influx response points to an agonist- 
induced capacitative calcium entry.
Extracellular adenine nucleotides interact with multiple cell surface receptors and 
these recognise ATP, ADP and a number of synthetic analogues of these nucleotides 
(Dubyak & El-Moatassim, 1993). These receptors are all sub-types of the P2 receptor 
class. These include the P2x and P2y purinergic receptors, which were originally 
identified from studies on smooth muscle cells, the P2j  receptor, which is an ADP 
activated receptor on thrombocytes, the P2z purinergic receptor, which serves a non- 
selective pore-forming function and finally, the P2u purinergic receptor, which is widely
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distributed on a variety of cell types (Gordon, 1986). With regard to the purinergic 
receptors bound by ATP on THP-1 cells, Alonso-Torre and Trautman observed that it 
was the P2u receptors on macrophages which induced both calcium mobilisation and 
calcium influx when bound by ATP (Alonso-Torre & Trautmann, 1993). Indeed, this 
was also demonstrated in THP-1 cells in this thesis using UTP. The P2u receptor is 
the only purinergic receptor which is known to respond to UTP stimulation.
There have been mixed reports as to whether the ATP receptors are coupled to 
pertussis toxin-sensitive G-proteins (Sipma et al. 1994) (Lang et al. 1994) and from 
the results presented in this thesis, the lack of effect of pertussis toxin demonstrated 
that the P2u receptor in THP-1 cells is not linked to either Gj or G0 G-proteins.
7.2.2 Disparate calcium signals generated bv MCP-1 in the CC CKR 2A and 2B 
transfected cells
This study has already demonstrated that THP-1 cells possess more than one 
receptor which is activated by MCP-1. Therefore, it is beneficial to be able to study the 
high affinity MCP-1 receptors separately. The CC CKR 2A transfected cells 
demonstrated no detectable increase in [Ca2+]j. Interestingly, when the CC CKR 2A 
and 2B were first identified by Charo et al. they were injected into Xenopus oocytes 
and both were found to be equally effective at calcium efflux when stimulated by MCP- 
1 (Charo et al. 1994). However, there have been no further reports of CC CKR 2A 
inducing any calcium response.
In contrast, MCP-1 is a very potent inducer of calcium transients when added to HEK 
293 cells expressing the CC CKR 2B. As yet, MCP-3 is the only other agonist active 
at this receptor. Results presented in this thesis demonstrated that MCP-3 induced a 
response only 25% of the response induced by an equivalent concentration of MCP-1.
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In contrast, another group studying HEK 293 cells transfected with CC CKR 2B found 
MCP-3 to be equipotent (Franci etal. 1995).
The source of calcium in the MCP-1-induced intracellular calcium transients in these 
cells, as seen with the monocytes and THP-1 cells, is very controversial. In the results 
presented in this thesis both EGTA and Mn2+ demonstrated a role for calcium influx in 
the MCP-1 response in the CC CKR 2B transfectants. However, interestingly, the 
PLC inhibitor U73122 completely inhibited the MCP-1-induced calcium response, in a 
similar manner to that seen in monocytes, indicating a very close correlation between 
the calcium influx and calcium mobilisation, perhaps through capacitative calcium 
entry. These results are in contrast to those published by Myers et al., who found that 
EGTA and Ni2+ had very little effect on the MCP-1-induced calcium flux in these cells 
except a small reduction in the T1/2 (Myers etal. 1995).
As demonstrated with the THP-1 cells in this thesis, there was a time -dependent 
increase in IP3 levels following MCP-1 stimulation of the CC CKR 2B transfectants, 
with the maximal increase preceding the rise in intracellular calcium. Again, this 
implicates PLC activation and the subsequent IP3 generation in the MCP-1-induced 
calcium transients. The more rapid return of the IP3 concentration to basal levels in 
the CC CKR 2B transfected cells compared to THP-1 cells could be due to the role of 
calcium influx in the transfected cells but not in THP-1 cells. Again, these results are 
in contrast to those observed by Myers etal. (Myers etal. 1995). They detected no 
increase in Ptdlns turnover in response to MCP-1 in HEK cells expressing CC CKR 2B 
and suggested a novel mechanism for calcium mobilisation other than IP3.
One very interesting observation from this thesis was that there was also a 
significant but very transient rise in the levels of IP3 in the CC CKR 2A transfected 
cells following MCP-1 stimulation. However, these cells did not demonstrate any
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increase in intracellular calcium. A possible explanation is that, as demonstrated by 
the binding of biotinylated MCP-1, only a small number of the cells express the 
receptor at any one time and it is not a large enough percentage to detect calcium 
responses on the fluorimeter. However, 107 cells are used for each point during the 
IP3 measurement and thus small changes may be detected.
The effects of pertussis toxin on the MCP-1-induced calcium transients in the CC CKR 
2B transfected cells were very similar in both my study and the study reported by 
Myers et al. (Myers et al. 1995). Even up to 250ng/ml pertussis toxin pre-treatment 
would only reduce the response to 20% of the control response. 100% inhibition was 
never observed. This is very interesting in light of a study carried out by Kuang et al. 
(Kuang et al. 1996). In this study they looked at the coupling of CC CKR 2A and 2B to 
a-subunits of the Gq class, which are insensitive to pertussis toxin. CC CKR 2B could 
couple to both Ga14 and Ga16 but CC CKR 2A could not. They also compared these 
two receptors to the CC CKR 1 and found the CC CKR 1 could only couple to Ga14. 
These a-subunits of the Gq class of G-proteins may be responsible for the residual 
pertussis toxin-insensitive calcium response seen in my study and by Myers et al. 
(Myers et al. 1995). The lack of a detectable calcium response in the CC CKR 2A 
transfectants meant that a comparison of the pertussis toxin sensitivity of CC CKR 2A 
and 2B could not be performed. Although the main expression of the Ga14,15 and 
16 is in hematopoetic cells (Wilkie etal. 1991), it may be that they are also present in 
these HEK 293 cells. However, it must be pointed out that in the THP-1 cells, the 
calcium response was completely inhibited by pertussis toxin. It is most likely that the 
high affinity MCP-1 receptors detected on THP-1 cells by the radioligand binding 
studies are of the CC CKR 2 group, which have already been identified on these cells 
(Charo etal. 1994). Therefore, the results obtained in these transfected cells may be 
due solely to the cells in which the receptors are transfected and not an effect of the 
receptor itself. It must be remembered that HEK 293 cells are epithelial cells and not
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monocytic cells. This may mean that epithelial cells and monocytes do not possess 
identical signalling pathways.
A similar explanation may also apply with regard to the differences in the calcium 
source in the transfected cells, THP-1 cells and monocytes. It is feasible that, 
although ATP identified a calcium influx mechanism in THP-1 cells, the MCP-1 
receptors may not be adequately coupled to these mechanisms. Thus, the results 
observed with the monocytes and CC CKR 2B transfected cells may provide a more 
relevant picture of calcium transients induced by MCP-1 due to the fact that they are 
mature cells. Adherence could also play a crucial role in the calcium response as 
monocytes, purified by adherence, and adherent HEK 293 cells transfected with the 
CC CKR 2B show similar responses, but suspension THP-1 cells do not. All these 
factors must be considered when analysing the mechanism of MCP-1-induced 
calcium fluxes.
7.2.3 Role for PLC and calcium in monocyte activation
A number of studies have been undertaken in the last few years to establish the role 
for the rise in intracellular calcium in MCP-1 stimulated monocytes. Locati et al. 
reported that MCP-1 stimulated the release of [3H] arachidonic acid from pre-labeled 
monocytes and THP-1 cells (Locati etal. 1994). They found that this arachidonic acid 
release was completely abrogated by the presence of EGTA or Ni2+, indicating a role 
for calcium influx. The same group also found that inhibition of calcium influx directly 
inhibited MCP-1-induced monocyte chemotaxis (Sozzani etal. 1993). However, the 
role for calcium influx in MCP-1-induced calcium transients and thus monocyte 
activation is debatable as demonstrated in the present study and in other published 
studies. As yet, no group has performed a detailed study of the role for PLC, IP3 and 
calcium mobilisation in monocyte activation and functional responses. However, 
Vaddi and Newton observed that, in the presence of EGTA-acetoxymethyl ester (AM),
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which chelates intracellular calcium, there was a 68% inhibition of the MCP-1-induced 
adhesion molecule upregulation (Vaddi & Newton, 1994b). Both intracellular and 
extracellular calcium had to be removed for complete inhibition, demonstrating a role 
for both calcium influx and calcium mobilisation in adhesion molecule upregulation. 
Although in the present study monocyte functional responses, such as chemotaxis 
and superoxide release, were observed, the donor variability and small signal to noise 
ratios made it very difficult to identify a role for calcium in these responses.
7.3 MCP-l-induced activation of PI 3-kinase
7.3.1 MCP-1 activates at least two PI 3-kinase isotvpes in THP-1 cells
The activation of PI 3-kinase has been identified in a number of different systems in 
response to various agonists which activate both tyrosine kinase -coupled and G- 
protein -coupled receptors. In this study two separate methods of assaying PI 3- 
kinase in THP-1 cells were used, namely the accumulation of D-3 Ptdlns lipids and an 
in vitro lipid kinase assay. Direct comparisons between the two separate assays are 
difficult since one is based on the measurement of PI 3-kinase products, such as 
Ptdlns(3,4,5)P3 in intact cells and the other depends on changes in PI 3-kinase activity 
that can be immunoprecipitated with a p85 antibody. Thus, in the intact cell assay, 
there may be other enzymes which may be contributing to the metabolism of the PI 3- 
Ikinase products. For example, the kinetics of Ptdlns(3,4)P2 and Ptdlns(3,4,5)P3 
•generation in both the time-course and the dose-response studies show the same 
trends. In both of these studies it is the Ptdlns(3,4,5)P3 which appears only transiently 
;amd it is the Ptdlns(3,4)P2 which demonstrates a more sustained rise. It is possible 
that o\ar time and at higher concentrations of MCP-1, the activation of a 5- 
jphiospliatase contributes to the generation and breakdown of Ptdlns(3,4)P2 and 
!PtdlnsQ,4,5)P3 respectively. Although a number of experiments have been 
performed by other groups to try to establish the enzymes responsible for the
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generation of these phospholipids (Stephens etal. 1991), the activation of a 
Ptdlns(3,4,5)P3 5-phosphatase cannot be ruled out in the present system. The 
activation of other enzymes involved in the generation and breakdown of the various 
phospholipids in this study is further confirmed in light of the fact that small changes 
were detected in Ptdlns(3)P following MCP-1 stimulation of CC CKR 2A transfected 
cells. In other systems, the levels of Ptdlns(3)P have been observed to remain 
unaltered upon agonist stimulation (Stephens etal. 1991). Again, the activation of 
other phosphatases may be important in the maintenance of this phospholipid. This 
latter observation may also be explained by the presence of a Ptdlns specific PI 3- 
kinase activity, similar to the Ptdlns-specific PI 3-kinase and the yeast Vps34 (Volinia 
et al. 1995) (Cardenas et al. 1988). This is particularly interesting in light of the fact 
that only the CC CKR 2A transfectants show notable increases in Ptdlns(3)P and not 
THP-1 cells or the CC CKR 2B transfectants.
However, taking into consideration the difficulties with direct comparisons between the 
two assay systems, there are a number of differences observed between the 
accumulation of PI 3-kinase products and the PI 3-kinase activity immunoprecipitated 
with the p85 antibody in THP-1 cells. 1) The time-course of activation appears to be 
very different, with Ptdlns(3,4,5)P3 appearing very rapidly but the activity of the 
immunoprecipitated PI 3-kinase only notably appearing at 1 minute and increasing 
with time. A similar difference is seen with the dose-response curves. It has already 
been reported that G-protein -coupled, PI 3-kinase y can elicit the most rapid 
accumulation of Ptdlns(3,4,5)P3 for example in fMLP stimulated neutrophils (Stephens 
etal. 1993). The dose-response and time-course of PI 3-kinase product accumulation 
following MCP-1 stimulation is very rapid and may constitute the activation of PI 3- 
kinase y. The p85 immunoprecipitates only isolate the classical PTK/SH2-coupled PI 
3-kinase and not the distinct PI 3-kinase y and the results presented in this thesis 
demonstrate that the time-course and dose-response curves for the activation of the
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PTK/SH2 -coupled PI 3-kinase isoform are much slower than observed for the 
accumulation of the PI 3-kinase products. The disparate results obtained with the two 
assays presented in this thesis were made even more apparent by the use of both 
wortmannin and pertussis toxin. 2) Wortmannin had no effect on the generation of PI 
3-kinase products when used at 100nM but potently inhibited the immunoprecipitated 
PI 3-kinase with an IC5o between 0.1 and 1nM. Stephens etal. reported that the ATP- 
induced stimulation of PI 3-kinase in U937 cells was due to the activation of a G- 
protein -coupled PI 3-kinase which was less sensitive to wortmannin (Stephens et al. 
1994). This group further identified that the sensitivity to wortmannin also differed 
depending on the assay used. Wortmannin was 2.5-fold less active on the isolated G- 
protein -coupled PI 3-kinase but this increased to 6.5-fold when intact cells were 
studied. The IC5o for wortmannin on the G-protein -coupled PI 3-kinase in intact cells 
was approximately 130nM. Thus, 100nM wortmannin may not markedly inhibit the 
MCP-1-induced accumulation of PI 3-kinase products if the PI 3-kinase y is the major 
PI 3-kinase activated in these cells. 3) The effects of pertussis toxin observed in this 
thesis on the two separate assays were very different to those of wortmannin. 
Pertussis toxin at 100ng/ml almost completely abrogated the generation of PI 3-kinase 
products but had no obvious effects on the immunoprecipitated PI 3-kinase. These 
results relate well to other published data, in which both the fMLP and ATP induced 
activation of the G-protein -coupled PI 3-kinase in neutrophils and U937 cells 
respectively were completely inhibited by 1.5jig/ml pertussis toxin pre-treatment 
(Stephens et al. 1993). Interestingly, fMLP stimulation of human neutrophils leads to 
the activation of both PI 3-kinase y and PTK/SH2 -coupled PI 3-kinases in a pertussis 
toxin-sensitive manner (Stephens etal. 1993). However, this is in contrast to the PI 3- 
kinase activity immunoprecipitated in my study following MCP-1 stimulation of THP-1 
cells, which was insensitive to pertussis toxin. Therefore, the results presented in this 
thesis have identified two separate PI 3-kinase activities, activated by MCP-1 in THP-1
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cells, characterised by their time-course of activation and susceptibility to wortmannin 
and pertussis toxin.
A recent study found similar data when stimulating THP-1 cells with concanavalin A 
(Con A) (Matsuo etal. 1996). By monitoring Ptdlns(3>4>5)P3 accumulation, the 
agonist-induced increases in Ptdlns(3,4,5)P3 were completely abrogated by pertussis 
toxin and yet the immunoprecipitated PI 3-kinase activity was insensitive to pertussis 
toxin. This was in contrast to the observations of Stephens etal. in neutrophils, in 
which both PI 3-kinase y and PTK/SH2 -coupled PI 3-kinases stimulated by fMLP were 
sensitive to pertussis toxin. As observed in my study the time-courses and dose- 
responses for the activation of the two PI 3-kinase activities by Con A in THP-1 cells 
were different. However, in contrast to the results presented in this thesis, the 
immunoprecipitated PI 3-kinase activity demonstrated more transient activity with 
much higher agonist concentrations being required than for the accumulation of PI 3- 
kinase phospholipid products. The major difference between the immunoprecipitates 
prepared by Matsuo et al. and those presented in this thesis is that Matsuo et al. 
assayed the PI 3-kinase activity in anti-phosphotyrosine immunoprecipitates, but the 
results presented in this thesis are following anti-p85 immunoprecipitation (Matsuo et 
al. 1996). The disadvantage of using anti-phosphotyrosine immunoprecipitates is that 
there are a large number of tyrosine phosphorylated proteins, e.g. cytoskeletal 
proteins, which may constitutively bind to either PI 3-kinase or other lipid kinases, thus 
providing a less accurate picture of specific PI 3-kinase activation (Pawson & 
Schlessinger, 1993). Thus, only anti-p85 immunoprecipitates were analysed in this 
study.
Matsuo et al. concluded that the ‘whole cell’ assay afforded a much more accurate 
picture of the In vivo activation of this enzyme. They proposed that the 
immunoprecipitated PI 3-kinase activity did not contribute significantly to the ‘total’
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enzyme activity detected in the ‘whole cell’ system and may only be involved in ‘local’ 
PI 3-kinase activation (Matsuo etal. 1996). A similar conclusion was reached by 
another group studying the activation of both PI 3-kinase isotypes in fMLP stimulated 
neutrophils (Stephens etal. 1993). Although fMLP stimulated the PTK/SH2 -coupled 
PI 3-kinase, they concluded that this activity only made a small contribution to the 
overall production of PI 3-kinase products. The results presented in this thesis also 
show that the overall PI 3-kinase activity is most likely to be due to the G-protein - 
coupled PI 3-kinase y, following the sensitivity of the D-3 Ptdlns lipid accumulation to 
pertussis toxin. PI 3-kinase y activation also explains the more rapid accumulation of 
D-3 phospholipids following the activation by MCP-1 as PI 3-kinase y confers very 
rapid Ptdlns(3,4,5)P3 production (Stephens etal. 1993).
The PTK/SH2 -coupled PI 3-kinase is also activated by MCP-1, but similar to the 
conclusion reached by both Matsuo etal. and Stephens etal., it is possible that this 
PTK/SH2 -coupled PI 3-kinase does not contribute significantly to the overall 
Ptdlns(3,4,5)P3 formation in intact cells, following the observation that the MCP-1 - 
induced accumulation of D-3 phospholipids but not the MCP-1-induced increase in PI 
3-kinase activity in p85 immunoprecipitates were sensitive to pertussis toxin. The 
observation that the PTK/SH2 -coupled PI 3-kinase activated by MCP-1 is insensitive 
to pertussis toxin indicates that it is not activated by a pertussis toxin-sensitive G- 
protein-coupled MCP-1 receptor. There are two possibilities, 1) there is a tyrosine 
kinase-coupled chemokine receptor and 2) the MCP-1 receptor which activates the 
PTK/SH2 -coupled PI 3-kinase may be coupled to a G-protein other than Gj or G0 
which, through calcium-induced PKC activation, stimulates the PTK/SH2 -coupled PI 
3-kinase, as proposed by Stephens et al. for fMLP stimulation of the PTK/SH2 - 
coupled PI 3-kinase (Stephens etal. 1993). It is interesting to note that a recent study 
by Okada et al. demonstrated that the PTK/SH2 -coupled PI 3-kinase in THP-1 cells 
can be stimulated by both tyrosine phosphorylated peptides and Gpy subunits (Okada
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et al. 1996). The combination of both phosphotyrosyl peptide and G(3y subunit 
stimulation produced a synergistic effect, with the accumulation of Ptdlns(3>4>5)P3 
being greater than the sum of the individual effects. Therefore, the activation of the 
PTK/SH2 -coupled PI 3-kinase through the proposed pertussis toxin-insensitive G- 
protein may be a direct effect of the G-protein sub-units on the PTK/SH2 -coupled PI 
3-kinase. Although the MCP-1-induced calcium response in THP-1 cells was 
completely abrogated by pertussis toxin, in the light of the pertussis toxin-insensitive 
residual calcium response in CC CKR 2B transfected cells, it is possible that there is 
an MCP-1 receptor coupled to G-proteins other than Gj or G0.
It is also possible that the PTK/SH2 -coupled PI 3-kinase, demonstrated to be 
activated by MCP-1 in this thesis, may have either an adaptor molecule or a serine 
kinase function. The p85 subunit has already been demonstrated to possess an 
adaptor function linking the insulin receptor to other binding proteins (Sung et al.
1994). Thus, it is possible that in MCP-1 activated cells, the PTK/SH2 -coupled PI 3- 
kinase functions as an adaptor molecule in preference to a 3-kinase. Also, the 
presence of the serine kinase tightly associated to the PI 3-kinase may also play an 
important role in MCP-1 signalling. Both of these functions might explain why this 
PTK/SH2 -coupled PI 3-kinase does not appear to be of primary importance in the 
MCP-1-induced accumulation of D-3 phospholipids.
Interestingly, only one other chemokine, to date, has been identified as activating PI 3- 
kinase. This is the RANTES stimulation of T lymphocytes and this activity was 
immunoprecipitated using a p85 antibody. It was sensitive to wortmannin but the 
effects of pertussis toxin were not investigated (Turner etal. 1995b).
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7.3.2 Disparate PI 3-kinase activation bv MCP-1 stimulation of CC CKR 
2A and 2B transfected cells
The use of the two separate assay systems for PI 3-kinase activation exhibited very 
marked differences when using HEK 293 cells transfected with either the CC CKR 2A 
or CC CKR 2B. By monitoring the MCP-1-induced accumulation of D-3 Ptdlns lipids, 
activation of the CC CKR 2A induced large, rapid increases in Ptdlns(3)P, 
Ptdlns(3,4)P2 and Ptdlns(3,4,5)P3. The use of EGF as a positive control also 
produced increases in these products and these increases were comparable with 
those reported in the literature for EGF on PC12 cells (Soltoff & Cantley, 1996) (Carter 
& Downes, 1992). In contrast, the CC CKR 2B cells showed a very high basal level of 
Ptdlns(3,4,5)P3 which, in some cases, decreased upon MCP-1 stimulation. The latter 
phenomenon may have been due to the activation of a receptor-coupled 5- 
phosphatase because when Ptdlns(3,4,5)P3 decreased there was an increase in 
Ptdlns(3,4)P2. The possible release of MCP-1 by these epithelial cells was briefly 
investigated as this may have been a possible explanation for the increased basal 
levels of Ptdlns(3,4,5)P3. Northern blot analysis and enzyme linked immunosorbant 
assay (ELISA) were used to investigate the possible expression of MCP-1 RNA and 
MCP-1 protein release respectively, in these cells. Preliminary data from one 
experiment indicated that these cells do not express or release detectable amounts of 
MCP-1. The possible effects of MCP-1 on the variation in the proliferation rates of the 
CC CKR 2A and 2B transfectants were also investigated because Ptdlns(3,4,5)P3 may 
moderate a proliferative / mitogenic signal as demonstrated by PDGF and CD28 
studies (Coughlin etal. 1989) (Ward etal. 1995). The lack of effect of pre-incubation 
with MCP-1 alone or in combination with MCP-1-antibody lead to the assumption that 
MCP-1 was not a contributing factor to the differing proliferation rates. Although 
wortmannin and pertussis toxin pre-treatment were not administered, the lack of effect 
of MCP-1 makes its mitogenic role unlikely. It is interesting to note that chemokines 
have been reported to mediate cellular proliferation. The C-X-C chemokine IL-8 has
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been reported to inhibit the proliferation of vascular smooth muscle cells in a dose- 
dependent manner (Yue etal. 1994). In another report, MCP-1 was demonstrated to 
induce vascular smooth muscle cell proliferation (Xu et al. 1996), but in contrast, in 
another report, vascular smooth muscle cell proliferation was inhibited by MCP-1 
(Ikeda et al. 1995). Thus, there are mixed reports as to the effects of chemokines on 
cellular proliferation.
The high Ptdlns(3,4,5)P3 levels observed in the CC CKR 2B transfectants may have 
been due to some sort of endogenous PI 3-kinase activity associated with the CC 
CKR 2B but not detected with the CC CKR 2A. Not even EGF produced a response 
in these CC CKR 2B transfected cells, indicating that PI 3-kinase may be maximally 
activated in these cells. Another possible explanation for this high basal level of 
Ptdlns(3,4,5)P3 may lie in the clonal differences in the transfected cells. Only one 
clone was made available and analysis of other clones may have provided slightly 
different results. Attempts were made to examine the effects of serum starvation on 
the levels of Ptdlns(3,4,5)P3, but unfortunately no conclusive results could be 
observed. Serum starvation of the cells for four hours had no effect on the basal 
Ptdlns(3,4,5)P3 levels in the CC CKR 2B transfected cells. Twelve hours serum 
starvation rendered the cells only 50% viable (as determined by trypan blue exclusion) 
and no MCP-1-induced increases in either CC CKR 2A or 2B transfected cells were 
detected.
In contrast to the results obtained by studying MCP-1-induced D-3 phospholipid 
accumulation in the receptor transfected cells, p85 immunoprecipitated PI 3-kinase 
activity was increased following MCP-1 stimulation in the CC CKR 2B transfectants 
but not the CC CKR 2A transfectants. The CC CKR 2A transfected cells showed no 
increase in PTK/SH2 -coupled PI 3-kinase activity following MCP-1 or EGF stimulation
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but the CC CKR 2B transfected cells showed a dose-dependent Increase in PTK/SH2 
-coupled PI 3-kinase activity in response to both agonists.
Following the results with THP-1 cells it would be tempting to speculate that the whole 
cell assay detects mainly the G-protein -coupled PI 3-kinase y and, of course, the 
immunoprecipitation technique only detects the PTK/SH2 -coupled PI 3-kinase. 
Therefore, it is possible that CC CKR 2A is coupled to PI 3-kinase y and the CC CKR 
2B is coupled to the PTK/SH2 -coupled PI 3-kinase. It is also interesting to note that, 
compared to both the CC CKR 2B transfectants and THP-1 cells, the CC CKR 2A 
transfected cells are the only group of cells examined in this study which 
demonstrated notable increases in Ptdlns(3)P. Although this can be generated by 
Ptdlns(3,4)P2 breakdown, it is also possible that a Ptdlns specific PI 3-kinase is 
activated by these receptors either uniquely or in parallel with the G-protein -coupled 
PI 3-kinase. The only difference between the CC CKR 2A and 2B is at the 
intracellular C-terminal domain. The CC CKR 2A has 14 extra amino acid residues at 
the C-terminus which are not displayed by the CC CKR 2B. It is possible that this 
difference leads to differential activation of signalling pathways by these receptors. 
The CC CKR 2B has already been demonstrated in this thesis to couple to pertussis 
toxin-insensitive pathway for a small part of the calcium response (see section 
4.2.2.3). Therefore, it is possible that this pertussis toxin-insensitive response may 
also be involved in PTK/SH2 -coupled PI 3-kinase activation.
The THP-1 cells have been shown to possess both the type A and type B MCP-1 
receptors (Charo etal. 1994). Therefore, from the data obtained using the receptor 
transfected cells it is possible that it is the CC CKR 2A that is responsible for the G- 
protein-coupled PI 3-kinase activity in THP-1 cells. Binding of MCP-1 to the CC CKR 
2B may confer the PTK/SH2-coupled PI 3-kinase activity observed in THP-1 cells, 
although higher concentrations of MCP-1 were required for maximal PI 3-kinase
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activation in the p85 immunoprecipitates in the THP-1 cells than were required for the 
maximal activation in the CC CKR 2B transfectants. There still also exists the 
difference in the Ptdlns(3)P accumulation between the THP-1 cells and the CC CKR 
2A transfected cells. Therefore, it is possible that THP-1 cells possess at least on 
other, as yet unidentified MCP-1 receptor.
7.3.3 MCP-1 induces the tyrosine phosphorylation of proteins in THP-1 cells 
and CC CKR 2B transfectants
The results presented in this thesis demonstrate that MCP-1 can phosphorylate 
tyrosine residues on three separate proteins of molecular weights 50, 80 and 120kDa. 
Although the characterisation of these proteins was not undertaken, it is possible to 
speculate about the identity of these proteins. For instance, the 120kDa protein may 
well be the focal adhesion associated kinase, FAK. FAK is a 125kDa protein which 
has been shown to be localised in areas of cell adhesion (Zachary & Rozengurt, 
1992). Because of its localisation, FAK has been thought to be involved in regulation 
of cell migration in response to adhesion to extracellular matrix proteins. FAK 
becomes phosphorylated either upon activation of cells by external stimuli such 
bombesin (Leeb-Lundberg & Song, 1991) or PDGF (Rankin & Rozengurt, 1994) or by 
direct cell adhesion to extracellular matrix proteins (Guan etal. 1991). Integrin 
clustering on the cell surface also stimulates tyrosine phosphorylation of FAK 
(Schaller etal. 1992) Therefore, its role in MCP-1-induced activation of monocytes 
would be important in the regulation of adhesion and subsequent diapedesis. If 
indeed the p120 band is FAK, this protein could be involved in the initiation of firm 
adhesion of the monocytes to the endothelial layer by integrins prior to diapedesis. It 
is interesting to note that the chemokine RANTES has been demonstrated to 
phosphorylate FAK in a time-dependent manner in a human antigen-specific T cell 
clone (Bacon etal. 1996). However, in contrast to the rapid tyrosine phosphorylation
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of the 120kDa band demonstrated in this thesis, RANTES induced a much slower 
phosphorylation of FAK with the maximal phosphorylation at 5 minutes. Variations in 
the receptors activated by MCP-1 and RANTES might explain the variations in the 
phosphorylation of the 120kDa band. Bacon etal. also observed the phosphorylation 
of paxillin, a 68kDa protein, previously observed to be tyrosine phosphorylated 
following the activation of integrins (Kornberg et al. 1992). However, no band 
corresponding to this molecular weight was detected in the blots presented in this 
thesis.
It was also considered that the 120kDa protein could be the accessory protein Cbl, 
originally identified as the cellular homologue of the transforming protein of murine 
Cas NS-1 retrovirus that induces pro-B, pre-B and myeloid tumours in mice (Langdon 
et al. 1989). Although Cbl has only really been demonstrated to be phosphorylated 
upon T cell, B cell and some cytokine receptor stimulation, there is evidence that PI 3- 
kinase associates with Cbl and that Cbl may communicate between PI 3-kinase and 
the FcyR-coupled srctype PTK (Tanaka etal. 1995) (Fukazawa etal. 1995) (Matsuo 
et al. 1996). However, attempts to strip the blots developed with 4G10 and to reprobe 
them with an anti-cbl antibody, showed no bands corresponding to the 120kDa cbl 
protein.
Identification of the other 50 and 80kDa proteins is not so easy. It was possible that 
these proteins may be involved in the activation of the PTK/SH2 -coupled PI 3-kinase 
identified in this system. However, there was one discrepancy. The 
immunoprecipitated PI 3-kinase activity stimulated by MCP-1 was insensitive to 
pertussis toxin but the tyrosine phosphorylation of these proteins was inhibited by 
pertussis toxin pre-treatment. The activation of pertussis toxin -sensitive tyrosine 
kinase activity may indicate a role for PKC, similar to the protein tyrosine 
phosphorylation observed upon fMLP stimulation of neutrophils (Berkow & Dodson,
207
1990) (Huang etal. 1990). Agonist-induced increases in intracellular calcium and 
DAG formation may either activate PKC which phosphorylates and thus activates 
PTKs or, in the case of calcium, activate the PTK directly, leading to the tyrosine 
phosphorylation of various proteins.
Con A stimulated THP-1 cells not only lead to the activation of both PTK/SH2 -coupled 
PI 3-kinase and PI 3-kinase y but also the time-dependent phosphorylation of a 
number of proteins (Matsuo etal. 1996). The tyrosine phosphorylation was maximal 
at 1 minute and then rapidly declined. Two of these proteins were of similar molecular 
weight to those observed in this thesis following MCP-1 stimulation of THP-1 cells. 
These two proteins were at approximately 120kDa and 80kDa. However, very little 
reference was made to the identity of these proteins, apart from to say that they had 
identified Lyn and GAP(Ras-p21 GTPase-activating protein)-associated p62. Neither 
of these proteins corresponded with the bands observed in the results presented in 
this thesis. Matsuo et al. proposed that the p120 band may have been the product of 
the proto-oncogene c-cb/but no evidence for this was presented (Matsuo etal. 1996).
The lack of effect of wortmannin on the MCP-1 -induced tyrosine phosphorylation 
demonstrated in this thesis indicates that this tyrosine phosphorylation is either 
upstream of PI 3-kinase; or is mediated by the wortmannin resistant G-protein-coupled 
PI 3-kinase y.
Due to the discrepancies in the sensitivity of tyrosine phosphorylation and 
immunoprecipitated PI 3-kinase activity to pertussis toxin, a different approach was 
taken to try to identify the phosphorylated proteins which activate the PTK/SH2 - 
coupled PI 3-kinase. This PI 3-kinase was immunoprecipitated using a p85a antibody 
and then tyrosine phosphorylated proteins were detected by Western blotting using an 
anti-phosphotyrosine antibody. Preliminary data showed that one band appeared,
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with delayed kinetics, at approximately 55kDa. This band appeared to be distinct from 
the 50kDa band observed in the phosphotyrosine immunoprecipitated blots as both 
the time-course and the migration distances were different. This 55kDa protein was 
not detected on the initial phosphotyrosine blot of whole cell lysates but was detected 
when only the tyrosine phosphorylated proteins associated with the p85 subunit were 
studied. Interestingly, the kinetics of the phosphorylation of this protein matched the 
kinetics of the activation of the immunoprecipitated PI 3-kinase. Although the PI 3- 
kinase activity was detected at 60 seconds post MCP-1 stimulation, the tyrosine 
phosphorylation of the 55kDa protein did not notably appear until 120 seconds but the 
maximal PI 3-kinase activation and tyrosine phosphorylation both occurred at 300 
seconds. It is possible that there are other, as yet unidentified protein(s) which are 
involved in the initiation of this PTK/SH2 -coupled PI 3-kinase activity. The earlier 
proposal that the 120kDa band may have been Cbl is even less likely following the 
inability to co-precipitate the 120kDa band with an anti-p85 antibody.
As to the possible identity of the 55kDa protein, it may be a non-receptor linked 
tyrosine kinase such as one of the src family tyrosine kinases. The role of src family 
tyrosine kinases, namely the T cell specific Ick, in PI 3-kinase activation has already 
been identified in systems such as TCR activation of PI 3-kinase (Carrera etal. 1994) 
(Ward et al. 1996). Therefore, comparing the molecular weight and the expression 
pattern of the various src family tyrosine kinases, it is possible that the 55kDa protein 
could be one of the following src kinases, fgr (55kDa), lyn (56kDa), hck (59kDa) or fyn 
(59kDa) (review (Woodgett, 1994)). However, further identification needs to be 
performed using Western blotting techniques.
The preliminary protein phosphorylation results obtained following MCP-1 stimulation 
of CC CKR 2A or 2B transfected cells were very interesting. There was very little 
tyrosine phosphorylation detected in the CC CKR 2A transfected cells with possibly a
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small phosphorylation of an 80kDa band. However, in contrast, the CC CKR 2B 
transfected cells showed phosphorylation of the three proteins detected in THP-1 
cells. It appears that only CC CKR 2B is markedly coupled to tyrosine kinases.
These results correlate well with the earlier hypothesis that only the CC CKR 2B is 
coupled to the PTK/SH2 -coupled PI 3-kinase.
Therefore, it would appear that the activation of protein tyrosine phosphorylation in the 
THP-1 cells by MCP-1 is through the CC CKR 2B, as the results in the CC CKR 2B 
transfectants and THP-1 cells are very similar. However, it is interesting to note that 
the time-course of phosphorylation of these proteins was slightly different in the two 
cell types and therefore, it is possible that the tyrosine phosphorylation in the THP-1 
cells also involves an as yet unidentified MCP-1 receptor. However, it cannot be ruled 
out that these differences may be due solely to disparate signalling mechanisms 
present in the THP-1 cells and the transfected cells.
There are a number of G-protein-coupled receptors which, whilst lacking tyrosine 
kinase activity, have been shown to have associated tyrosine kinase activity upon 
receptor stimulation. These include receptors for bombesin (Zachary et al. 1991), 
vasopressin (Leeb-Lundberg & Song, 1991) and bradykinin (Hordijk etal. 1994). With 
respect to chemokines, very little data has been published on their ability to induce 
tyrosine phosphorylation. However, the C-X-C chemokine IL-8 has been observed to 
activate the serine/threonine kinase p42/p44 MAP kinase also known as extracellular 
signal regulated kinase (ERK)-2 (Jones etal. 1995). ERK-2 is activated by 
phosphorylation of tyrosine/threonine residues (Rossomando etal. 1991) (Nel etal. 
1990) and is responsible for the regulation of several different proteins. Its role in the 
activation of cytoskeleta! elements (Gotoh etal. 1991) has led to the proposal that 
ERK-2 is involved in chemokine-induced cellular responses. This is further confirmed 
by the time-dependent, pertussis toxin-sensitive activation of ERK-2 by IL-8 in Jurkat
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cells transfected with either the IL-8 RA or RB (Jones et al. 1995). Another group has 
also identified the tyrosine phosphorylation of a p130 src substrate and a 70kDa 
protein following stimulation of a placental cell line transfected with the IL-8 RB by the 
C-X-C chemokine MGSA (Schraw & Richmond, 1995).
Apart from the report discussed previously, demonstrating RANTES-induced FAK 
phosphorylation (Bacon et al. 1996) only one other report has been published on C-C 
chemokine tyrosine kinase activation (Bacon etal. 1995). Bacon etal. observed that 
RANTES activation of human clonal T lymphocytes led to a biphasic calcium response 
and tyrosine phosphorylation of a number of different proteins. The latter was 
proposed as being responsible for the second phase of the calcium response, due to 
the inhibitory effects of tyrosine kinase inhibitors (Bacon et al. 1995). However, the 
concentration of RANTES required for these responses was 1^M, which is at least 
100 times the concentration required for RANTES-induced chemotaxis in T cells 
(Schall etal. 1990).
The results from the PI 3-kinase data and the tyrosine phosphorylation data presented 
in this thesis, demonstrate the activation of both pertussis toxin-sensitive and 
pertussis toxin-insensitive pathways in THP-1 cells following MCP-1 stimulation. The 
identification of a 55kDa protein which co-precipitates with the p85 subunit of PI 3- 
kinase, suggests that the pertussis toxin-insensitive pathway is activated by a receptor 
associated with a non-receptor-coupled PTK, for example a src kinase. This provides 
more evidence for the earlier hypothesis that a tyrosine kinase-coupled MCP-1 
receptor associates with the PTK/SH2 coupled PI 3-kinase and is responsible for its 
activation. As yet, no corroborative evidence for the presence of a pertussis toxin- 
insensitive G-protein-coupled MCP-1 receptor has been obtained.
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Although CC CKR 2B has been proposed as the receptor on THP-1 cells responsible 
for the activation of the PTK/SH2-coupled PI 3-kinase and protein tyrosine 
phosphorylation, discrepancies in both the MCP-1 concentrations required for 
PTK/SH2-coupled PI 3-kinase activation and the time-courses of tyrosine 
phosphorylation indicate that THP-1 cells may possess an as yet unidentified MCP-1 
receptor, possibly coupled to a src kinase. Although DARC has yet to be shown to 
possess biological activity (Horuk etal. 1996), it is not a G-protein coupled receptor 
and either it, or another receptor, may be important in MCP-1-induced PI 3-kinase 
activation. It is interesting to note that DARC, or a similar chemokine receptor was 
observed in the calcium desensitisation experiments.
7.3.4 Activation of potential downstream effectors of PI 3-kinase
The results presented in this thesis identified the phosphorylation of p70 S6 kinase in 
a time-dependent manner in response to MCP-1. However, the pattern of 
phosphorylation was not quite as expected. In studies which examined the 
phosphorylation of p70 S6 kinase, there is a single band which appears at 70kDa. 
Upon agonist stimulation, this phosphorylated protein has reduced gel mobility and the 
band to appears to move upwards (Kilgour et al. 1996) (Parry & Ward, 1996). The 
results presented in this thesis demonstrated a different picture. There were three 
bands which were present at 70 kDa in the unstimulated samples. The number of 
bands increased to a maximum of four bands by 15 minutes and then started to return 
to background levels by 30 minutes. Interestingly, published reports of experiments 
performed on purified p70 S6 kinase have demonstrated the presence of a number of 
p70 S6 kinase polypeptides using SDS-PAGE. The major polypeptide was at 70kDa 
which appeared with a ladder of slightly smaller polypeptides at 68 and 66kDa (Price 
etal. 1989) (review (Woodgett, 1994)). Another minor set of polypeptides migrated at 
93/95kDa. These two isoforms are known as the all and al isoforms respectively.
The only difference between the two is an amino terminal 23 residue peptide on the al
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isoform (Grove et al. 1991). This segment is very basic and causes the anomalously 
slow electrophoretic mobility despite its calculated molecular weight of 59kDa. Both 
the al and all peptides are recognised by the p70 S6 kinase antibody and feature in 
the blots obtained in my study. It appears to be the all isoform that is phosphorylated 
but rather than demonstrating a straightforward band shift, there is an increase in the 
number of bands. It is most likely that MCP-1 induces the phosphorylation of the 
70kDa band, as seen in the other reports, but the other two bands remain relatively 
unaffected. Different protein separation (i.e. the use of 10% or 15% resolving gels in 
SDS-PAGE) might explain the varying results of these ‘band shift’ assays.
Therefore, the activation of PI 3-kinase and the increased phosphorylation of p70 S6 
kinase in response to MCP-1, demonstrated in this thesis, indicates that p70 S6 
kinase may be a downstream target of PI 3-kinase in this system. p70 S6 kinase can 
regulate the entry of cells into cell cycle (Downward, 1994) and it is possible that the 
MCP-1-induced activation of p70 S6 kinase might be important in the eventual 
differentiation of monocytes into macrophages which occurs once the monocytes have 
entered into the tissue.
7.3.5 Role for PI 3-kinase and tvrosine phosphorylation in monocyte 
activation
There are a number of functional responses which have recently been connected to PI 
3-kinase activation. Stimulation of THP-1 cells by Con A not only leads to the 
activation of two PI 3-kinase activities but also induces a respiratory burst (Matsuo et 
al. 1996). This respiratory burst is sensitive to pertussis toxin and is proposed as 
being activated by the G-protein -coupled PI 3-kinase y. Hence, this is the functionally 
coupled isoform with respect to respiratory burst. The PTK/SH2 -coupled PI 3-kinase 
may be coupled to another function.
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Interestingly, in another system which possesses both tyrosine kinase and G-protein - 
coupled PI 3-kinase activity, namely thrombin activation of platelets, it is the PTK/SH2 
-coupled PI 3-kinase which has been implicated in functional responses (Zhang et al. 
1996). Stimulation of platelets with thrombin promotes the conversion of platelet 
integrin anbp3 into a fibrinogen binding form required for platelet aggregation. By 
studying the differential inhibition of the PI 3-kinases by wortmannin and comparing it 
to wortmannin inhibition of anbp3 activation, it was concluded that the tyrosine kinase - 
coupled PI 3-kinase induces activation of this platelet integrin. It is interesting to note 
that, in this study, PI 3-kinase y was demonstrated to be almost insensitive to PMA but 
the PTK/SH2 -coupled PI 3-kinase was potently stimulated by PMA. The use of PMA 
might help in dissecting out the relative roles of the PI 3-kinase isoforms in monocytes 
and monocytic cells lines.
Other functional responses associated with PI 3-kinase include respiratory burst and 
superoxide release from fMLP stimulated neutrophils (Arcaro & Wymann, 1993) 
(Vlahos et al. 1995) and RANTES stimulated eosinophils (Bourne et al. 1995) as well 
as RANTES induced actin polymerisation and chemotaxis in T lymphocytes (Turner et 
al. 1995a) (Turner etal. 1995b) (see table 1.7 in section 1.6.2.4).
Therefore, the role of PI 3-kinase in MCP-1 stimulated monocytes could be in 
superoxide release, actin polymerisation or adhesion molecule expression. Although 
preliminary data indicates that the adhesion molecule expression in this study was not 
inhibited by wortmannin it may be the G-protein -coupled PI 3-kinase which activates 
adhesion molecule expression which is much less sensitive to wortmannin. 
Unfortunately, it was not possible to observe the effects of both wortmannin and 
pertussis toxin on MCP-1-induced monocyte functional responses in this system. This 
was due to a number of reasons including donor variation, poor signal to noise ratios
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and, in the case of adhesion molecules, problems encountered whilst pre-incubating 
the cells with pertussis toxin.
With regard to the role of tyrosine phosphorylation, Bacon et al. demonstrated that 
herbimycin A, a src family tyrosine kinase inhibitor, potently inhibited the pertussis 
toxin-insensitive calcium influx phase of the RANTES induced calcium response 
indicating a role for tyrosine kinases in calcium influx. RANTES induced T cell 
proliferation was also inhibited by herbimycin A but unaffected by pertussis toxin 
(Bacon etal. 1995). The role of tyrosine kinases is less likely to be important in MCP- 
1-induced calcium transients in THP-1 cells as pertussis toxin completely abrogates 
the response. It is possible, however, that it is more important in the CC CKR 2B 
transfected cells due to the pertussis toxin-insensitive element of the calcium 
response.
7.5 MCP-l-induced functional responses in human monocytes and 
THP-1 cells
This study has identified a number of functional responses induced by MCP-1 in 
human monocytes which include chemotaxis, adhesion molecule upregulation and 
superoxide release. The major problem encountered whilst studying these responses 
was the large donor variation and the relatively small responses. Also, the monocyte 
purification step was by plastic adherence, which makes it likely that the monocytes 
are activated at the start of the experiment, making any study of MCP-1 -induced 
monocyte activation very difficult. Other methods of monocyte purification were 
tested, such as negative selection, but, unfortunately, the viability of the cells was 
much lower.
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The results presented in this study demonstrated that MCP-1-induced a dose- 
dependent chemotactic response in both human monocytes and THP-1 cells. The 
EC5o for this response was between 0.1 -1nM. The chemotactic response of human 
monocytes to MCP-1 has already been reported with EC50 values for this response 
varying from 0.1-0.5nM (Yoshimura & Leonard, 1990) (Sozzani etal. 1991). However, 
the MCP-1-induced chemotactic response in THP-1 cells has only been observed by 
some groups. Vaddi and Newton reported seeing no significant chemotactic response 
to MCP-1 in THP-1 cells (Vaddi & Newton, 1994a). In contrast, Ming Wang etal. 
found that THP-1 cells produced a dose-dependent chemotactic response to MCP-1 
with an EC5o of around 1nM (Ming Wang etal. 1993). The results presented in this 
thesis compare well with the findings of Ming Wang etal.. The main difference 
between the present study and that of Wang et al. was the size of the chemotactic 
response. The chemotactic index in my study was approximately half of that observed 
by Ming Wang etal.. Variations in both experimental procedures and the clone of 
THP-1 cells used, might explain the different chemotactic responses observed with 
THP-1 cells.
The results presented in this thesis also demonstrated that MCP-1 dose-dependently 
upregulated both CD11b and CD11c expression on human monocytes. VLA-4 
expression was not observed to increase upon MCP-1 stimulation. Similar results 
have also been reported by other groups. Jiang et al. observed that MCP-1 induced 
the upregulation of both CD11 b and CD11c but there was no agonist induced 
upregulation of either CD11a or VLA-4 (Jiang etal. 1992). These results were 
confirmed and extended by Vaddi and Newton in 1994 (Vaddi & Newton, 1994b).
Jiang et al. chose a 30 minute timepoint for their studies but Vaddi and Newton 
performed a time-course and observed that although there was a significant increase 
at 30 minutes, the maximum increase in both CD11b and CD11c was at four hours. 
The results presented in this thesis were obtained following a 30 minute incubation
216
with MCP-1 and the results obtained were very similar to those observed by Jiang et 
al. Consistent in both the results presented in this thesis and those published by 
other groups is the maximal 2-fold increase in both CD11b and CD11c following 
approximately 30nM MCP-1 stimulation. Also consistent in all these studies was the 
higher basal level of CD11 b compared to CD11c on human monocytes.
One of the main problems encountered when studying adhesion molecule expression 
on monocytes is the upregulation of these adhesion molecules by Ficoll during the 
monocyte purification process. Thus, by the time the agonist is administered, the 
adhesion molecule levels are already higher than expected. Therefore, in my study 
this was overcome by treating whole blood with MCP-1 and then lysing the red blood 
cells and separating the monocyte population by scatter properties and CD14 positive 
fluorescence on the FACS. However, this methodology creates its own problems, in 
as much as chemokines bind to the Duffy antigen on the red blood cells. Therefore, 
the shift is probably not as large as would be expected. It may be possible to block 
MCP-1 binding to red blood cells by adding another chemokine, such as IL-8, which 
will bind to the Duffy antigen but not to the monocytes and thus leave the MCP-1 free 
to induce monocyte adhesion molecule upregulation.
The MCP-1-induced upregulation of CD11b and CD11c but not VLA-4 following a 30 
minute stimulation period was probably due to the intracellular location of these 
adhesion molecules. Miller et al. observed that CD11 b and CD11 c are mobilised from 
latent pools in monocytes whereas the upregulation of VLA-4, as well as the p2 
integrin CD11a, requires protein synthesis and longer time periods (Miller etal. 1987). 
However, it must be considered that, for all the adhesion molecules investigated in the 
present study, an increase in avidity of the adhesion molecules for their counter 
receptors may also play an important role in MCP-1-induced adhesion which would
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not be detected as an upregulation. This can, however, be detected using antibodies 
to specific active sites of the adhesion molecules (Landis etal. 1993).
The results presented in this thesis also demonstrated the MCP-1-induced superoxide 
release from human monocytes. However, this response was only detected by 
monitoring the reduction of ferricytochrome C and not by the production of H2O2 in 
response to MCP-1. It is possible that the relatively low concentrations of superoxide 
produced by MCP-1 compared to the other agonists may make the detection of H20 2, 
which relies on the spontaneous conversion of superoxide to H2O2 by SOD present in 
the cells, more difficult to detect. However, by monitoring the direct production of 
superoxide using the reduction of ferricytochrome C, the small changes in superoxide 
production may be more readily detectable. It is interesting to note that there have 
been mixed reports as to the effectiveness of MCP-1 at inducing superoxide release 
from human monocytes. Leonard et al. reported detecting little or no release of 
superoxide in monocytes in response to MCP-1 (Leonard & Yoshimura, 1990). In 
contrast, Zachariae et al. and Rollins et al. both reported MCP-1 -induced superoxide 
release from human monocytes (Zachariae etal. 1990) (Rollins etal. 1991). In a 
similar manner to the differences observed in the method of detection of the 
superoxide release by MCP-1 in this thesis, this might also explain the discrepancies 
between reports as to the effects of MCP-1 on monocyte superoxide release.
The other functional response that was investigated in monocytes stimulated with 
MCP-1 was the upregulation of the low affinity IgE receptor, CD23. Various cytokines 
such as IL-3, IL-4, GM-CSF and macrophage-colony stimulating factor (M-CSF) all 
upregulate CD23 expression on monocytes (Williams etal. 1992) (Alderson etal. 
1992). Allergic diseases are characterised by the development of an IgE immune 
response to low concentrations of environmental allergens. The identification of MCP- 
1 in tissue from asthmatic patients suggests a role for MCP-1 in allergic diseases
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(Sousa etal. 1994). The specific role of MCP-1 in asthma has not been well 
characterised and this study was initiated to determine whether the upregulation of the 
low affinity IgE receptor CD23 was involved. However, having chosen an MCP-1 
concentration optimal for other functional responses and a timepoint optimal for the 
other cytokines no MCP-1 induced CD23 upregulation was observed, although IL-3 
induced a response. Therefore, although a complete time-course and dose-response 





There are a number of conclusions which can be drawn from the results presented in
this thesis.
1) MCP-1 binds to high affinity receptors on the surface of THP-1 cells and cells 
transfected with the CC CKR 2B as determined by Scatchard analysis. Although 
biotinylated MCP-1 binding to a population of the CC CKR 2A transfected cells was 
detected, it is possible that the receptors are only transiently expressed on a 
proportion of the cells at any one time.
2) MCP-1 induces a rise in intracellular calcium in THP-1 cells and CC CKR 2B 
transfected cells. In both cell types this involves the activation of PLC and the 
generation of IP3. In the CC CKR 2B cells, however, this generation of IP3 also 
leads to the activation of a calcium influx pathway, possibly through capacitative 
calcium entry. A similar dual calcium pathway was also detected in human 
monocytes. In contrast, the CC CKR 2A does not appear to be coupled to a 
calcium pathway as the transfected cells showed no obvious calcium response to 
MCP-1, although the increase in IP3 indicates that the calcium response may be 
below the level of detection. Although the MCP-1-induced calcium responses in 
both THP-1 cells and CC CKR 2B transfectants were inhibited by pertussis toxin, 
the residual pertussis toxin-insensitive response in CC CKR 2B transfectants 
implicates a second pertussis toxin-insensitive pathway.
3) MCP-1 induces a dose- and time-dependent increase in PI 3-kinase products in 
THP-1 cells which is coupled to a Gj or G0 G-protein, as demonstrated by the 
almost complete abrogation of the response by pertussis toxin and the relative 
insensitivity of the response to wortmannin. The activation of the distinct PTK/SH2 
-coupled PI 3-kinase, observed by p85 antibody immunoprecipitation, is unlikely to
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play a major role in MCP-1-induced PI 3-kinase activation and is activated by either 
a pertussis toxin-insensitive G-protein or by distinct PTK -coupled MCP-1 receptor. 
The activation of a separate receptor linked to a non-receptor-coupled tyrosine 
kinase is further supported by the observation of a 55kDa tyrosine phosphorylated 
protein co-precipitating with the p85 PI 3-kinase sub-unit.
4) Assuming from the THP-1 results that accumulation of PI 3-kinase products is 
primarily as a result of G-protein -coupled PI 3-kinase activity and the activity in p85 
immunoprecipitates can only be as a result of PTK/SH2 -coupled PI 3-kinase 
activity, then the CC CKR 2A is only coupled to PI 3-kinase y and the CC CKR 2B 
is only coupled to the PTK/SH2 -linked PI 3-kinase. It is most likely the differential 
coupling of the alternatively spliced C-terminal tails of these two receptors that lead 
to the disparate signal transduction pathways.
5) MCP-1 induces tyrosine phosphorylation of three proteins in THP-1 cells and CC 
CKR 2B transfected cells. No notable tyrosine phosphorylation was observed in 
the CC CKR 2A transfected cells. The fact that only the CC CKR 2B and not the 
CC CKR 2A shows tyrosine phosphorylation further confirms the differential 
coupling to signal transduction pathways and the activation of tyrosine kinases by 
the CC CKR 2B. The MCP-1-induced tyrosine phosphorylation in the THP-1 cells 
was via a G-protein -coupled receptor due to its sensitivity to pertussis toxin. This 
is most likely to involve the increase in intracellular calcium and PKC.
6) MCP-1 activates a number of monocyte functional responses including chemotaxis, 
adhesion molecule upregulation and superoxide release. It does not appear that 
the adhesion molecule upregulation is via the wortmannin -sensitive PI 3-kinase.
8.2 Proposed pathways activated bv MCP-1
The activation of monocytes by MCP-1 is potentially very important in understanding
their role in inflammation. This study has identified the activation of three separate
signal transduction pathways activated by MCP-1. However, when looking closely at
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the individual receptor subtypes rather than at THP-1 cells some fundamental 
differences appear. Figure 8.1 shows both the proposed pathways activated in THP-1 
cells, known to possess both CC CKR 2A and 2B, as well as those activated in the CC 
CKR 2A and 2B receptor transfected cells. In THP-1 cells, MCP-1 activates both a 
pertussis toxin -sensitive and a pertussis toxin-insensitive PI 3-kinase. Pertussis toxin 
also inhibits the MCP-1 induced calcium transient. These results indicate the role for 
Gj and G0 G-proteins in the activation of both PI 3-kinase and PLC activation. The PI 
3-kinase not inhibited by pertussis toxin is separate from the other PI 3-kinase 
activated by MCP-1 and is not coupled to a pertussis toxin -sensitive G-protein.
By comparing the results seen in the THP-1 cells with the receptor transfected cells, it 
appears that only the CC CKR 2A is coupled to the G-protein -linked PI 3-kinase but 
not significantly to PLC and calcium transients. In contrast, the CC CKR 2B is 
coupled to PLC p, which is activated by pertussis toxin-sensitive and possibly a 
second, pertussis toxin-insensitive G-protein or to PLC y via a PTK. Only the classical 
PTK/SH2 -coupled PI 3-kinase appears to be activated by the CC CKR 2B. The 
results observed in the THP-1 cells can be accounted for by the fact that both of these 
MCP-1 receptors are present in these cells. However, there are still differences 
between the THP-1 cells and the transfected cells, such as pertussis toxin sensitivity 
for the calcium responses, Ptdlns(3)P generation and the disparate time-course and 
dose-responses for the PTK/SH2-coupled PI 3-kinase activation and tyrosine 
phosphorylation respectively, which may be due to other receptors present on the 
THP-1 cells.
This study has also highlighted the variations which occur not only between cell lines 
and primary cells but also differences arising from purification techniques and the cells 
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Figure 8.1 - Schematic diagram to represent the proposed pathways activated by MCP-1. a) the
pathways activated in THP-1 cells and b) the pathways activated in CC CKR 2A and 2B transfected cells.




kinase G-protein'P I 3A  
kinase,
















|jDf 50, 80 and 120kDa proteins^
Figure 8.2 - Schematic diagram to show proposed roles for the signalling pathways activated by MCP-1.
The intermediate siganlling molecules have not yet been identified and have been omitted for clarity. The bold 
boxes represent possible functional responses and the dashed boxes represent cellular responses.
comparing data as variations may be due to differential cellular responses rather than 
agonist induced responses.
From results obtained in this study and from published work by other groups, figure
8.2 shows a schematic diagram of the proposed roles of these signalling pathways in 
monocyte activation. Although some of the intermediate pathways have yet to be 
investigated, MCP-1 appears to activate three separate pathways. The majority of the 
responses are activated by pertussis toxin -sensitive G-proteins. However, MCP-1 
also activates a PTK/SH2 -coupled PI 3-kinase which is insensitive to pertussis toxin 
and which is possibly activated by an as yet unidentified MCP-1 receptor which is 
coupled to a non-receptor PTK. The activation of PI 3-kinase is likely to be involved in 
both monocyte chemotaxis and other functional responses as well as their 
differentiation into tissue macrophages. The rise in intracellular calcium, be it either 
mobilisation, influx or a combination, may be important in similar pathways as PI 3- 
kinase, namely monocyte movement and functional responses. However, it may also 
play an important role in the phosphorylation of certain proteins by activation of PKC 
and subsequently PTKs. These phosphorylated proteins may help to modulate 
monocyte chemotaxis and functional responses by both direct mechanisms but also 
by activating other pathways which in turn modulate the responses.
Table 8.1 summarises all the responses which have been demonstrated to be 
activated by MCP-1 in this thesis. It is possible to correlate the activation of these 
responses with the events which take place in vivo. For example, the activation of 
PLC and the intracellular calcium rise is induced very rapidly by lower concentrations 
of MCP-1. Thus, these may be activated when the chemotactic gradient is very low. 
As the MCP-1 concentration increases down the gradient, the activation of pathways 
such as PI 3-kinase occurs possibly leading to the functional responses induced by 
higher concentrations of MCP-1 such as adhesion molecule upregulation. The
225
observation that the chemotactic response is induced by low concentrations of MCP-1 
but adhesion molecules involved in the firm adhesion and diapedesis of monocytes 
are activated by higher concentrations of MCP-1 indicates the important role of an 
MCP-1 gradient in monocyte movement and activation. Functional responses such as 
superoxide release, although induced by lower concentrations of MCP-1 require much 
longer time-course. Therefore, it may be possible to apply the results obtained in this 
study to effects already observed in vivo.
There is a great deal of work left to be carried out before a clear picture as to the 
signalling pathways activated by MCP-1 and their role in the functional responses is 
obtained. However, the identification of MCP-1 in a number of inflammatory 
responses means that a full understanding of its mechanisms of action may be 
invaluable in therapeutic treatments in the future.
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Table 8.1 - Summary of MCP-1-induced responses and the optimal 
concentrations and times. This table compares the concentrations and times 
required to stimulate the various responses detected after MCP-1 stimulation. The 
asterisks denote where only one concentration or timepoint was studied.
Response Optimal [MCP-1] Optimal time
IP3 generation *12.5nM 5 seconds
Intracellular calcium rise 12.5nM 10 seconds
G-protein -linked PI 3- 
kinase
60nM 30 seconds














Chemotaxis 3nM *90 minutes
Superoxide release 12.5nM 120 minutes
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8.3 Future directions
Although this study has gone part of the way to identifying the signalling pathways 
activated by MCP-1, there are a number of further studies that could be carried out to 
further characterise the MCP-1-induced activation of monocytes and monocytic cell 
lines.
1) To identify the possible transient nature of the expression of the CC CKR 2A 
receptor, the cells which are observed to bind MCP-1 using biotinylated MCP-1 
could be sorted from the cells not expressing the receptor and then cultured. The 
cellular distribution of the receptors could then be monitored with time to see if a 
similar heterogeneity of receptor expression develops.
2) More investigation into the possible activation of PLC in the CC CKR 2A 
transfectants following MCP-1 stimulation, again by monitoring the possible 
increases in [Ca2+]j in these cells following MCP-1 stimulation of the FACS. Any 
cells which may respond to MCP-1 by demonstrating an increase in [Ca2+]j could be 
sorted from the non-responding cells and the possible changes in the cells which 
respond to MCP-1 with time could be studied.
3) Further investigation into the pertussis toxin-insensitive part of the MCP-1-induced 
calcium response in CC CKR 2B cells using PTK inhibitors may provide more 
evidence as to the possible coupling of the CC CKR 2B to tyrosine kinases. 
Following on from this, it would be useful to determine the relative expression of all 
the different Ga subunits of G-proteins in the HEK 293 cells as well as in THP-1 
cells and human monocytes to further investigate the effects demonstrated by 
Kuang et al.. This could be achieved if antibodies to these G-protein subunits were 
available.
4) Further characterisation of the disparate PI 3-kinase activities stimulated by MCP-1 
in the CC CKR 2A and 2B transfected cells using the pharmacological agents 
pertussis toxin and wortmannin. This would be particularly useful in trying to further 
elucidate the cause of the very high basal levels of Ptdlns(3,4,5)P3 in the CC CKR
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2B cells. It would also further confirm the proposed variation in PI 3-kinase 
activities which are coupled to each of these receptors i.e. the CC CKR 2A is 
coupled to PI 3-kinase y and the CC CKR 2B is coupled to the PTK/SH2 -coupled 
PI 3-kinase.
5) Further investigation is required into the proteins tyrosine phosphorylated by MCP-1 
in THP-1 cells as well as CC CKR 2A and 2B transfected cells. This includes 
identifying the 120, 80, 55 and 50kDa proteins in THP-1 cells as well as studying 
the possible co-precipitation of the 55kDa protein with the p85 subunit of PI 3- 
kinase in CC CKR 2A and 2B transfectants. This would possibly provide further 
evidence for the diversity of the signalling pathways activated by MCP-1 binding to 
these receptors. Also, the effects of pertussis toxin and wortmannin on the 
phosphorylation of the 55kDa protein would possibly confirm the role of this protein 
in the activation of the pertussis toxin-insensitive PTK/SH2 -coupled PI-3 kinase. 
Also, the possibility that other proteins might also be required for the activation of 
the PTK/SH2 -coupled PI 3-kinase activation due to the slight delay in the 
appearance of the 55kDa band compared to the immunoprecipitated PI 3-kinase 
activity needs to be further investigated.
6) The expression of active and dominant negative p85 and p110 mutants may 
provide vital clues as to the role of PI 3-kinase in monocyte function and 
differentiation as well as the role of PI 3-kinase in MCP-1-induced responses.
7) To further characterise the phosphorylation of p70 S6 kinase by MCP-1 using both 
pertussis toxin and wortmannin and to try to determine whether this is a 
downstream effector of MCP-1 -induced PI 3-kinase activation. PMA could be used 
as a positive control for p70 S6 kinase activation.
8) The identity of the proposed PTK -coupled MCP-1 receptor and/or the MCP-1 
receptor coupled to a pertussis toxin-insensitive G-protein must be identified. 
Characterisation of the DARC receptor as well as attempting to clone other MCP-1
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receptors which may be present in THP-1 cells would be very useful in the 
identification of this receptor.
9) The role of both PLC and the PI 3-kinase isoforms in monocyte functional












HEK 293 cells 
MEM
0.1 mM MEM non-essential amino acids 
2mM glutamine 
1 mM sodium pyruvate







1 mM CaCI2 
5mM MgCI2 
0.5% BSA (w/v)
pH adjusted to 7.2
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Appendix 3






pH adjusted to 7.4
1% NP40 (v/v)
The following protease/phosphatase inhibitors were added immediately prior to use
1 mM sodium orthovanadate 
1 pg/ml leupeptin 









pH adjusted to pH 7.4
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Appendix 5




162mM Tris(hydroxymethyl)aminomethane (Tris) (pH 6.8) 
9% 2-mercaptoethanol (v/v)
1mg bromophenol blue
Make up to correct volume with distilled water
Running buffer 
25mM Tris base 
192mM glycine 
0.1% SDS (w/v)
pH must be above 8.3
Transfer buffer 
39mM glycine 
48mM Tris base 
0.0375% SDS (w/v)
20% methanol (v/v)
Tris buffered saline (TBS)
20mM Tris base 
2mM NaCI
adjust pH to 7.5




1 % ovalbumin (w/v)
0.05% azide (w/v)
Make up to final volume in TBS
Coomassie blue stain 
0.25% Coomassie blue (w/v) 
45.4% methanol (v/v)
9.2% glacial acetic acid (v/v)
Make up to final volume in H20
Destain solution 
45.4% methanol (v/v)
9.2% glacial acetic acid (v/v)
Make up to final volume in H2Q
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Table A5 - Recipes for various percentage SDS-gels
(Resolving gel - 5 ml is sufficient for 1 mini gel and 40 ml is sufficient for 1 
large gel
Stacking gel -1 ml is sufficient for 1 mini gel and 8 ml is sufficient for 1 large 
gel).









(1 ml [8 ml])
H20 2.35 2 9.2 0.68 [5.5]
30% Acrylamide mix 
(w/v)
1.25 1.7 20 0.17 [1.3]
1M Tris (pH 8.8) 
{1M Tris (pH 6.8) for 
stacking gel}
1.3 1.3 10 0.13 [1]
10% SDS (w/v) 0.05 0.05 0.4 0.01 [0.08]
10% ammonium 
persulphate (APS) 
(w/v) - made up 
immediately prior to 
use








Scopoletin assay for H20 2
Reaction mixture 
69pg/ml scopoletin 
15mM sodium azide 
1 mg/ml Horseradish peroxidase 
2mM Ca2+
2mM Mg2+
Made up to final volume in HBSS without Ca2+ and Mg2+
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